Norine

Norine Team contributions

2843 NRPs submission(s) or modification(s) for Norine Team ([CRIStAL (UMR CNRS 9189), ex-LIFL, France, Charles Viollette Institute, ProBioGEM team, Lille, France, University of Lille, France])

• Keanumycin A, submitted on 2023-02-01 , validated by Norine Team the 2023-02-01 (modification)
  

  Add taxId for organism

• edeine D, submitted on 2015-08-24 , validated by Norine Team the 2015-08-24 (modification)
  

  Add atomic structure image

• syringafactin D, submitted on 2013-06-18 (modification)

  Components of biosurfactant complex produced by some isolates of P. syringae. A bioinformatics analysis of the C/E domains of the synthetase has predicted that Leu2, Leu3, Gln4, Thr6 and Leu8 probably have a D-isomery but it has not yet been evidenced by structural determination.

• syringafactin F, submitted on 2013-06-18 (modification)

  Components of biosurfactant complex produced by some isolates of P. syringae. A bioinformatics analysis of the C/E domains of the synthetase has predicted that Leu2, Leu3, Gln4, Thr6 and Leu8 probably have a D-isomery but it has not yet been evidenced by structural determination.

• syringafactin C, submitted on 2013-06-18 (modification)

  Components of biosurfactant complex produced by some isolates of P. syringae. A bioinformatics analysis of the C/E domains of the synthetase has predicted that Leu2, Leu3, Gln4, Thr6 and Leu8 probably have a D-isomery but it has not yet been evidenced by structural determination.

• syringafactin B, submitted on 2013-06-18 (modification)

  Components of biosurfactant complex produced by some isolates of P. syringae. A bioinformatics analysis of the C/E domains of the synthetase has predicted that Leu2, Leu3, Gln4, Thr6 and Leu8 probably have a D-isomery but it has not yet been evidenced by structural determination.

• syringafactin A, submitted on 2013-06-18 (modification)

  Components of biosurfactant complex produced by some isolates of P. syringae. A bioinformatics analysis of the C/E domains of the synthetase has predicted that Leu2, Leu3, Gln4, Thr6 and Leu8 probably have a D-isomery but it has not yet been evidenced by structural determination.

• syringafactin E, submitted on 2013-06-18 (modification)

  Components of biosurfactant complex produced by some isolates of P. syringae. A bioinformatics analysis of the C/E domains of the synthetase has predicted that Leu2, Leu3, Gln4, Thr6 and Leu8 probably have a D-isomery but it has not yet been evidenced by structural determination.

• HM A2, submitted on 2010-12-09 (creation)

• HM A1, submitted on 2010-12-09 (creation)

• HM B4, submitted on 2010-12-09 (creation)

• scytalidamide B, submitted on 2010-12-09 (creation)

• coelichelin, submitted on 2010-12-09 (creation)

• micropeptin B, submitted on 2010-12-09 (creation)

• microginin FR9, submitted on 2010-12-09 (creation)

• cyanostatin A, submitted on 2010-12-09 (creation)

• micropeptin A, submitted on 2010-12-09 (creation)

• PA VI, submitted on 2010-12-09 (creation)

• PA IX, submitted on 2010-12-09 (creation)

• PA IV, submitted on 2010-12-09 (creation)

• HM B5, submitted on 2010-12-09 (creation)

• scytalidamide A, submitted on 2010-12-09 (creation)

• PA V, submitted on 2010-12-09 (creation)

• HM B1, submitted on 2010-12-09 (creation)

• cyanostatin B, submitted on 2010-12-09 (creation)

• PA VIII, submitted on 2010-12-09 (creation)

• TVB IV, submitted on 2010-12-09 (creation)

• PA II, submitted on 2010-12-09 (creation)

• tiglicamide C, submitted on 2010-12-09 (creation)

• HM A4, submitted on 2010-12-09 (creation)

• PAU4, submitted on 2010-12-09 (creation)

• HM B3a, submitted on 2010-12-09 (creation)

• TVB II, submitted on 2010-12-09 (creation)

• kempopeptin A, submitted on 2010-12-09 (creation)

• microginin T2, submitted on 2010-12-09 (creation)

• TVB I, submitted on 2010-12-09 (creation)

• microginin 711, submitted on 2010-12-09 (creation)

• somamide B, submitted on 2010-12-09 (creation)

• microginin FR5, submitted on 2010-12-09 (creation)

• microginin FR3, submitted on 2010-12-09 (creation)

• somamide A, submitted on 2010-12-09 (creation)

• HM B2, submitted on 2010-12-09 (creation)

• Methyl ester largamide A, submitted on 2010-12-09 (creation)

• HM A5a, submitted on 2010-12-09 (creation)

• largamide A, submitted on 2010-12-09 (creation)

• HM B3b, submitted on 2010-12-09 (creation)

• tiglicamide B, submitted on 2010-12-09 (creation)

• tiglicamide A, submitted on 2010-12-09 (creation)

• HM A5, submitted on 2010-12-09 (creation)

• HM A3, submitted on 2010-12-09 (creation)

• Leu1-zervamicin, submitted on 2010-11-22 (modification)

• echinomycin, submitted on 2010-08-05 (modification)

  Echinomycin binds to DNA and inhibits RNA synthesis. Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• triostin A, submitted on 2010-08-05 (modification)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• echinomycin, submitted on 2010-08-02 (modification)

  Echinomycin binds to DNA and inhibits RNA synthesis. Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• decaplanin, submitted on 2010-08-02 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• triostin A, submitted on 2010-08-02 (modification)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• MM47761, submitted on 2010-08-02 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• decaplanin, submitted on 2010-04-28 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• MM47761, submitted on 2010-04-28 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloropolysporin B, submitted on 2010-04-08 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• daptomycin, submitted on 2010-01-08 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• ADEP-1, submitted on 2010-01-08 (modification)

• ADEP-1, submitted on 2010-01-08 (creation)

• quinomycin B, submitted on 2009-11-25 (modification)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• triostin C, submitted on 2009-11-25 (modification)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• quinomycin C, submitted on 2009-11-25 (modification)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• triostin A, submitted on 2009-11-25 (modification)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• triostin A, submitted on 2009-11-25 (creation)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• quinomycin C, submitted on 2009-11-25 (creation)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• quinomycin B, submitted on 2009-11-25 (creation)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• triostin C, submitted on 2009-11-25 (creation)

  Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• echinomycin, submitted on 2009-11-24 (modification)

  Echinomycin binds to DNA and inhibits RNA synthesis. Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• echinomycin, submitted on 2009-11-24 (creation)

  Echinomycin binds to DNA and inhibits RNA synthesis. Quinomycins contain a thioacetal cross bridge. In the tiostin analogues, a disulfide bond replaces the thioacetal cross-link.

• arylomycin A3, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B7, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B6, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B5, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B4, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B3, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B2, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B1, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A5, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A4, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A2, submitted on 2009-10-14 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B1, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B2, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B3, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B4, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B5, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B6, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin B7, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A2, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A3, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A4, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A5, submitted on 2009-10-14 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A1, submitted on 2009-10-13 (modification)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• arylomycin A1, submitted on 2009-10-13 (creation)

  Arylomycins represent the first examples of biaryl-bridged lipopeptides.

• apicidin B, submitted on 2009-09-18 (modification)

• apicidin C, submitted on 2009-09-18 (modification)

• apicidin D2, submitted on 2009-09-18 (modification)

• apicidin D3, submitted on 2009-09-18 (modification)

• apicidin A, submitted on 2009-09-18 (modification)

• apicidin D1, submitted on 2009-09-18 (modification)

• apicidin C, submitted on 2009-09-18 (creation)

• apicidin D1, submitted on 2009-09-18 (creation)

• apicidin D2, submitted on 2009-09-18 (creation)

• apicidin D3, submitted on 2009-09-18 (creation)

• apicidin A, submitted on 2009-09-18 (creation)

• apicidin B, submitted on 2009-09-18 (creation)

• trichotoxin A-40 I, submitted on 2009-09-17 (modification)

• trichotoxin A-50 J, submitted on 2009-09-17 (modification)

• trichotoxin A-50 I, submitted on 2009-09-17 (modification)

• trichotoxin A-50 H, submitted on 2009-09-17 (modification)

• trichotoxin A-50 G, submitted on 2009-09-17 (modification)

• trichotoxin A-50 F, submitted on 2009-09-17 (modification)

• trichotoxin A-40 II, submitted on 2009-09-17 (modification)

• trichotoxin A-50 E, submitted on 2009-09-17 (modification)

• trichotoxin A-40 Va, submitted on 2009-09-17 (modification)

• trichotoxin A-40 V, submitted on 2009-09-17 (modification)

• trichotoxin A-40 IV, submitted on 2009-09-17 (modification)

• Leu1-zervamicin, submitted on 2009-09-17 (modification)

• A54145 B, submitted on 2009-09-17 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• zervamicin IIB, submitted on 2009-09-17 (modification)

• trichotoxin A-40 III, submitted on 2009-09-17 (modification)

• trichotoxin A-40, submitted on 2009-09-17 (modification)

• zervamicin IIA, submitted on 2009-09-17 (modification)

• trichotoxin A-40 I, submitted on 2009-09-17 (creation)

• trichotoxin A-50 J, submitted on 2009-09-17 (creation)

• trichotoxin A-50 I, submitted on 2009-09-17 (creation)

• trichotoxin A-50 H, submitted on 2009-09-17 (creation)

• trichotoxin A-50 G, submitted on 2009-09-17 (creation)

• trichotoxin A-50 F, submitted on 2009-09-17 (creation)

• trichotoxin A-50 E, submitted on 2009-09-17 (creation)

• trichotoxin A-40 Va, submitted on 2009-09-17 (creation)

• trichotoxin A-40 V, submitted on 2009-09-17 (creation)

• trichotoxin A-40 IV, submitted on 2009-09-17 (creation)

• trichotoxin A-40 III, submitted on 2009-09-17 (creation)

• trichotoxin A-40 II, submitted on 2009-09-17 (creation)

• trichotoxin A-40, submitted on 2009-09-17 (creation)

• Leu1-zervamicin, submitted on 2009-09-17 (creation)

• zervamicin IIB, submitted on 2009-09-17 (creation)

• zervamicin IIA, submitted on 2009-09-17 (creation)

• zervamicin II-1, submitted on 2009-09-15 (modification)

• zervamicin IC, submitted on 2009-09-15 (modification)

• zervamicin IB prime, submitted on 2009-09-15 (modification)

• zervamicin IB, submitted on 2009-09-15 (modification)

• zervamicin IA, submitted on 2009-09-15 (modification)

• zervamicin II-5, submitted on 2009-09-15 (modification)

• zervamicin II-4, submitted on 2009-09-15 (modification)

• zervamicin II-3, submitted on 2009-09-15 (modification)

• zervamicin II-2, submitted on 2009-09-15 (modification)

• A54145 A, submitted on 2009-09-15 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• zervamicin II-3, submitted on 2009-09-15 (creation)

• zervamicin IB, submitted on 2009-09-15 (creation)

• zervamicin II-4, submitted on 2009-09-15 (creation)

• zervamicin IA, submitted on 2009-09-15 (creation)

• zervamicin II-1, submitted on 2009-09-15 (creation)

• zervamicin II-2, submitted on 2009-09-15 (creation)

• zervamicin IC, submitted on 2009-09-15 (creation)

• zervamicin II-5, submitted on 2009-09-15 (creation)

• zervamicin IB prime, submitted on 2009-09-15 (creation)

• feglymycin, submitted on 2009-06-30 (modification)

  As well as having weak antibacterial activity, feglymycin inhibits the replication of the human immunodeficiency virus (HIV) in vitro.

• daptomycin, submitted on 2009-06-30 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• feglymycin, submitted on 2009-06-30 (creation)

  As well as having weak antibacterial activity, feglymycin inhibits the replication of the human immunodeficiency virus (HIV) in vitro.

• MM49721, submitted on 2009-04-26 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• actinoidin B, submitted on 2008-10-29 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• A21978C2, submitted on 2008-10-29 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• cyclosporin N, submitted on 2008-10-29 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• actinoidin A, submitted on 2008-10-29 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• actinoidin A2, submitted on 2008-10-29 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• callynormine A, submitted on 2008-10-27 (modification)

  Callynormine is a putative NRPS product (no synthetase genes identified).

• keramamide J, submitted on 2008-10-20 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• oriamide, submitted on 2008-10-20 (modification)
  

• keramamide K, submitted on 2008-10-20 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide H, submitted on 2008-10-20 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide F, submitted on 2008-10-20 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide G, submitted on 2008-10-20 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• bottromycin A2, submitted on 2008-10-20 (modification)

  3Me-Phe -> bMe-Phe

• ornibactin C4, submitted on 2008-10-14 (modification)

• Ile-polymyxin E8, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• Val-polymyxin E1, submitted on 2008-10-13 (modification)

  This component is a minor component of polymyxin E mixture.

• Nva-polymyxin E1, submitted on 2008-10-13 (modification)

  This component is a minor component of polymyxin E mixture.

• Ile-polymyxin E1, submitted on 2008-10-13 (modification)

  This component is a minor component of polymyxin E mixture.

• polymyxin E1, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• polymyxin B6, submitted on 2008-10-13 (modification)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin B3, submitted on 2008-10-13 (modification)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin B5, submitted on 2008-10-13 (modification)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin B4, submitted on 2008-10-13 (modification)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin B1, submitted on 2008-10-13 (modification)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin E7, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• polymyxin B2, submitted on 2008-10-13 (modification)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin E4, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• polymyxin E3, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• Ile-polymyxin B1, submitted on 2008-10-13 (modification)

  This component is a minor component of polymyxin B mixture.

• Val-polymyxin E2, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• syringopeptin 22 PhvA, submitted on 2008-10-13 (modification)

  Syringopeptin 22 Phv was less active than syringopeptin 22 in inhibiting the growth of the test fungi Rhodotorula pilimanae and Geotrichum candidum and of the Gram-positive bacterium Bacillus megaterium. The amino acid stereochemistry has not been identified.

• Ile-polymyxin E2, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• polymyxin E2, submitted on 2008-10-13 (modification)

  Polymyxin E is a mixture of several components.

• polymyxin M, submitted on 2008-10-13 (modification)

  It contain 6-methyloctanoicacid

• Val-polymyxin E2, submitted on 2008-10-13 (creation)

  Polymyxin E is a mixture of several components.

• polymyxin B4, submitted on 2008-10-13 (creation)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin B3, submitted on 2008-10-13 (creation)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• Ile-polymyxin E8, submitted on 2008-10-13 (creation)

  Polymyxin E is a mixture of several components.

• polymyxin E7, submitted on 2008-10-13 (creation)

  Polymyxin E is a mixture of several components.

• polymyxin E4, submitted on 2008-10-13 (creation)

  Polymyxin E is a mixture of several components.

• polymyxin E3, submitted on 2008-10-13 (creation)

  Polymyxin E is a mixture of several components.

• polymyxin B2, submitted on 2008-10-13 (creation)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• Ile-polymyxin E2, submitted on 2008-10-13 (creation)

  Polymyxin E is a mixture of several components.

• polymyxin E2, submitted on 2008-10-13 (creation)

  Polymyxin E is a mixture of several components.

• polymyxin B6, submitted on 2008-10-13 (creation)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• polymyxin B5, submitted on 2008-10-13 (creation)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• LP237 F7, submitted on 2008-10-10 (modification)

• LP237 F5, submitted on 2008-10-10 (modification)

• LP237 F8, submitted on 2008-10-10 (modification)

• paracelsin E, submitted on 2008-10-07 (modification)

• atroviridin B, submitted on 2008-10-07 (modification)

  They showed antimicrobial activity against Gram-positive bacteria and phytopathogenic fungi, and exhibited significant cytotoxicity to human cancer cell lines in vitro. Atroviridins showed significant membrane-perturbing activity responsible to their antibiotic action.

• paracelsin D, submitted on 2008-10-07 (modification)

• atroviridin C, submitted on 2008-10-07 (modification)

  They showed antimicrobial activity against Gram-positive bacteria and phytopathogenic fungi, and exhibited significant cytotoxicity to human cancer cell lines in vitro. Atroviridins showed significant membrane-perturbing activity responsible to their antibiotic action.

• paracelsin C, submitted on 2008-10-07 (modification)

• bergofungin A, submitted on 2008-10-07 (modification)
  

• paracelsin B, submitted on 2008-10-07 (modification)

• bergofungin B, submitted on 2008-10-07 (modification)
  

• paracelsin A, submitted on 2008-10-07 (modification)

• bergofungin C, submitted on 2008-10-07 (modification)
  

• LP237 F7, submitted on 2008-10-07 (modification)

• bergofungin D, submitted on 2008-10-07 (modification)
  

• LP237 F5, submitted on 2008-10-07 (modification)

• boletusin, submitted on 2008-10-07 (modification)

  This peptide showed antimicrobial activity against several Gram-positive bacteria.

• LP237 F8, submitted on 2008-10-07 (modification)

• cephaibol A, submitted on 2008-10-07 (modification)

  The striking biological property of cephaibol A is its pronounced anthelmintic action and activity against ectoparasites.

• longibrachin B2, submitted on 2008-10-07 (modification)

• cephaibol A2, submitted on 2008-10-07 (modification)

• longibrachin B1, submitted on 2008-10-07 (modification)

• cephaibol B, submitted on 2008-10-07 (modification)

• longibrachin A4, submitted on 2008-10-07 (modification)

• cephaibol C, submitted on 2008-10-07 (modification)

• longibrachin A3, submitted on 2008-10-07 (modification)

• cephaibol D, submitted on 2008-10-07 (modification)

• longibrachin A2, submitted on 2008-10-07 (modification)

• cephaibol E, submitted on 2008-10-07 (modification)

• longibrachin A1, submitted on 2008-10-07 (modification)

• cephaibol P, submitted on 2008-10-07 (modification)

• hypomurocin B5, submitted on 2008-10-07 (modification)

• cephaibol Q, submitted on 2008-10-07 (modification)

• hypomurocin B4, submitted on 2008-10-07 (modification)

• cervinin 1, submitted on 2008-10-07 (modification)

  They exhibited weak antibacterial as well as cytotoxic activities. They are the first secondary metabolites described from M. cervina.

• hypomurocin B3b, submitted on 2008-10-07 (modification)

• cervinin 2, submitted on 2008-10-07 (modification)

  They exhibited weak antibacterial as well as cytotoxic activities. They are the first secondary metabolites described from M. cervina.

• hypomurocin B3a, submitted on 2008-10-07 (modification)

• chrysospermin A, submitted on 2008-10-07 (modification)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• hypomurocin B2, submitted on 2008-10-07 (modification)

• hypomurocin B1, submitted on 2008-10-07 (modification)

• chrysospermin B, submitted on 2008-10-07 (modification)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• hypomurocin A5a, submitted on 2008-10-07 (modification)

• chrysospermin C, submitted on 2008-10-07 (modification)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• hypomurocin A5, submitted on 2008-10-07 (modification)

• chrysospermin D, submitted on 2008-10-07 (modification)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• hypomurocin A4, submitted on 2008-10-07 (modification)

• emerimicin IIA, submitted on 2008-10-07 (modification)

• hypomurocin A3, submitted on 2008-10-07 (modification)

• emerimicin IIB, submitted on 2008-10-07 (modification)

• hypomurocin A2, submitted on 2008-10-07 (modification)

• emerimicin III, submitted on 2008-10-07 (modification)

• hypomurocin A1, submitted on 2008-10-07 (modification)

• emerimicin IV, submitted on 2008-10-07 (modification)

• heptaibin, submitted on 2008-10-07 (modification)

• harzianin HB I, submitted on 2008-10-07 (modification)

• harzianin PCU4, submitted on 2008-10-07 (modification)

• harzianin HC I, submitted on 2008-10-07 (modification)

• harzianin HK VI, submitted on 2008-10-07 (modification)

• harzianin HC III, submitted on 2008-10-07 (modification)

• harzianin HC XIV, submitted on 2008-10-07 (modification)

• harzianin HC VI, submitted on 2008-10-07 (modification)

• harzianin HC XIII, submitted on 2008-10-07 (modification)

• harzianin HC VIII, submitted on 2008-10-07 (modification)

• harzianin HC XI, submitted on 2008-10-07 (modification)

• harzianin HC IX, submitted on 2008-10-07 (modification)

• harzianin HC XV, submitted on 2008-10-07 (modification)

• actinoidin A2, submitted on 2008-10-07 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• actinoidin B, submitted on 2008-10-07 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• harzianin HC X, submitted on 2008-10-07 (modification)

• harzianin HC XII, submitted on 2008-10-07 (modification)

• polymyxin M, submitted on 2008-10-07 (modification)

  It contain 6-methyloctanoicacid

• avoparcin-alpha, submitted on 2008-10-07 (modification)

  Avoparcin consists of a mixture of several structurally similar glycopeptide analogs, of which alpha and beta avoparcin are the major components. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• Nva-polymyxin E1, submitted on 2008-10-07 (modification)

  This component is a minor component of polymyxin E mixture.

• avoparcin-beta, submitted on 2008-10-07 (modification)

  Avoparcin consists of a mixture of several structurally similar glycopeptide analogs, of which alpha and beta avoparcin are the major components. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• Val-polymyxin E1, submitted on 2008-10-07 (modification)

  This component is a minor component of polymyxin E mixture.

• avoparcin-epsilon, submitted on 2008-10-07 (modification)

  Avoparcin consists of a mixture of several structurally similar glycopeptide analogs, of which alpha and beta avoparcin are the major components. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• Ile-polymyxin E1, submitted on 2008-10-07 (modification)

  This component is a minor component of polymyxin E mixture.

• chloropolysporin C, submitted on 2008-10-07 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• polymyxin E1, submitted on 2008-10-07 (modification)

  Polymyxin E is a mixture of several components.

• chloropolysporin B, submitted on 2008-10-07 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• Ile-polymyxin B1, submitted on 2008-10-07 (modification)

  This component is a minor component of polymyxin B mixture.

• galacardin A, submitted on 2008-10-07 (modification)

  They showed strong antimicrobial activity against Gram-positive bacteria and also showed excellent in vivo protective activity against Staphylococcus aureus infection in mice. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• polymyxin B1, submitted on 2008-10-07 (modification)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• galacardin B, submitted on 2008-10-07 (modification)

  They showed strong antimicrobial activity against Gram-positive bacteria and also showed excellent in vivo protective activity against Staphylococcus aureus infection in mice. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• trichobrachin B4, submitted on 2008-10-07 (modification)

• helvecardin A, submitted on 2008-10-07 (modification)

  Helvecardins were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, but they were inactive against Gram-negative bacteria and fungi. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• trichobrachin B3, submitted on 2008-10-07 (modification)

• helvecardin B, submitted on 2008-10-07 (modification)

  Helvecardins were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, but they were inactive against Gram-negative bacteria and fungi. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• trichobrachin B2, submitted on 2008-10-07 (modification)

• ampullosporin A, submitted on 2008-10-07 (modification)

  Ampullosporin displays narrow-spectrum antibacterial and antifungal activity, induces pigment formation by Phoma destructiva, causes hypothermia and decreased spontaneous locomotor activity in mice.

• trichobrachin B1, submitted on 2008-10-07 (modification)

• ampullosporin B, submitted on 2008-10-07 (modification)

  Peptaibol-type ampullosporins B and D are capable of forming ion-conducting pores in planar lipid bilayer membrane prepared from soybean phosphatidylcholine in a similar manner as it was shown for ampullosporin A.

• trichobrachin A4, submitted on 2008-10-07 (modification)

• ampullosporin C, submitted on 2008-10-07 (modification)

• trichobrachin A3, submitted on 2008-10-07 (modification)

• ampullosporin D, submitted on 2008-10-07 (modification)

  Peptaibol-type ampullosporins B and D are capable of forming ion-conducting pores in planar lipid bilayer membrane prepared from soybean phosphatidylcholine in a similar manner as it was shown for ampullosporin A.

• trichobrachin A2, submitted on 2008-10-07 (modification)

• ampullosporin E1, submitted on 2008-10-07 (modification)

• trichobrachin A1, submitted on 2008-10-07 (modification)

• ampullosporin E2, submitted on 2008-10-07 (modification)

• stilboflavin B10, submitted on 2008-10-07 (modification)

• ampullosporin E3, submitted on 2008-10-07 (modification)

• stilboflavin B9, submitted on 2008-10-07 (modification)

• ampullosporin E4, submitted on 2008-10-07 (modification)

• stilboflavin B8, submitted on 2008-10-07 (modification)

• antiamoebin I, submitted on 2008-10-07 (modification)

• stilboflavin B7, submitted on 2008-10-07 (modification)

• antiamoebin II, submitted on 2008-10-07 (modification)

• stilboflavin B6, submitted on 2008-10-07 (modification)

• antiamoebin III, submitted on 2008-10-07 (modification)

• stilboflavin B5, submitted on 2008-10-07 (modification)

• antiamoebin IV, submitted on 2008-10-07 (modification)

• stilboflavin B4, submitted on 2008-10-07 (modification)

• antiamoebin V, submitted on 2008-10-07 (modification)

• stilboflavin B3, submitted on 2008-10-07 (modification)

• antiamoebin VI, submitted on 2008-10-07 (modification)

• stilboflavin B2, submitted on 2008-10-07 (modification)

• antiamoebin VII, submitted on 2008-10-07 (modification)

• stilboflavin B1, submitted on 2008-10-07 (modification)

• antiamoebin VIII, submitted on 2008-10-07 (modification)

• stilboflavin A7, submitted on 2008-10-07 (modification)

• antiamoebin IX, submitted on 2008-10-07 (modification)

• stilboflavin A6, submitted on 2008-10-07 (modification)

• actinoidin A, submitted on 2008-10-07 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• stilboflavin A5, submitted on 2008-10-07 (modification)

• antiamoebin X, submitted on 2008-10-07 (modification)

• stilboflavin A4, submitted on 2008-10-07 (modification)

• antiamoebin XI, submitted on 2008-10-07 (modification)

• stilboflavin A3, submitted on 2008-10-07 (modification)

• antiamoebin XII, submitted on 2008-10-07 (modification)

• stilboflavin A2, submitted on 2008-10-07 (modification)

• antiamoebin XIII, submitted on 2008-10-07 (modification)

• stilboflavin A1, submitted on 2008-10-07 (modification)

• antiamoebin XIV, submitted on 2008-10-07 (modification)

• peptaivirin B, submitted on 2008-10-07 (modification)

• antiamoebin XV, submitted on 2008-10-07 (modification)

• peptaivirin A, submitted on 2008-10-07 (modification)

• antiamoebin XVI, submitted on 2008-10-07 (modification)

• peptaibolin, submitted on 2008-10-07 (modification)

• atroviridin A, submitted on 2008-10-07 (modification)

  They showed antimicrobial activity against Gram-positive bacteria and phytopathogenic fungi, and exhibited significant cytotoxicity to human cancer cell lines in vitro. Atroviridins showed significant membrane-perturbing activity responsible to their antibiotic action.

• antiamoebin X, submitted on 2008-10-07 (creation)

• polymyxin M, submitted on 2008-10-07 (creation)

  It contain 6-methyloctanoicacid

• Nva-polymyxin E1, submitted on 2008-10-07 (creation)

  This component is a minor component of polymyxin E mixture.

• Val-polymyxin E1, submitted on 2008-10-07 (creation)

  This component is a minor component of polymyxin E mixture.

• Ile-polymyxin E1, submitted on 2008-10-07 (creation)

  This component is a minor component of polymyxin E mixture.

• polymyxin E1, submitted on 2008-10-07 (creation)

  Polymyxin E is a mixture of several components.

• Ile-polymyxin B1, submitted on 2008-10-07 (creation)

  This component is a minor component of polymyxin B mixture.

• polymyxin B1, submitted on 2008-10-07 (creation)

  Polymyxin B is a mixture of 6 components that differ on their fatty acid moety.

• trichobrachin B4, submitted on 2008-10-07 (creation)

• trichobrachin B3, submitted on 2008-10-07 (creation)

• trichobrachin B2, submitted on 2008-10-07 (creation)

• trichobrachin B1, submitted on 2008-10-07 (creation)

• trichobrachin A4, submitted on 2008-10-07 (creation)

• trichobrachin A3, submitted on 2008-10-07 (creation)

• trichobrachin A2, submitted on 2008-10-07 (creation)

• trichobrachin A1, submitted on 2008-10-07 (creation)

• stilboflavin B10, submitted on 2008-10-07 (creation)

• stilboflavin B9, submitted on 2008-10-07 (creation)

• stilboflavin B8, submitted on 2008-10-07 (creation)

• stilboflavin B7, submitted on 2008-10-07 (creation)

• stilboflavin B6, submitted on 2008-10-07 (creation)

• stilboflavin B5, submitted on 2008-10-07 (creation)

• stilboflavin B4, submitted on 2008-10-07 (creation)

• stilboflavin B3, submitted on 2008-10-07 (creation)

• stilboflavin B2, submitted on 2008-10-07 (creation)

• stilboflavin B1, submitted on 2008-10-07 (creation)

• stilboflavin A7, submitted on 2008-10-07 (creation)

• stilboflavin A6, submitted on 2008-10-07 (creation)

• stilboflavin A5, submitted on 2008-10-07 (creation)

• stilboflavin A4, submitted on 2008-10-07 (creation)

• stilboflavin A3, submitted on 2008-10-07 (creation)

• stilboflavin A2, submitted on 2008-10-07 (creation)

• stilboflavin A1, submitted on 2008-10-07 (creation)

• peptaivirin B, submitted on 2008-10-07 (creation)

• peptaivirin A, submitted on 2008-10-07 (creation)

• peptaibolin, submitted on 2008-10-07 (creation)

• paracelsin E, submitted on 2008-10-07 (creation)

• paracelsin D, submitted on 2008-10-07 (creation)

• paracelsin C, submitted on 2008-10-07 (creation)

• paracelsin B, submitted on 2008-10-07 (creation)

• paracelsin A, submitted on 2008-10-07 (creation)

• LP237 F7, submitted on 2008-10-07 (creation)

• LP237 F5, submitted on 2008-10-07 (creation)

• LP237 F8, submitted on 2008-10-07 (creation)

• longibrachin B2, submitted on 2008-10-07 (creation)

• longibrachin B1, submitted on 2008-10-07 (creation)

• longibrachin A4, submitted on 2008-10-07 (creation)

• longibrachin A3, submitted on 2008-10-07 (creation)

• longibrachin A2, submitted on 2008-10-07 (creation)

• longibrachin A1, submitted on 2008-10-07 (creation)

• hypomurocin B5, submitted on 2008-10-07 (creation)

• hypomurocin B4, submitted on 2008-10-07 (creation)

• hypomurocin B3b, submitted on 2008-10-07 (creation)

• hypomurocin B3a, submitted on 2008-10-07 (creation)

• hypomurocin B2, submitted on 2008-10-07 (creation)

• hypomurocin B1, submitted on 2008-10-07 (creation)

• hypomurocin A5a, submitted on 2008-10-07 (creation)

• hypomurocin A5, submitted on 2008-10-07 (creation)

• hypomurocin A4, submitted on 2008-10-07 (creation)

• hypomurocin A3, submitted on 2008-10-07 (creation)

• hypomurocin A2, submitted on 2008-10-07 (creation)

• hypomurocin A1, submitted on 2008-10-07 (creation)

• heptaibin, submitted on 2008-10-07 (creation)

• harzianin PCU4, submitted on 2008-10-07 (creation)

• harzianin HK VI, submitted on 2008-10-07 (creation)

• harzianin HC XIV, submitted on 2008-10-07 (creation)

• harzianin HC XIII, submitted on 2008-10-07 (creation)

• harzianin HC XI, submitted on 2008-10-07 (creation)

• harzianin HC XV, submitted on 2008-10-07 (creation)

• harzianin HC XII, submitted on 2008-10-07 (creation)

• harzianin HC X, submitted on 2008-10-07 (creation)

• harzianin HC IX, submitted on 2008-10-07 (creation)

• harzianin HC VIII, submitted on 2008-10-07 (creation)

• harzianin HC VI, submitted on 2008-10-07 (creation)

• harzianin HC III, submitted on 2008-10-07 (creation)

• harzianin HC I, submitted on 2008-10-07 (creation)

• harzianin HB I, submitted on 2008-10-07 (creation)

• emerimicin IV, submitted on 2008-10-07 (creation)

• emerimicin III, submitted on 2008-10-07 (creation)

• emerimicin IIB, submitted on 2008-10-07 (creation)

• emerimicin IIA, submitted on 2008-10-07 (creation)

• chrysospermin D, submitted on 2008-10-07 (creation)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• chrysospermin C, submitted on 2008-10-07 (creation)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• chrysospermin B, submitted on 2008-10-07 (creation)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• chrysospermin A, submitted on 2008-10-07 (creation)

  The chrysospermins display antibacterial and antifungal activity, and induce pigment formation by the fungus Phoma destructiva.

• cervinin 2, submitted on 2008-10-07 (creation)

  They exhibited weak antibacterial as well as cytotoxic activities. They are the first secondary metabolites described from M. cervina.

• cervinin 1, submitted on 2008-10-07 (creation)

  They exhibited weak antibacterial as well as cytotoxic activities. They are the first secondary metabolites described from M. cervina.

• cephaibol Q, submitted on 2008-10-07 (creation)

• cephaibol P, submitted on 2008-10-07 (creation)

• cephaibol E, submitted on 2008-10-07 (creation)

• cephaibol D, submitted on 2008-10-07 (creation)

• cephaibol C, submitted on 2008-10-07 (creation)

• cephaibol B, submitted on 2008-10-07 (creation)

• cephaibol A2, submitted on 2008-10-07 (creation)

• cephaibol A, submitted on 2008-10-07 (creation)

  The striking biological property of cephaibol A is its pronounced anthelmintic action and activity against ectoparasites.

• boletusin, submitted on 2008-10-07 (creation)

  This peptide showed antimicrobial activity against several Gram-positive bacteria.

• bergofungin D, submitted on 2008-10-07 (creation)
  
• bergofungin C, submitted on 2008-10-07 (creation)
  
• bergofungin B, submitted on 2008-10-07 (creation)
  
• bergofungin A, submitted on 2008-10-07 (creation)
  
• atroviridin C, submitted on 2008-10-07 (creation)

  They showed antimicrobial activity against Gram-positive bacteria and phytopathogenic fungi, and exhibited significant cytotoxicity to human cancer cell lines in vitro. Atroviridins showed significant membrane-perturbing activity responsible to their antibiotic action.

• atroviridin B, submitted on 2008-10-07 (creation)

  They showed antimicrobial activity against Gram-positive bacteria and phytopathogenic fungi, and exhibited significant cytotoxicity to human cancer cell lines in vitro. Atroviridins showed significant membrane-perturbing activity responsible to their antibiotic action.

• atroviridin A, submitted on 2008-10-07 (creation)

  They showed antimicrobial activity against Gram-positive bacteria and phytopathogenic fungi, and exhibited significant cytotoxicity to human cancer cell lines in vitro. Atroviridins showed significant membrane-perturbing activity responsible to their antibiotic action.

• antiamoebin XVI, submitted on 2008-10-07 (creation)

• antiamoebin XV, submitted on 2008-10-07 (creation)

• antiamoebin XIV, submitted on 2008-10-07 (creation)

• antiamoebin XIII, submitted on 2008-10-07 (creation)

• antiamoebin XII, submitted on 2008-10-07 (creation)

• antiamoebin XI, submitted on 2008-10-07 (creation)

• antiamoebin IX, submitted on 2008-10-07 (creation)

• antiamoebin VIII, submitted on 2008-10-07 (creation)

• antiamoebin VII, submitted on 2008-10-07 (creation)

• antiamoebin VI, submitted on 2008-10-07 (creation)

• antiamoebin V, submitted on 2008-10-07 (creation)

• antiamoebin IV, submitted on 2008-10-07 (creation)

• antiamoebin III, submitted on 2008-10-07 (creation)

• antiamoebin II, submitted on 2008-10-07 (creation)

• antiamoebin I, submitted on 2008-10-07 (creation)

• ampullosporin E4, submitted on 2008-10-07 (creation)

• ampullosporin E3, submitted on 2008-10-07 (creation)

• ampullosporin E2, submitted on 2008-10-07 (creation)

• ampullosporin E1, submitted on 2008-10-07 (creation)

• ampullosporin D, submitted on 2008-10-07 (creation)

  Peptaibol-type ampullosporins B and D are capable of forming ion-conducting pores in planar lipid bilayer membrane prepared from soybean phosphatidylcholine in a similar manner as it was shown for ampullosporin A.

• ampullosporin C, submitted on 2008-10-07 (creation)

• ampullosporin B, submitted on 2008-10-07 (creation)

  Peptaibol-type ampullosporins B and D are capable of forming ion-conducting pores in planar lipid bilayer membrane prepared from soybean phosphatidylcholine in a similar manner as it was shown for ampullosporin A.

• ampullosporin A, submitted on 2008-10-07 (creation)

  Ampullosporin displays narrow-spectrum antibacterial and antifungal activity, induces pigment formation by Phoma destructiva, causes hypothermia and decreased spontaneous locomotor activity in mice.

• helvecardin B, submitted on 2008-10-07 (creation)

  Helvecardins were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, but they were inactive against Gram-negative bacteria and fungi. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• helvecardin A, submitted on 2008-10-07 (creation)

  Helvecardins were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, but they were inactive against Gram-negative bacteria and fungi. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• galacardin B, submitted on 2008-10-07 (creation)

  They showed strong antimicrobial activity against Gram-positive bacteria and also showed excellent in vivo protective activity against Staphylococcus aureus infection in mice. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• galacardin A, submitted on 2008-10-07 (creation)

  They showed strong antimicrobial activity against Gram-positive bacteria and also showed excellent in vivo protective activity against Staphylococcus aureus infection in mice. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• chloropolysporin B, submitted on 2008-10-07 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloropolysporin C, submitted on 2008-10-07 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• avoparcin-epsilon, submitted on 2008-10-07 (creation)

  Avoparcin consists of a mixture of several structurally similar glycopeptide analogs, of which alpha and beta avoparcin are the major components. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• avoparcin-beta, submitted on 2008-10-07 (creation)

  Avoparcin consists of a mixture of several structurally similar glycopeptide analogs, of which alpha and beta avoparcin are the major components. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• avoparcin-alpha, submitted on 2008-10-07 (creation)

  Avoparcin consists of a mixture of several structurally similar glycopeptide analogs, of which alpha and beta avoparcin are the major components. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• actinoidin B, submitted on 2008-10-07 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• actinoidin A2, submitted on 2008-10-07 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• actinoidin A, submitted on 2008-10-07 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• neoviridogrisein III, submitted on 2008-10-06 (modification)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• azotobactin 87 -1, submitted on 2008-10-06 (modification)

• azotobactin 87 -2, submitted on 2008-10-06 (modification)

• pyoverdin BTP16, submitted on 2008-10-06 (modification)

• pyoverdin C, submitted on 2008-10-06 (modification)

• viridogrisein, submitted on 2008-10-06 (modification)

  Etamycin is a putative NRPS product (no synthetase genes identified).

• neoviridogrisein I, submitted on 2008-10-06 (modification)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• neoviridogrisein II, submitted on 2008-10-06 (modification)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• CDA2fa, submitted on 2008-09-29 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2fb, submitted on 2008-09-29 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• putisolvin II, submitted on 2008-09-29 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• putisolvin III, submitted on 2008-09-29 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• CDA2d, submitted on 2008-09-29 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• putisolvin III, submitted on 2008-09-29 (creation)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• actinomycin Z2, submitted on 2008-09-09 (modification)

• actinomycin Z4, submitted on 2008-09-09 (modification)

• actinomycin Z5, submitted on 2008-09-09 (modification)

• ACV, submitted on 2008-09-09 (modification)

  ACV is the penicillin and cephalosporin precursor.

• actinomycin Z3, submitted on 2008-09-09 (modification)

• actinomycin Z1, submitted on 2008-09-09 (modification)

• cyclosporin G, submitted on 2008-09-02 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• beauverolide D, submitted on 2008-09-02 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• MM49721, submitted on 2008-09-02 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• MM47761, submitted on 2008-09-02 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• enniatin B4, submitted on 2008-09-02 (modification)

• cyclosporin 32, submitted on 2008-09-02 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• vibriobactin, submitted on 2008-09-01 (modification)
  

• [Dhb5]nodularin, submitted on 2008-09-01 (modification)

• [D-Asp3.ADMAdda5.Dhb7]microcystin-RR, submitted on 2008-09-01 (modification)

• [D-Asp3.ADMAdda5.Dhb7]microcystin-LR, submitted on 2008-09-01 (modification)

• [DAsp3.ADMAdda5.Dhb7]microcystin-HtyR, submitted on 2008-09-01 (modification)

• chrysobactin, submitted on 2008-09-01 (modification)

• nazumamide A, submitted on 2008-09-01 (modification)

• oriamide, submitted on 2008-09-01 (modification)
  

• enterobactin, submitted on 2008-09-01 (modification)

• bacillibactin, submitted on 2008-09-01 (modification)

• carmabin B, submitted on 2008-09-01 (modification)

  Carmabin is a putative NRPS product (no synthetase genes identified).

• pseudobactin, submitted on 2008-08-22 (modification)

• kapakahine G, submitted on 2008-08-22 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine F, submitted on 2008-08-22 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine E, submitted on 2008-08-22 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine B, submitted on 2008-08-22 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine A, submitted on 2008-08-22 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.Kapakahines C and D differ from A by the addition of the elements of H2O to the indole double bond of Trp-1 together with the formation of a bond between C-4 and N-1.

• bacitracin F, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin C, submitted on 2008-08-22 (modification)

• bacitracin H3, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin C-E, submitted on 2008-08-22 (modification)

• bacitracin H2, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin D-TR133, submitted on 2008-08-22 (modification)

• bacitracin I3, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin BTP2, submitted on 2008-08-22 (modification)

• bacitracin H1, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin G173, submitted on 2008-08-22 (modification)

• bacitracin I2, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin G4R, submitted on 2008-08-22 (modification)

• bacitracin I1, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin GM, submitted on 2008-08-22 (modification)

• bacitracin B1, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin I-III, submitted on 2008-08-22 (modification)

• bacitracin D2, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin CHAO, submitted on 2008-08-22 (modification)

• bacitracin D1, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin P19, submitted on 2008-08-22 (modification)

• bacitracin E, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin Pau, submitted on 2008-08-22 (modification)

• bacitracin C, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin B3, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin B2, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin A2, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin A1, submitted on 2008-08-22 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin D47, submitted on 2008-08-22 (modification)

• pyoverdin PL7, submitted on 2008-08-22 (modification)

• pyoverdin 6-10, submitted on 2008-08-22 (modification)

• pyoverdin PL8, submitted on 2008-08-22 (modification)

• pyoverdin Thai, submitted on 2008-08-22 (modification)

• pyoverdin R, submitted on 2008-08-22 (modification)

• isopyoverdin 90-44, submitted on 2008-08-22 (modification)

• pyoverdin 1.2, submitted on 2008-08-22 (modification)

• pyoverdin 3b, submitted on 2008-08-22 (modification)

• pyoverdin 96.188, submitted on 2008-08-22 (modification)

• pyoverdin 13525, submitted on 2008-08-22 (modification)

• pyoverdin 13525, submitted on 2008-08-22 (modification)

• pseudobactin A225-II, submitted on 2008-08-22 (modification)

• pyoverdin R prime, submitted on 2008-08-22 (modification)

• pseudobactin 36167-I, submitted on 2008-08-22 (modification)

• pseudobactin A225-I, submitted on 2008-08-22 (modification)

• pyoverdin T II, submitted on 2008-08-22 (modification)

• pseudobactin 36167-II, submitted on 2008-08-22 (modification)

• bacitracin I3, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin F, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin H3, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin H2, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin H1, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin I2, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin I1, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin B1, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin D2, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin D1, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin E, submitted on 2008-08-22 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin D47, submitted on 2008-08-22 (creation)

• pyoverdin 6-10, submitted on 2008-08-22 (creation)

• pyoverdin Thai, submitted on 2008-08-22 (creation)

• pseudobactin A225-II, submitted on 2008-08-22 (creation)

• pseudobactin A225-I, submitted on 2008-08-22 (creation)

• pseudobactin 36167-II, submitted on 2008-08-22 (creation)

• pseudobactin 36167-I, submitted on 2008-08-22 (creation)

• pyoverdin CHAO, submitted on 2008-08-22 (creation)

• pyoverdin 1.2 dihydro, submitted on 2008-08-21 (modification)

• pyoverdin BTP16, submitted on 2008-08-21 (modification)

• pyoverdin 9AW, submitted on 2008-08-21 (modification)

• pyoverdin 96-318, submitted on 2008-08-21 (modification)

• pyoverdin 96-312, submitted on 2008-08-21 (modification)

• pyoverdin 96.188, submitted on 2008-08-21 (modification)

• pyoverdin 95-275, submitted on 2008-08-21 (modification)

• pyoverdin 90-51, submitted on 2008-08-21 (modification)

• pyoverdin 51W, submitted on 2008-08-21 (modification)

• pyoverdin 4a, submitted on 2008-08-21 (modification)

• pyoverdin 3b, submitted on 2008-08-21 (modification)

• pyoverdin 2908, submitted on 2008-08-21 (modification)

• pyoverdin 2798, submitted on 2008-08-21 (modification)

• pyoverdin 2461, submitted on 2008-08-21 (modification)

• pyoverdin 2392, submitted on 2008-08-21 (modification)

• pyoverdin 2192, submitted on 2008-08-21 (modification)

• pyoverdin 19310, submitted on 2008-08-21 (modification)

• pyoverdin 18-1, submitted on 2008-08-21 (modification)

• pyoverdin 17400, submitted on 2008-08-21 (modification)

• pyoverdin 1547, submitted on 2008-08-21 (modification)

• pyoverdin 13525, submitted on 2008-08-21 (modification)

• pyoverdin 1.3, submitted on 2008-08-21 (modification)

• pyoverdin 12, submitted on 2008-08-21 (modification)

• pyoverdin 11370, submitted on 2008-08-21 (modification)

• pseudobactin A214, submitted on 2008-08-21 (modification)

• pseudobactin 589A, submitted on 2008-08-21 (modification)

• pseudobactin A, submitted on 2008-08-21 (modification)

• pseudobactin, submitted on 2008-08-21 (modification)

• PaB, submitted on 2008-08-21 (modification)

• isopyoverdin BTP1, submitted on 2008-08-21 (modification)

• azoverdin, submitted on 2008-08-21 (modification)

• isopyoverdin 90-44, submitted on 2008-08-21 (modification)

• isopyoverdin 90-33, submitted on 2008-08-21 (modification)

• azotobactin delta, submitted on 2008-08-21 (modification)

• azotobactin D, submitted on 2008-08-21 (modification)

• azotobactin 87 -2, submitted on 2008-08-21 (modification)

• azotobactin 87 -1, submitted on 2008-08-21 (modification)

• lichenysin A aC17, submitted on 2008-08-21 (modification)

  This variant represents 0,3 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC17, submitted on 2008-08-21 (modification)

  This variant represents 0,55 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC16, submitted on 2008-08-21 (modification)

  This variant represents 1,2 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC16, submitted on 2008-08-21 (modification)

  This variant represents 0,35 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC15, submitted on 2008-08-21 (modification)

  This variant represents 1,2 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A aC15, submitted on 2008-08-21 (modification)

  This variant represents 19,5 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC15, submitted on 2008-08-21 (modification)

  This variant represents 38,6 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC14, submitted on 2008-08-21 (modification)

  This variant represents 21,2 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC14, submitted on 2008-08-21 (modification)

  This variant represents 8,7 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC13, submitted on 2008-08-21 (modification)

  This variant represents 1,1 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A aC13, submitted on 2008-08-21 (modification)

  This variant represents 2,4 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC13, submitted on 2008-08-21 (modification)

  This variant represents 3,8 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC12, submitted on 2008-08-21 (modification)

  This variant represents 0,8 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC12, submitted on 2008-08-21 (modification)

  This variant represents 0,3 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC15, submitted on 2008-08-21 (creation)

  This variant represents 1,2 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A aC15, submitted on 2008-08-21 (creation)

  This variant represents 19,5 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC15, submitted on 2008-08-21 (creation)

  This variant represents 38,6 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC14, submitted on 2008-08-21 (creation)

  This variant represents 21,2 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC14, submitted on 2008-08-21 (creation)

  This variant represents 8,7 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC13, submitted on 2008-08-21 (creation)

  This variant represents 1,1 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A aC13, submitted on 2008-08-21 (creation)

  This variant represents 2,4 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC13, submitted on 2008-08-21 (creation)

  This variant represents 3,8 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• pyoverdin 1.2 dihydro, submitted on 2008-08-21 (creation)

• lichenysin A nC12, submitted on 2008-08-21 (creation)

  This variant represents 0,8 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• pseudobactin A, submitted on 2008-08-21 (creation)

• azotobactin delta, submitted on 2008-08-21 (creation)

• azotobactin 87 -2, submitted on 2008-08-21 (creation)

• lichenysin A aC17, submitted on 2008-08-21 (creation)

  This variant represents 0,3 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC17, submitted on 2008-08-21 (creation)

  This variant represents 0,55 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A nC16, submitted on 2008-08-21 (creation)

  This variant represents 1,2 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• lichenysin A iC16, submitted on 2008-08-21 (creation)

  This variant represents 0,35 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• capreomycin IIA, submitted on 2008-08-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• viomycin, submitted on 2008-08-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• massetolide D, submitted on 2008-08-20 (modification)

• capreomycin IIB, submitted on 2008-08-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• viscosin, submitted on 2008-08-20 (modification)

• capreomycin IB, submitted on 2008-08-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• massetolide F, submitted on 2008-08-20 (modification)

• capreomycin IA, submitted on 2008-08-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• White Line Inducing Principle, submitted on 2008-08-20 (modification)

  WLIP is structurally similar to viscosin, except for the chirality of leucine in position 5 which has D configuration in WLIP and L configuration in viscosin.

• viscosinamide, submitted on 2008-08-20 (modification)

• massetolide E, submitted on 2008-08-20 (modification)

• massetolide L, submitted on 2008-08-20 (modification)

• pseudophomin B, submitted on 2008-08-20 (modification)

  Pseudophomin B is a diastereoisomer of massetolide C.

• pseudophomin A, submitted on 2008-08-20 (modification)

  Pseudophomin A is a diastereoisomer of massetolide A.

• massetolide B, submitted on 2008-08-20 (modification)

• massetolide H, submitted on 2008-08-20 (modification)

• massetolide A, submitted on 2008-08-20 (modification)
  

• massetolide C, submitted on 2008-08-20 (modification)

• virginiamycin S, submitted on 2008-08-20 (modification)

  Virginiamycin S is a member of the streptogramin B group.

• massetolide G, submitted on 2008-08-20 (modification)

• tyrocidine A, submitted on 2008-08-20 (modification)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• massetolide C, submitted on 2008-08-20 (creation)

• massetolide L, submitted on 2008-08-20 (creation)

• massetolide G, submitted on 2008-08-20 (creation)

• pseudophomin B, submitted on 2008-08-20 (creation)

  Pseudophomin B is a diastereoisomer of massetolide C.

• massetolide B, submitted on 2008-08-20 (creation)

• massetolide H, submitted on 2008-08-20 (creation)

• tripropeptin A, submitted on 2008-08-19 (modification)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• tripropeptin Z, submitted on 2008-08-19 (modification)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• tripropeptin E, submitted on 2008-08-19 (modification)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• tripropeptin D, submitted on 2008-08-19 (modification)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• tripropeptin C, submitted on 2008-08-19 (modification)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• tripropeptin B, submitted on 2008-08-19 (modification)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• tolaasin C, submitted on 2008-08-19 (modification)

  Tolaasin C is the linear form of tolaasin I.

• tolaasin E, submitted on 2008-08-19 (modification)

• tolaasin D, submitted on 2008-08-19 (modification)

• tolaasin B, submitted on 2008-08-19 (modification)

• tolaasin II, submitted on 2008-08-19 (modification)

• tolaasin A, submitted on 2008-08-19 (modification)

  Tolaasin I and tolaasin A are structurally similar and the only difference is the number of carbons in the hydroxy fatty acyl moiety.

• tolaasin I, submitted on 2008-08-19 (modification)

  Tolaasin I and tolaasin A are structurally similar and the only difference is the number of carbons in the hydroxy fatty acyl moiety.

• syringopeptin 508B, submitted on 2008-08-19 (modification)

  The amino acid stereochemistry has not been identified.

• syringopeptin 508A, submitted on 2008-08-19 (modification)

  The amino acid stereochemistry has not been identified.

• [Phe25]syringopeptin 25A, submitted on 2008-08-19 (modification)

• syringopeptin 25B, submitted on 2008-08-19 (modification)

• syringopeptin 25A, submitted on 2008-08-19 (modification)

• syringopeptin SC 2, submitted on 2008-08-19 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified.

• syringopeptin SC 1, submitted on 2008-08-19 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified.

• syringopeptin 22 PhvB, submitted on 2008-08-19 (modification)

  Syringopeptin 22 Phv was less active than syringopeptin 22 in inhibiting the growth of the test fungi Rhodotorula pilimanae and Geotrichum candidum and of the Gram-positive bacterium Bacillus megaterium. The amino acid stereochemistry has not been identified.

• syringopeptin 22 PhvA, submitted on 2008-08-19 (modification)

  Syringopeptin 22 Phv was less active than syringopeptin 22 in inhibiting the growth of the test fungi Rhodotorula pilimanae and Geotrichum candidum and of the Gram-positive bacterium Bacillus megaterium. The amino acid stereochemistry has not been identified.

• syringopeptin 22B, submitted on 2008-08-19 (modification)

• syringopeptin 22A, submitted on 2008-08-19 (modification)

• fuscopeptin B, submitted on 2008-08-19 (modification)

  Fuscopeptins are channel forming peptides active on biological and model membranes.

• fuscopeptin A, submitted on 2008-08-19 (modification)

  Fuscopeptins are channel forming peptides active on biological and model membranes.

• corpeptin B, submitted on 2008-08-19 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified.

• corpeptin A, submitted on 2008-08-19 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified.

• tokaramide A, submitted on 2008-08-19 (modification)

• theonellamide E, submitted on 2008-08-19 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• theonellamide D, submitted on 2008-08-19 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• syringotoxin B, submitted on 2008-08-19 (modification)

• syringostatin B, submitted on 2008-08-19 (modification)

• syringostatin A, submitted on 2008-08-19 (modification)

• syringomycin G, submitted on 2008-08-19 (modification)

• syringomycin A1, submitted on 2008-08-19 (modification)

• syringomycin E, submitted on 2008-08-19 (modification)

• pseudomycin C2, submitted on 2008-08-19 (modification)

  The pseudomycin A is the major pseudomycin.

• pseudomycin C, submitted on 2008-08-19 (modification)

  The pseudomycin A is the major pseudomycin.

• pseudomycin B, submitted on 2008-08-19 (modification)

  The pseudomycin A is the major pseudomycin.

• pseudomycin A, submitted on 2008-08-19 (modification)

  The pseudomycin A is the major pseudomycin.

• cormycin A, submitted on 2008-08-19 (modification)

• pseudomycin C2, submitted on 2008-08-19 (creation)

  The pseudomycin A is the major pseudomycin.

• syringomycin A1, submitted on 2008-08-19 (creation)

• syringopeptin 25B, submitted on 2008-08-19 (creation)

• tripropeptin D, submitted on 2008-08-19 (creation)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• pseudomycin C, submitted on 2008-08-19 (creation)

  The pseudomycin A is the major pseudomycin.

• tripropeptin E, submitted on 2008-08-19 (creation)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• syringopeptin 508A, submitted on 2008-08-19 (creation)

  The amino acid stereochemistry has not been identified.

• pseudomycin B, submitted on 2008-08-19 (creation)

  The pseudomycin A is the major pseudomycin.

• syringostatin B, submitted on 2008-08-19 (creation)

• tripropeptin Z, submitted on 2008-08-19 (creation)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• corpeptin B, submitted on 2008-08-19 (creation)

  The stereoisomers (D or L form) of the amino acids are not identified.

• tripropeptin C, submitted on 2008-08-19 (creation)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• fuscopeptin B, submitted on 2008-08-19 (creation)

  Fuscopeptins are channel forming peptides active on biological and model membranes.

• tolaasin C, submitted on 2008-08-19 (creation)

  Tolaasin C is the linear form of tolaasin I.

• syringopeptin 22B, submitted on 2008-08-19 (creation)

• tripropeptin B, submitted on 2008-08-19 (creation)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• syringopeptin 22 PhvB, submitted on 2008-08-19 (creation)

  Syringopeptin 22 Phv was less active than syringopeptin 22 in inhibiting the growth of the test fungi Rhodotorula pilimanae and Geotrichum candidum and of the Gram-positive bacterium Bacillus megaterium. The amino acid stereochemistry has not been identified.

• syringopeptin 508B, submitted on 2008-08-19 (creation)

  The amino acid stereochemistry has not been identified.

• syringomycin G, submitted on 2008-08-19 (creation)

• tolaasin A, submitted on 2008-08-19 (creation)

  Tolaasin I and tolaasin A are structurally similar and the only difference is the number of carbons in the hydroxy fatty acyl moiety.

• syringopeptin SC 2, submitted on 2008-08-19 (creation)

  The stereoisomers (D or L form) of the amino acids are not identified.

• [Leu4]surfactin, submitted on 2008-08-18 (modification)

• [Ile7]surfactin, submitted on 2008-08-18 (modification)

• [Ile7]surfactin, submitted on 2008-08-18 (modification)

• [Ile4]surfactin, submitted on 2008-08-18 (modification)

• [Ile4.7]surfactin, submitted on 2008-08-18 (modification)

  This variant has increased surface properties compared with that of surfactin.

• [Ile2.4.7]surfactin, submitted on 2008-08-18 (modification)

  This variant has increased surface properties compared with that of surfactin.

• [Gln1]surfactin aC15, submitted on 2008-08-18 (modification)

  Isohalobacillin is a mixture of iso and anteiso C15 hydroxy fatty acid.

• [Gln1]surfactin iC15, submitted on 2008-08-18 (modification)

  Isohalobacillin is a mixture of iso and anteiso C15 hydroxy fatty acid.

• [Ala4]surfactin nC15, submitted on 2008-08-18 (modification)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The nC15 isoform represents 2% of total isoforms.

• [Gln1]surfactin, submitted on 2008-08-18 (modification)

• [Ala4]surfactin aC15, submitted on 2008-08-18 (modification)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The aC15 isoform represents 24% of total isoforms.

• [Ala4]surfactin iC15, submitted on 2008-08-18 (modification)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The iC15 isoform represents 37% of total isoforms.

• [Ala4]surfactin nC14, submitted on 2008-08-18 (modification)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The C14 isoform represents 26% of total isoforms.

• [Ala4]surfactin iC14, submitted on 2008-08-18 (modification)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The iC14 isoform represents 11% of total isoforms.

• stylopeptide II, submitted on 2008-08-18 (modification)

  Stylopeptide is a putative NRPS product (no synthetase genes identified)

• serrawettin W2, submitted on 2008-08-18 (modification)

  Serrawettin W2 is produced by strain NS 25.

• serrawettin W1, submitted on 2008-08-18 (modification)

  Serrawettin W1 is produced by strain 274 and ATCC 13880.

• ramoplanin A3, submitted on 2008-08-18 (modification)

  Ramoplanin factors A1, A2, and A3 were isolated in 12, 72, and 16% yields, respectively, from purification of the culture broth of Actinoplanes strain ATCC 33076.

• ramoplanin A2, submitted on 2008-08-18 (modification)

  Ramoplanin factors A1, A2, and A3 were isolated in 12, 72, and 16% yields, respectively, from purification of the culture broth of Actinoplanes strain ATCC 33076.

• surfactin iC12, submitted on 2008-08-18 (modification)

• surfactin iC16, submitted on 2008-08-18 (modification)

• surfactin nC13, submitted on 2008-08-18 (modification)

• surfactin aC13, submitted on 2008-08-18 (modification)

• [Val7]surfactin, submitted on 2008-08-18 (modification)

• surfactin iC15, submitted on 2008-08-18 (modification)
  

• surfactin nC15, submitted on 2008-08-18 (modification)

• ramoplanin A1, submitted on 2008-08-18 (modification)

  Ramoplanin factors A1, A2, and A3 were isolated in 12, 72, and 16% yields, respectively, from purification of the culture broth of Actinoplanes strain ATCC 33076.

• surfactin iC14, submitted on 2008-08-18 (modification)

• surfactin nC14, submitted on 2008-08-18 (modification)

• surfactin aC15, submitted on 2008-08-18 (modification)

• surfactin nC15, submitted on 2008-08-18 (creation)

• surfactin iC12, submitted on 2008-08-18 (creation)

• surfactin iC16, submitted on 2008-08-18 (creation)

• surfactin nC13, submitted on 2008-08-18 (creation)

• surfactin aC13, submitted on 2008-08-18 (creation)

• surfactin iC15, submitted on 2008-08-18 (creation)
  
• surfactin iC14, submitted on 2008-08-18 (creation)

• surfactin nC14, submitted on 2008-08-18 (creation)

• [Gln1]surfactin aC15, submitted on 2008-08-18 (creation)

  Isohalobacillin is a mixture of iso and anteiso C15 hydroxy fatty acid.

• [Gln1]surfactin iC15, submitted on 2008-08-18 (creation)

  Isohalobacillin is a mixture of iso and anteiso C15 hydroxy fatty acid.

• [Ala4]surfactin nC15, submitted on 2008-08-18 (creation)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The nC15 isoform represents 2% of total isoforms.

• [Ala4]surfactin aC15, submitted on 2008-08-18 (creation)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The aC15 isoform represents 24% of total isoforms.

• [Ala4]surfactin iC15, submitted on 2008-08-18 (creation)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The iC15 isoform represents 37% of total isoforms.

• [Ala4]surfactin nC14, submitted on 2008-08-18 (creation)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The C14 isoform represents 26% of total isoforms.

• stylopeptide II, submitted on 2008-08-18 (creation)

  Stylopeptide is a putative NRPS product (no synthetase genes identified)

• ramoplanin A3, submitted on 2008-08-18 (creation)

  Ramoplanin factors A1, A2, and A3 were isolated in 12, 72, and 16% yields, respectively, from purification of the culture broth of Actinoplanes strain ATCC 33076.

• ramoplanin A2, submitted on 2008-08-18 (creation)

  Ramoplanin factors A1, A2, and A3 were isolated in 12, 72, and 16% yields, respectively, from purification of the culture broth of Actinoplanes strain ATCC 33076.

• plusbacin A1, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• putisolvin II, submitted on 2008-08-14 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• putisolvin I, submitted on 2008-08-14 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• pupukeamide, submitted on 2008-08-14 (modification)

  Pupukeamide is a putative NRPS product (no synthetase genes identified)

• pseudotheonamide D, submitted on 2008-08-14 (modification)

• pseudotheonamide C, submitted on 2008-08-14 (modification)

• pseudotheonamide B2, submitted on 2008-08-14 (modification)

• polydiscamide B, submitted on 2008-08-14 (modification)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• polydiscamide A, submitted on 2008-08-14 (modification)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• plusbacin B4, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin B3, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin B2, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin B1, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin A4, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin A3, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin A2, submitted on 2008-08-14 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• phosphinothricin tripeptide, submitted on 2008-08-14 (modification)

• pseudotheonamide A1, submitted on 2008-08-14 (modification)

• polydiscamide D, submitted on 2008-08-14 (modification)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• polydiscamide C, submitted on 2008-08-14 (modification)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• pseudotheonamide B2, submitted on 2008-08-14 (creation)

• plusbacin B4, submitted on 2008-08-14 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin A3, submitted on 2008-08-14 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• polydiscamide D, submitted on 2008-08-14 (creation)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• plusbacin B3, submitted on 2008-08-14 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• polydiscamide C, submitted on 2008-08-14 (creation)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• plusbacin A4, submitted on 2008-08-14 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• polydiscamide B, submitted on 2008-08-14 (creation)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• plusbacin B2, submitted on 2008-08-14 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin A2, submitted on 2008-08-14 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• obyanamide, submitted on 2008-08-13 (modification)

  Obyanamide is a putative NRPS product (no synthetase genes identified).

• PF1022E, submitted on 2008-08-13 (modification)

• PF1022D, submitted on 2008-08-13 (modification)

• PF1022C, submitted on 2008-08-13 (modification)

• PF1022B, submitted on 2008-08-13 (modification)

• PF1022A, submitted on 2008-08-13 (modification)

  It possesses strong anthelmintic properties.

• perthamide B, submitted on 2008-08-13 (modification)

  Perthamide B is a putative NRPS product (no synthetase genes identified)

• papuamide D, submitted on 2008-08-13 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• papuamide C, submitted on 2008-08-13 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• papuamide B, submitted on 2008-08-13 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• papuamide A, submitted on 2008-08-13 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• oscillamide C, submitted on 2008-08-13 (modification)

• oscillamide B, submitted on 2008-08-13 (modification)

• ornibactin C8, submitted on 2008-08-13 (modification)

• [MeO-Glu4]nodularin, submitted on 2008-08-13 (modification)

• [Dhb5]nodularin, submitted on 2008-08-13 (modification)

• [DMAdda3]nodularin, submitted on 2008-08-13 (modification)

• [D-Asp1]nodularin, submitted on 2008-08-13 (modification)

• linear nodularin, submitted on 2008-08-13 (modification)

• motuporin, submitted on 2008-08-13 (modification)

• nodularin-Har, submitted on 2008-08-13 (modification)

• nodularin R, submitted on 2008-08-13 (modification)

• nodulapeptin B, submitted on 2008-08-13 (modification)

• ornibactin C6, submitted on 2008-08-13 (modification)

• ornibactin C4, submitted on 2008-08-13 (modification)

• oriamide, submitted on 2008-08-13 (modification)
  

• onchidin B, submitted on 2008-08-13 (modification)

  onchidin B is a putative NRPS product (no synthetase genes identified).

• onchidin, submitted on 2008-08-13 (modification)

  onchidin is a putative NRPS product (no synthetase genes identified).

• nodulapeptin A, submitted on 2008-08-13 (modification)

• ornibactin C8, submitted on 2008-08-13 (creation)

• [MeO-Glu4]nodularin, submitted on 2008-08-13 (creation)

• ornibactin C6, submitted on 2008-08-13 (creation)

• motuporin, submitted on 2008-08-13 (creation)

• [Dhb5]nodularin, submitted on 2008-08-13 (creation)

• linear nodularin, submitted on 2008-08-13 (creation)

• [DMAdda3]nodularin, submitted on 2008-08-13 (creation)

• nodularin-Har, submitted on 2008-08-13 (creation)

• [D-Asp1]nodularin, submitted on 2008-08-13 (creation)

• miraziridine A, submitted on 2008-08-12 (modification)

• nocardicin G, submitted on 2008-08-12 (modification)

• nocardicin F, submitted on 2008-08-12 (modification)

• nocardicin E, submitted on 2008-08-12 (modification)

• nocardicin D, submitted on 2008-08-12 (modification)

• nocardicin C, submitted on 2008-08-12 (modification)

• nocardicin B, submitted on 2008-08-12 (modification)

• nocardicin A, submitted on 2008-08-12 (modification)

• viridogrisein, submitted on 2008-08-12 (modification)

  Etamycin is a putative NRPS product (no synthetase genes identified).

• nazumamide A, submitted on 2008-08-12 (modification)

• nagahamide A, submitted on 2008-08-12 (modification)

  Nagahamide A is a putative NRPS product (no synthetase genes identified).

• mycobacillin, submitted on 2008-08-12 (modification)

• montanastatin, submitted on 2008-08-12 (modification)

  Montanastatin is a putative NRPS product (no synthetase genes identified).

• microspinosamide, submitted on 2008-08-12 (modification)

  Microspinosamide is a putative NRPS product (no synthetase genes identified).

• micromide, submitted on 2008-08-12 (modification)

  micromide is a putative NRPS product (no synthetase genes identified)

• [D-Asp3.Dha7]microcystin-RR, submitted on 2008-08-12 (modification)

• [D-Asp3.Dha7]microcystin-EE(OMe), submitted on 2008-08-12 (modification)

• [ADMAdda5]microcystin-LR, submitted on 2008-08-12 (modification)

• [D-Asp3.ADMAdda5]microcystin-LHar, submitted on 2008-08-12 (modification)

• microcystin LF, submitted on 2008-08-12 (modification)

• microcystin LW, submitted on 2008-08-12 (modification)

• microcystin YR, submitted on 2008-08-12 (modification)

• microcystin RR, submitted on 2008-08-12 (modification)

• microcystin LL, submitted on 2008-08-12 (modification)

• microcystin LR, submitted on 2008-08-12 (modification)

• microcystin LY, submitted on 2008-08-12 (modification)

• nocardicin G, submitted on 2008-08-12 (creation)

• nocardicin F, submitted on 2008-08-12 (creation)

• nocardicin E, submitted on 2008-08-12 (creation)

• nocardicin D, submitted on 2008-08-12 (creation)

• nocardicin C, submitted on 2008-08-12 (creation)

• nocardicin B, submitted on 2008-08-12 (creation)

• [ADMAdda5]microcystin-LHar, submitted on 2008-08-11 (modification)

• microcystin AR, submitted on 2008-08-11 (modification)

• [L-MeSer7]microcytin-LR, submitted on 2008-08-11 (modification)

• [D-Asp3.Dha7]microcystin-RR, submitted on 2008-08-11 (modification)

• [D-Asp3.ADMAdda5.Dhb7]microcystin-LR, submitted on 2008-08-11 (modification)

• [ADMAdda5]microcystin-LR, submitted on 2008-08-11 (modification)

• [ADMAdda5.MeSer7]microcystin-LR, submitted on 2008-08-11 (modification)

  paf!

• microcystin LAib, submitted on 2008-08-11 (modification)

• microcystin-YM(O), submitted on 2008-08-11 (modification)

• microcystin YA, submitted on 2008-08-11 (modification)

• microcystin-WR, submitted on 2008-08-11 (modification)

• microcystin-M(O)R, submitted on 2008-08-11 (modification)

• microcystin-HtyR, submitted on 2008-08-11 (modification)

• microcystin HilR, submitted on 2008-08-11 (modification)

• microcystin FR, submitted on 2008-08-11 (modification)

• [L-Ser7]microcystin-HtyR, submitted on 2008-08-11 (modification)

• [L-Ser7]microcystin-E(OMe)E(OMe), submitted on 2008-08-11 (modification)

• [L-MeLan7]microcystin-LR, submitted on 2008-08-11 (modification)

• [D-Ser1. ADMAdda5]microcystin-LR, submitted on 2008-08-11 (modification)

• [DMAdda5]microcystin-LR, submitted on 2008-08-11 (modification)

• [Dha7]microcystin-LR, submitted on 2008-08-11 (modification)

• [Dha7]microcystin-HtyR, submitted on 2008-08-11 (modification)

• [Dha7]microcystin-HphR, submitted on 2008-08-11 (modification)

• [D-Glu(OCH3)6]microcystin-LR, submitted on 2008-08-11 (modification)

• [D-Asp3.Ser7]microcystin-E(OMe)E(OMe), submitted on 2008-08-11 (modification)

• [D-Asp3]microcystin-RR, submitted on 2008-08-11 (modification)

• [D-Asp3]microcystin-LR, submitted on 2008-08-11 (modification)

• [D-Asp3]microcystin-HtyR, submitted on 2008-08-11 (modification)

• [D-Asp3.Dha7]microcystin-LR, submitted on 2008-08-11 (modification)

• [D-Asp3. Dha7]microcystin-HtyR, submitted on 2008-08-11 (modification)

• [D-Asp3.ADMAdda5]microcystin-LR, submitted on 2008-08-11 (modification)

• [D-Asp3.ADMAdda5.Dhb7]microcystin-RR, submitted on 2008-08-11 (modification)

• [DAsp3.ADMAdda5.Dhb7]microcystin-HtyR, submitted on 2008-08-11 (modification)

• [D-Asp3.ADMAdda5.Dhb7]microcystin-LR, submitted on 2008-08-11 (creation)

• microcystin LAib, submitted on 2008-08-11 (creation)

• marinobactin A, submitted on 2008-08-08 (modification)

• marinobactin E, submitted on 2008-08-08 (modification)

• marinobactin D2, submitted on 2008-08-08 (modification)

• marinobactin D1, submitted on 2008-08-08 (modification)

• marinobactin C, submitted on 2008-08-08 (modification)

• marinobactin B, submitted on 2008-08-08 (modification)

• malformin B2, submitted on 2008-08-08 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin C, submitted on 2008-08-08 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin B1, submitted on 2008-08-08 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin A2, submitted on 2008-08-08 (modification)

  The two cysteins have a disulfide bridge between them.

• allomalformin, submitted on 2008-08-08 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin A1, submitted on 2008-08-08 (modification)

  The two cysteins have a disulfide bridge between them.

• majusculamide C, submitted on 2008-08-08 (modification)

  Majusculamide C is a putative NRPS product (no synthetase genes identified)

• kulomo opunalide 2, submitted on 2008-08-08 (modification)

  Kulomo opunalide is a putative NRPS product (no synthetase genes identified).

• kulomo opunalide 2, submitted on 2008-08-08 (modification)

  Kulomo opunalide is a putative NRPS product (no synthetase genes identified).

• kulomo opunalide 1, submitted on 2008-08-08 (modification)

  Kulomo opunalide is a putative NRPS product (no synthetase genes identified).

• kulolide 3, submitted on 2008-08-08 (modification)

  kulolides are putative NRPS products (no synthetase genes identified).

• kulolide 2, submitted on 2008-08-08 (modification)

  kulolides are putative NRPS products (no synthetase genes identified).

• kulolide 1, submitted on 2008-08-08 (modification)

  kulolides are putative NRPS products (no synthetase genes identified).

• kulolide 2, submitted on 2008-08-08 (creation)

  kulolides are putative NRPS products (no synthetase genes identified).

• marinobactin D2, submitted on 2008-08-08 (creation)

• kulolide 3, submitted on 2008-08-08 (creation)

  kulolides are putative NRPS products (no synthetase genes identified).

• marinobactin D1, submitted on 2008-08-08 (creation)

• kulomo opunalide 2, submitted on 2008-08-08 (creation)

  Kulomo opunalide is a putative NRPS product (no synthetase genes identified).

• marinobactin C, submitted on 2008-08-08 (creation)

• marinobactin E, submitted on 2008-08-08 (creation)

• marinobactin B, submitted on 2008-08-08 (creation)

• kahalalide G, submitted on 2008-08-07 (modification)

  Kahalalide G is the acyclic analog of kahalalide F.

• kahalalide X, submitted on 2008-08-07 (modification)

  Kahalalide X is the acyclic form of kahalalide C.

• kahalalide C, submitted on 2008-08-07 (modification)

• kahalalide W, submitted on 2008-08-07 (modification)

• kahalalide A, submitted on 2008-08-07 (modification)

  Kahalalide A and F from Bryopsis sp. were noted for their in vitro activity against Mycobacterium tuberculosis

• kahalalide V, submitted on 2008-08-07 (modification)

• kahalalide D, submitted on 2008-08-07 (modification)

• kahalalide E, submitted on 2008-08-07 (modification)

  Kahalalide E was selective in action against the Herpes simplex II virus.

• kahalalide S, submitted on 2008-08-07 (modification)

• kahalalide R, submitted on 2008-08-07 (modification)

• kahalalide F, submitted on 2008-08-07 (modification)

  Kahalalide F alters the function of the lysosomal membrane, a mechanism that distinguishes it from all other known anti-tumour agents.

• kahalalide K, submitted on 2008-08-07 (modification)

• kahalalide J, submitted on 2008-08-07 (modification)

• kahalalide H, submitted on 2008-08-07 (modification)

• kahalalide Y, submitted on 2008-08-07 (modification)

• kahalalide B, submitted on 2008-08-07 (modification)

• kahalalide W, submitted on 2008-08-07 (creation)

• kahalalide Y, submitted on 2008-08-07 (creation)

• kahalalide X, submitted on 2008-08-07 (creation)

  Kahalalide X is the acyclic form of kahalalide C.

• kahalalide V, submitted on 2008-08-07 (creation)

• kahalalide S, submitted on 2008-08-07 (creation)

• kahalalide R, submitted on 2008-08-07 (creation)

• bacillomycin D-5, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• jaspamide, submitted on 2008-08-06 (modification)

  Jaspamide showed ability to interact with actin filaments and in particular to produce structural and biophysical changes of cytoskeletal dynamics, resulting in a potent antiproliferative activity.

• mycosubtilin 3, submitted on 2008-08-06 (modification)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• iturin C-3, submitted on 2008-08-06 (modification)

  Iturins C are inactive metabolites (no antibiotic activity).

• iturin C-2, submitted on 2008-08-06 (modification)

  Iturins C are inactive metabolites (no antibiotic activity).

• iturin C-1, submitted on 2008-08-06 (modification)

  Iturins C are inactive metabolites (no antibiotic activity).

• iturin A-8, submitted on 2008-08-06 (modification)

• iturin A-7, submitted on 2008-08-06 (modification)

• iturin A-6, submitted on 2008-08-06 (modification)

• iturin A-5, submitted on 2008-08-06 (modification)

• iturin A-4, submitted on 2008-08-06 (modification)

• iturin A-3, submitted on 2008-08-06 (modification)

• iturin A-1, submitted on 2008-08-06 (modification)

• iturin A-2, submitted on 2008-08-06 (modification)

  The iturin A-2 isomer is the predominat isomer.

• bacillomycin F-5, submitted on 2008-08-06 (modification)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• bacillomycin F-4, submitted on 2008-08-06 (modification)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• bacillomycin F-3, submitted on 2008-08-06 (modification)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• bacillomycin D-2, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin F-2, submitted on 2008-08-06 (modification)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• bacillomycin D-3, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin F-1, submitted on 2008-08-06 (modification)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• bacillomycin D-4, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin F-6, submitted on 2008-08-06 (modification)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• bacillomycin L-2, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin L-5, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin L-4, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin D-1, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin L-3, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin L-1, submitted on 2008-08-06 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• mycosubtilin 2, submitted on 2008-08-06 (modification)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• mycosubtilin 1, submitted on 2008-08-06 (modification)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• mycosubtilin 4, submitted on 2008-08-06 (modification)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• iturin C-4, submitted on 2008-08-06 (modification)

  Iturins C are inactive metabolites (no antibiotic activity).

• mycosubtilin 3, submitted on 2008-08-06 (creation)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• iturin A-1, submitted on 2008-08-06 (creation)

• mycosubtilin 2, submitted on 2008-08-06 (creation)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• bacillomycin D-4, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• mycosubtilin 1, submitted on 2008-08-06 (creation)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• bacillomycin L-5, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin F-5, submitted on 2008-08-06 (creation)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• iturin C-4, submitted on 2008-08-06 (creation)

  Iturins C are inactive metabolites (no antibiotic activity).

• bacillomycin L-3, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• iturin C-3, submitted on 2008-08-06 (creation)

  Iturins C are inactive metabolites (no antibiotic activity).

• bacillomycin F-4, submitted on 2008-08-06 (creation)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• iturin C-2, submitted on 2008-08-06 (creation)

  Iturins C are inactive metabolites (no antibiotic activity).

• bacillomycin D-2, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin F-1, submitted on 2008-08-06 (creation)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• iturin A-8, submitted on 2008-08-06 (creation)

• bacillomycin L-2, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• iturin A-7, submitted on 2008-08-06 (creation)

• bacillomycin F-3, submitted on 2008-08-06 (creation)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• iturin A-6, submitted on 2008-08-06 (creation)

• bacillomycin D-3, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• iturin A-5, submitted on 2008-08-06 (creation)

• bacillomycin L-4, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• iturin A-4, submitted on 2008-08-06 (creation)

• bacillomycin D-5, submitted on 2008-08-06 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• iturin A-3, submitted on 2008-08-06 (creation)

• bacillomycin F-2, submitted on 2008-08-06 (creation)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• Val-gramicidin C, submitted on 2008-08-05 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Brevibacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• isariin D, submitted on 2008-08-05 (modification)

  Isariins are putative NRPS products (no synthetase genes identified).

• isariin C, submitted on 2008-08-05 (modification)

  Isariins are putative NRPS products (no synthetase genes identified).

• isariin B, submitted on 2008-08-05 (modification)

  Isariins are putative NRPS products (no synthetase genes identified).

• isariin, submitted on 2008-08-05 (modification)

  Isariins are putative NRPS products (no synthetase genes identified).

• isaridin A, submitted on 2008-08-05 (modification)

  Isaridins are putative NRPS products (no synthetase genes identified).

• isaridin B, submitted on 2008-08-05 (modification)

  Isaridins are putative NRPS products (no synthetase genes identified).

• hemiasterlin C, submitted on 2008-08-05 (modification)

• hemiasterlin B, submitted on 2008-08-05 (modification)

• hemiasterlin A, submitted on 2008-08-05 (modification)

• hemiasterlin, submitted on 2008-08-05 (modification)

• criamide B, submitted on 2008-08-05 (modification)

• criamide A, submitted on 2008-08-05 (modification)

• corticiamide A, submitted on 2008-08-05 (modification)

  Corticiamide A is a putative NRPS product (no synthetase genes identified). The absolute stereochemistry was not determined.

• callipeltin M, submitted on 2008-08-05 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin I, submitted on 2008-08-05 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• halipeptin C, submitted on 2008-08-05 (modification)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• halipeptin D, submitted on 2008-08-05 (modification)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• andrimid, submitted on 2008-08-05 (modification)

  andrimid is a NRPS-PKS product. Moiramide differs on the fatty acid moiety.

• halicylindramide C, submitted on 2008-08-05 (modification)

• gymnangiamide, submitted on 2008-08-05 (modification)

  Gymnangiamide is a putative NRPS product (no synthetase genes identified).

• gratisin, submitted on 2008-08-05 (modification)

  Gratisin is a putative NRPS product (no synthetase genes identified).

• Val-gramicidin B, submitted on 2008-08-05 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Val-gramicidin A, submitted on 2008-08-05 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria.Gramicidin A is a naturally-occurring ion channel-forming pentadecapeptide. The association of two gramicidin A peptides causes the formation of a monovalent cation-selective ion channel.

• Ile-gramicidin C, submitted on 2008-08-05 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Ile-gramicidin B, submitted on 2008-08-05 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Ile-gramicidin A, submitted on 2008-08-05 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• ureido-balhimycin, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• rhamnosyl-balhimycin, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• OA7653, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• MM49721, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• MM47761, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• methylbalhimycin, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• demethylbalhimycin, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• deglucobalhimycin, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• dechloro-balhimycin V, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin E, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin B, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• balhimycin V, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• balhimycin, submitted on 2008-08-05 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• isariin D, submitted on 2008-08-05 (creation)

  Isariins are putative NRPS products (no synthetase genes identified).

• isariin B, submitted on 2008-08-05 (creation)

  Isariins are putative NRPS products (no synthetase genes identified).

• isariin C, submitted on 2008-08-05 (creation)

  Isariins are putative NRPS products (no synthetase genes identified).

• enniatin I, submitted on 2008-08-04 (modification)
  

• A83850, submitted on 2008-08-04 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• SF-1902 A5, submitted on 2008-08-04 (modification)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• enniatin L, submitted on 2008-08-04 (modification)

• enniatin G, submitted on 2008-08-04 (modification)

• enniatin F, submitted on 2008-08-04 (modification)
  

• enniatin C, submitted on 2008-08-04 (modification)

• enniatin B4, submitted on 2008-08-04 (modification)

• enniatin B1, submitted on 2008-08-04 (modification)

• enniatin B, submitted on 2008-08-04 (modification)

• enniatin A1, submitted on 2008-08-04 (modification)

• enniatin A, submitted on 2008-08-04 (modification)

• enniatin H, submitted on 2008-08-04 (modification)
  

• SF-1902 A4b, submitted on 2008-08-04 (modification)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• SF-1902 A4a, submitted on 2008-08-04 (modification)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• SF-1902 A2, submitted on 2008-08-04 (modification)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• SF-1902 A3, submitted on 2008-08-04 (modification)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• globomycin, submitted on 2008-08-04 (modification)

  Globomycin is a putative NRPS product (no synthetase genes identified).

• neosiphoniamolide A, submitted on 2008-08-04 (modification)

  Neosiphoniamolide A is a putative NRPS product (no synthetase genes identified)

• geodiamolide TA, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide R, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide Q, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide P, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide O, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide N, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide M, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide L, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide K, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide J, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide I, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide H, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide G, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide F, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide E, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide D, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide C, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide B, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide A, submitted on 2008-08-04 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• friulimicin D, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• friulimicin C, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• friulimicin B, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• friulimicin A, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• amphomycin A1437 D, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• amphomycin A1437 E, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• amphomycin A1437 B, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• amphomycin A1437 A, submitted on 2008-08-04 (modification)

  The acyl residue is essential for antibiotic activity.

• ferintoic acid B, submitted on 2008-08-04 (modification)

• ferintoic acid A, submitted on 2008-08-04 (modification)

• fengycin B, submitted on 2008-08-04 (modification)

  The lipid moiety of both analogs is more variable, as fatty acids have been identified as anteiso-pentadecanoic acid (ai-C15), iso-hexadecanoic acid (i-C16), n-hexadecanoic acid (n-C16), and there is evidence for further saturated and unsaturated residues up to C18.

• fengycin A, submitted on 2008-08-04 (modification)

  The lipid moiety of both analogs is more variable, as fatty acids have been identified as anteiso-pentadecanoic acid (ai-C15), iso-hexadecanoic acid (i-C16), n-hexadecanoic acid (n-C16), and there is evidence for further saturated and unsaturated residues up to C18.

• MK1688, submitted on 2008-08-04 (modification)

• enniatin N, submitted on 2008-08-04 (modification)

• SF-1902 A5, submitted on 2008-08-04 (creation)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• friulimicin B, submitted on 2008-08-04 (creation)

  The acyl residue is essential for antibiotic activity.

• SF-1902 A4b, submitted on 2008-08-04 (creation)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• amphomycin A1437 B, submitted on 2008-08-04 (creation)

  The acyl residue is essential for antibiotic activity.

• SF-1902 A4a, submitted on 2008-08-04 (creation)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• friulimicin D, submitted on 2008-08-04 (creation)

  The acyl residue is essential for antibiotic activity.

• SF-1902 A2, submitted on 2008-08-04 (creation)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• amphomycin A1437 E, submitted on 2008-08-04 (creation)

  The acyl residue is essential for antibiotic activity.

• friulimicin C, submitted on 2008-08-04 (creation)

  The acyl residue is essential for antibiotic activity.

• amphomycin A1437 D, submitted on 2008-08-04 (creation)

  The acyl residue is essential for antibiotic activity.

• [Hysp2]didemnin B, submitted on 2008-08-01 (modification)

• enduracidin B, submitted on 2008-08-01 (modification)

  Ramoplanin is known to show a similar primary structure than enduracidins.

• nordidemnin C, submitted on 2008-08-01 (modification)

• nordidemnin B, submitted on 2008-08-01 (modification)

• nordidemnin A, submitted on 2008-08-01 (modification)

• [Hysp2]didemnin B, submitted on 2008-08-01 (modification)

• [Hap2]didemnin B, submitted on 2008-08-01 (modification)

• didemnin Y, submitted on 2008-08-01 (modification)

• didemnin X, submitted on 2008-08-01 (modification)

• didemnin N, submitted on 2008-08-01 (modification)

• didemnin M, submitted on 2008-08-01 (modification)

• didemnin C, submitted on 2008-08-01 (modification)
  

• didemnin C, submitted on 2008-08-01 (modification)
  

• dehydrodidemnin B, submitted on 2008-08-01 (modification)

  Aplidine is a compound found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers.

• acyclodidemnin A, submitted on 2008-08-01 (modification)

• tamandarin B, submitted on 2008-08-01 (modification)

• tamandarin A, submitted on 2008-08-01 (modification)

• nordidemnin N, submitted on 2008-08-01 (modification)

• didemnin B, submitted on 2008-08-01 (modification)

• didemnin A, submitted on 2008-08-01 (modification)

• destruxin F, submitted on 2008-08-01 (modification)

• protoDestruxin, submitted on 2008-08-01 (modification)

• hydroxyhomoDestruxin B, submitted on 2008-08-01 (modification)

• hydroxyDestruxin B, submitted on 2008-08-01 (modification)

• homoDestruxin B, submitted on 2008-08-01 (modification)

• destruxin E diol, submitted on 2008-08-01 (modification)

• destruxin E chlorohydrin, submitted on 2008-08-01 (modification)

• destruxin E2 chlorohydrin, submitted on 2008-08-01 (modification)

• destruxin E2, submitted on 2008-08-01 (modification)

• destruxin E1, submitted on 2008-08-01 (modification)

• destruxin E, submitted on 2008-08-01 (modification)

• destruxin D2, submitted on 2008-08-01 (modification)

• destruxin D1, submitted on 2008-08-01 (modification)

• destruxin D, submitted on 2008-08-01 (modification)

• destruxin C, submitted on 2008-08-01 (modification)

• destruxin C2, submitted on 2008-08-01 (modification)

• destruxin B2, submitted on 2008-08-01 (modification)

• destruxin B1, submitted on 2008-08-01 (modification)

• destruxin B, submitted on 2008-08-01 (modification)
  

• enduracidin A, submitted on 2008-08-01 (modification)

  Ramoplanin is known to show a similar primary structure than enduracidins.

• empedopeptin, submitted on 2008-08-01 (modification)

  empedopeptin is a putative NRPS product (no synthetase genes identified).

• edeine F, submitted on 2008-08-01 (modification)

• edeine D, submitted on 2008-08-01 (modification)
  

• edeine B, submitted on 2008-08-01 (modification)

• edeine A, submitted on 2008-08-01 (modification)

• discodermin H, submitted on 2008-08-01 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discodermin G, submitted on 2008-08-01 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discodermin F, submitted on 2008-08-01 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discodermin A, submitted on 2008-08-01 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• nordidemnin N, submitted on 2008-08-01 (modification)

• destruxin F, submitted on 2008-08-01 (creation)

• enduracidin B, submitted on 2008-08-01 (creation)

  Ramoplanin is known to show a similar primary structure than enduracidins.

• cyclotheonamide A, submitted on 2008-07-31 (modification)

• cyclosporin 32, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin W, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin H, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin G, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin F, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin D, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin C, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin B, submitted on 2008-07-31 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclonellin, submitted on 2008-07-31 (modification)

  cyclonellin is a putative NRPS product (no synthetase genes identified).

• corticiamide A, submitted on 2008-07-31 (modification)

  Corticiamide A is a putative NRPS product (no synthetase genes identified). The absolute stereochemistry was not determined.

• cyclocinamide B, submitted on 2008-07-31 (modification)

  Cyclocinamide is a putative NRPS product (no synthetase genes identified)

• destruxin A4 chlorohydrin, submitted on 2008-07-31 (modification)

• destruxin A4, submitted on 2008-07-31 (modification)

• destruxin A3, submitted on 2008-07-31 (modification)

• destruxin A2, submitted on 2008-07-31 (modification)

• destruxin A1, submitted on 2008-07-31 (modification)

• destruxin A, submitted on 2008-07-31 (modification)

• desmethylDestruxin C, submitted on 2008-07-31 (modification)

• desmethylDestruxin B2, submitted on 2008-07-31 (modification)

• desmethylDestruxin B, submitted on 2008-07-31 (modification)

• desmethylDestruxin A, submitted on 2008-07-31 (modification)

• beta-D-Glucopyranosyl-hydroxyDestruxin B, submitted on 2008-07-31 (modification)

• A21978C3, submitted on 2008-07-31 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• cyclotheonamide E5, submitted on 2008-07-31 (modification)

• cyclotheonamide B, submitted on 2008-07-31 (modification)

• A21978C2, submitted on 2008-07-31 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• A21978C1, submitted on 2008-07-31 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• daptomycin, submitted on 2008-07-31 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• A21978C2, submitted on 2008-07-31 (creation)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• desmethylDestruxin B, submitted on 2008-07-31 (creation)

• corticiamide A, submitted on 2008-07-31 (creation)

  Corticiamide A is a putative NRPS product (no synthetase genes identified). The absolute stereochemistry was not determined.

• cyclocinamide B, submitted on 2008-07-31 (creation)

  Cyclocinamide is a putative NRPS product (no synthetase genes identified)

• A21978C3, submitted on 2008-07-31 (creation)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• A21978C1, submitted on 2008-07-31 (creation)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• CDA2fb, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• astin B, submitted on 2008-07-30 (modification)

• hydroxycyclochlorotine, submitted on 2008-07-30 (modification)

• cyclochlorotine, submitted on 2008-07-30 (modification)

• corrugatin, submitted on 2008-07-30 (modification)

• N-coronafacoyl-L-threonine, submitted on 2008-07-30 (modification)

• N-coronafacoyl-L-serine, submitted on 2008-07-30 (modification)

• N-coronafacoyl-L-alloisoleucine, submitted on 2008-07-30 (modification)

• N-coronafacoyl-L-isoleucine, submitted on 2008-07-30 (modification)

• N-coronafacoyl-L-valine, submitted on 2008-07-30 (modification)

• norcoronatine, submitted on 2008-07-30 (modification)

• norcoronatine, submitted on 2008-07-30 (modification)

• coronatine, submitted on 2008-07-30 (modification)

  Coronatine contributes to virulence in several host-pathogen interactions and elicits diffuse chlorosis in a wide variety of plant species and also induces hypertrophy, inhibits root elongation, and stimulates ethylene production.

• chrysobactin, submitted on 2008-07-30 (modification)

• carmabin B, submitted on 2008-07-30 (modification)

  Carmabin is a putative NRPS product (no synthetase genes identified).

• carmabin A, submitted on 2008-07-30 (modification)

  Carmabin is a putative NRPS product (no synthetase genes identified).

• neamphamide A, submitted on 2008-07-30 (modification)

  Neamphamide A is a putative NRPS product (no synthetase genes identified).

• callipeltin M, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin L, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin K, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin J, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin I, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin H, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin G, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin F, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin E, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin D, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin C, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin B, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin A, submitted on 2008-07-30 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• CDA4b, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA4a, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA3b, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA3a, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2fa, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2d, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2b, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2a, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA1b, submitted on 2008-07-30 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• callipeltin F, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin G, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin H, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin I, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin J, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin K, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin L, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin M, submitted on 2008-07-30 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• N-coronafacoyl-L-valine, submitted on 2008-07-30 (creation)

• N-coronafacoyl-L-isoleucine, submitted on 2008-07-30 (creation)

• N-coronafacoyl-L-alloisoleucine, submitted on 2008-07-30 (creation)

• N-coronafacoyl-L-serine, submitted on 2008-07-30 (creation)

• N-coronafacoyl-L-threonine, submitted on 2008-07-30 (creation)

• hydroxycyclochlorotine, submitted on 2008-07-30 (creation)

• astin B, submitted on 2008-07-30 (creation)

• beauverolide F, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide VIII, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide VII, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide VI, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide V, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide IV, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide N, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide M, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ka, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ja, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide H, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Fa, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ea, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide E, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide D, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ca, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide C, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ba, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide B, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide A, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide III, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide II, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide La, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide L, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide i, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide I, submitted on 2008-07-28 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aurilide C, submitted on 2008-07-28 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• aurilide B, submitted on 2008-07-28 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• aurilide, submitted on 2008-07-28 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• aquachelin D, submitted on 2008-07-28 (modification)

  4 variants which differ on the fatty acid moiety are encountered.

• aquachelin C, submitted on 2008-07-28 (modification)

  4 variants which differ on the fatty acid moiety are encountered.

• aquachelin B, submitted on 2008-07-28 (modification)

  4 variants which differ on the fatty acid moiety are encountered.

• aquachelin A, submitted on 2008-07-28 (modification)

  4 variants which differ on the fatty acid moiety are encountered.

• apramide G, submitted on 2008-07-28 (modification)

  Apramides are putative NRPS products (no synthetase genes identified).

• apramide F, submitted on 2008-07-28 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• apramide E, submitted on 2008-07-28 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• apramide D, submitted on 2008-07-28 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• apramide C, submitted on 2008-07-28 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• apramide B, submitted on 2008-07-28 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• apramide A, submitted on 2008-07-28 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• moiramide B, submitted on 2008-07-28 (modification)

  The pseudopeptide pyrrolidinedione natural products moiramide B and andrimid represent a new class of antibiotics that target bacterial fatty acid biosynthesis.

• andrimid, submitted on 2008-07-28 (modification)

  andrimid is a NRPS-PKS product. Moiramide differs on the fatty acid moiety.

• tensin, submitted on 2008-07-28 (modification)

  The peptide shows structural resemblance to the non-ribosomal cyclic lipopeptide fengycin from Bacillus subtilis.

• pholipeptin, submitted on 2008-07-28 (modification)

  Pholipeptin inhibited PI-PLC of human carcinoma A431 cells.

• lokisin, submitted on 2008-07-28 (modification)

  Anikasin is a synonymous of lokisin. Only anikasin structure was experimentally elucidated.

• arthrofactin, submitted on 2008-07-28 (modification)

  Arthrofactin was found to be five to seven times more effective than surfactin.

• amphisin, submitted on 2008-07-28 (modification)

  Amphisin is a close analogue of the cyclic lipopeptides tensin and pholipeptin produced by Pseudomonas fluorescens.

• beauverolide V, submitted on 2008-07-28 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• apramide B, submitted on 2008-07-28 (creation)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• beauverolide VI, submitted on 2008-07-28 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aquachelin B, submitted on 2008-07-28 (creation)

  4 variants which differ on the fatty acid moiety are encountered.

• beauverolide VII, submitted on 2008-07-28 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• apramide E, submitted on 2008-07-28 (creation)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• beauverolide VIII, submitted on 2008-07-28 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• moiramide B, submitted on 2008-07-28 (creation)

  The pseudopeptide pyrrolidinedione natural products moiramide B and andrimid represent a new class of antibiotics that target bacterial fatty acid biosynthesis.

• apramide C, submitted on 2008-07-28 (creation)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• aquachelin C, submitted on 2008-07-28 (creation)

  4 variants which differ on the fatty acid moiety are encountered.

• aquachelin D, submitted on 2008-07-28 (creation)

  4 variants which differ on the fatty acid moiety are encountered.

• apramide F, submitted on 2008-07-28 (creation)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• beauverolide IV, submitted on 2008-07-28 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aciculitin C, submitted on 2008-07-25 (modification)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• A54145 B, submitted on 2008-07-25 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 A1, submitted on 2008-07-25 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 D, submitted on 2008-07-25 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• amphibactin I, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin H, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin G, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin F, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin E, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin D, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin C, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin B, submitted on 2008-07-25 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• aciculitin A, submitted on 2008-07-25 (modification)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• aciculitin B, submitted on 2008-07-25 (modification)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• A54145 F, submitted on 2008-07-25 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 C, submitted on 2008-07-25 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 E, submitted on 2008-07-25 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 B1, submitted on 2008-07-25 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• amphibactin I, submitted on 2008-07-25 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin C, submitted on 2008-07-25 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• aciculitin B, submitted on 2008-07-25 (creation)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• aciculitin C, submitted on 2008-07-25 (creation)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• A54145 A1, submitted on 2008-07-25 (creation)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 D, submitted on 2008-07-25 (creation)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• amphibactin F, submitted on 2008-07-25 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• A54145 B1, submitted on 2008-07-25 (creation)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• amphibactin E, submitted on 2008-07-25 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin G, submitted on 2008-07-25 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• A54145 E, submitted on 2008-07-25 (creation)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• amphibactin H, submitted on 2008-07-25 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphibactin D, submitted on 2008-07-25 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• A54145 A, submitted on 2008-07-24 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• CDA2d, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• beauvericin, submitted on 2008-07-21 (modification)

  This antibiotic is active against Gram-positive bacteria and mycobacteria, as well against insects.

• CDA2b, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• cereulide, submitted on 2008-07-21 (modification)

• beauvericin A, submitted on 2008-07-21 (modification)

  Isomery from pubChem entry 3010885

• beauvericin B, submitted on 2008-07-21 (modification)

• beauverolide L, submitted on 2008-07-21 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauvericin E, submitted on 2008-07-21 (modification)

• ceratospongamide, submitted on 2008-07-21 (modification)

  Ceratospongamide is a putative NRPS product (no synthetase genes identified)

• beauverolide i, submitted on 2008-07-21 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide III, submitted on 2008-07-21 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauvericin E, submitted on 2008-07-21 (modification)

• CDA4a, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA4b, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2fb, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2fa, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2a, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• beauverolide La, submitted on 2008-07-21 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• CDA3a, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA1b, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• beauvericin C, submitted on 2008-07-21 (modification)

• CDA3b, submitted on 2008-07-21 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• beauvericin B, submitted on 2008-07-21 (creation)

• beauvericin C, submitted on 2008-07-21 (creation)

• AM-toxin I, submitted on 2008-07-15 (modification)

• A54145 A, submitted on 2008-07-15 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 B, submitted on 2008-07-15 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 C, submitted on 2008-07-15 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 F, submitted on 2008-07-15 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• aciculitin A, submitted on 2008-07-15 (modification)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• actinomycin I, submitted on 2008-07-15 (modification)

• actinomycin Z1, submitted on 2008-07-15 (modification)

• actinomycin Z2, submitted on 2008-07-15 (modification)

• actinomycin Z3, submitted on 2008-07-15 (modification)

• actinomycin Z4, submitted on 2008-07-15 (modification)

• actinomycin Z5, submitted on 2008-07-15 (modification)

• amphibactin B, submitted on 2008-07-15 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• amphisin, submitted on 2008-07-15 (modification)

  Amphisin is a close analogue of the cyclic lipopeptides tensin and pholipeptin produced by Pseudomonas fluorescens.

• arthrofactin, submitted on 2008-07-15 (modification)

  Arthrofactin was found to be five to seven times more effective than surfactin.

• lokisin, submitted on 2008-07-15 (modification)

  Anikasin is a synonymous of lokisin. Only anikasin structure was experimentally elucidated.

• pholipeptin, submitted on 2008-07-15 (modification)

  Pholipeptin inhibited PI-PLC of human carcinoma A431 cells.

• tensin, submitted on 2008-07-15 (modification)

  The peptide shows structural resemblance to the non-ribosomal cyclic lipopeptide fengycin from Bacillus subtilis.

• AM-toxin II, submitted on 2008-07-15 (modification)

• AM-toxin III, submitted on 2008-07-15 (modification)

• anabaenopeptilide 90B, submitted on 2008-07-15 (modification)

• anabaenopeptin A, submitted on 2008-07-15 (modification)

• aquachelin A, submitted on 2008-07-15 (modification)

  4 variants which differ on the fatty acid moiety are encountered.

• aureobasidin A, submitted on 2008-07-15 (modification)

• aureobasidin B, submitted on 2008-07-15 (modification)
  

• aureobasidin E, submitted on 2008-07-15 (modification)

• aureobasidin G, submitted on 2008-07-15 (modification)

• aurilide B, submitted on 2008-07-15 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• aurilide C, submitted on 2008-07-15 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• axinellin C, submitted on 2008-07-15 (modification)

  axinellin is a putative NRPS product (no synthetase genes identified)

• bacillibactin, submitted on 2008-07-15 (modification)

• bacilysin, submitted on 2008-07-15 (modification)

  Some experimental results indicated that the mechanism of bacilysin biosynthesis is not typical of the general multicarrier thiotemplate model.

• amphomycin A1437 A, submitted on 2008-06-13 (modification)

  The acyl residue is essential for antibiotic activity.

• ureido-balhimycin, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• MM49721, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• rhamnosyl-balhimycin, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• methylbalhimycin, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• demethylbalhimycin, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• deglucobalhimycin, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• dechloro-balhimycin V, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin D, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin C, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin B, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin A, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• OA7653, submitted on 2007-05-25 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• dechloro-balhimycin V, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• OA7653, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• ureido-balhimycin, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin D, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• rhamnosyl-balhimycin, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin A, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• methylbalhimycin, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin C, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• demethylbalhimycin, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• MM49721, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• deglucobalhimycin, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• orienticin B, submitted on 2007-05-25 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• BT1583, submitted on 2007-02-12 (modification)

• MM47761, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43F, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43D, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43C, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43B, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43A, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• eremomycin, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• decaplanin, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin E, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin D, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin C, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin B, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin A, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• balhimycin V, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• balhimycin, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• A83850, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• A51568, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• A42867, submitted on 2007-02-12 (modification)

  Two bonds of the central Hpg are due to oxidative ring closure.

• vancomycin, submitted on 2007-02-12 (modification)

  Vancomycin is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of "last resort", used only after treatment with other antibiotics had failed, although the emergence of vancomycin-resistant organisms means that it is increasingly being displaced from this role by linezolid and the carbapenems. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• chloroorienticin D, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• A42867, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• MM47761, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin C, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43F, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• A83850, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43D, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin B, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43C, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• BT1583, submitted on 2007-02-12 (creation)

• M43B, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• chloroorienticin A, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• M43A, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• A51568, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• eremomycin, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• balhimycin V, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• decaplanin, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• vancomycin, submitted on 2007-02-12 (creation)

  Vancomycin is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of "last resort", used only after treatment with other antibiotics had failed, although the emergence of vancomycin-resistant organisms means that it is increasingly being displaced from this role by linezolid and the carbapenems. Two bonds of the central Hpg are due to oxidative ring closure reactions.

• chloroorienticin E, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• balhimycin, submitted on 2007-02-12 (creation)

  Two bonds of the central Hpg are due to oxidative ring closure.

• majusculamide C, submitted on 2006-11-20 (modification)

  Majusculamide C is a putative NRPS product (no synthetase genes identified)

• virginiamycin S, submitted on 2006-11-20 (modification)

  Virginiamycin S is a member of the streptogramin B group.

• pristinamycin IC, submitted on 2006-11-20 (modification)

  Pristinamycins I are members of the streptogramin B group.

• pristinamycin IB, submitted on 2006-11-20 (modification)

  Pristinamycins I are members of the streptogramin B group.

• pristinamycin IA, submitted on 2006-11-20 (modification)

  Pristinamycins I are members of the streptogramin B group.

• neoviridogrisein III, submitted on 2006-11-20 (modification)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• neoviridogrisein II, submitted on 2006-11-20 (modification)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• neoviridogrisein I, submitted on 2006-11-20 (modification)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• viridogrisein, submitted on 2006-11-20 (modification)

  Etamycin is a putative NRPS product (no synthetase genes identified).

• phosphinothricin tripeptide, submitted on 2006-11-20 (modification)

• edeine F, submitted on 2006-11-20 (modification)

• edeine D, submitted on 2006-11-20 (modification)
  

• edeine B, submitted on 2006-11-20 (modification)

• edeine A, submitted on 2006-11-20 (modification)

• antipain, submitted on 2006-11-20 (modification)

  Antipain is a putative NRPS product (no synthetase genes identified).

• nocardicin A, submitted on 2006-11-20 (modification)

• ramoplanin A1, submitted on 2006-11-20 (modification)

  Ramoplanin factors A1, A2, and A3 were isolated in 12, 72, and 16% yields, respectively, from purification of the culture broth of Actinoplanes strain ATCC 33076.

• enduracidin A, submitted on 2006-11-20 (modification)

  Ramoplanin is known to show a similar primary structure than enduracidins.

• mycobacillin, submitted on 2006-11-20 (modification)

• montanastatin, submitted on 2006-11-20 (modification)

  Montanastatin is a putative NRPS product (no synthetase genes identified).

• valinomycin, submitted on 2006-11-20 (modification)

  Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.

• gratisin, submitted on 2006-11-20 (modification)

  Gratisin is a putative NRPS product (no synthetase genes identified).

• cereulide, submitted on 2006-11-20 (modification)

• lysobactin, submitted on 2006-11-20 (modification)

• plusbacin B1, submitted on 2006-11-20 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• plusbacin A1, submitted on 2006-11-20 (modification)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• tripropeptin A, submitted on 2006-11-20 (modification)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• empedopeptin, submitted on 2006-11-20 (modification)

  empedopeptin is a putative NRPS product (no synthetase genes identified).

• isaridin A, submitted on 2006-11-20 (modification)

  Isaridins are putative NRPS products (no synthetase genes identified).

• isaridin B, submitted on 2006-11-20 (modification)

  Isaridins are putative NRPS products (no synthetase genes identified).

• isariin, submitted on 2006-11-20 (modification)

  Isariins are putative NRPS products (no synthetase genes identified).

• SF-1902 A3, submitted on 2006-11-20 (modification)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• globomycin, submitted on 2006-11-20 (modification)

  Globomycin is a putative NRPS product (no synthetase genes identified).

• kulomo opunalide 1, submitted on 2006-11-20 (modification)

  Kulomo opunalide is a putative NRPS product (no synthetase genes identified).

• pupukeamide, submitted on 2006-11-20 (modification)

  Pupukeamide is a putative NRPS product (no synthetase genes identified)

• kulokainalide, submitted on 2006-11-20 (modification)

  kulokainalide is a putative NRPS product (no synthetase genes identified)

• kulolide 1, submitted on 2006-11-20 (modification)

  kulolides are putative NRPS products (no synthetase genes identified).

• capreomycin IIB, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• capreomycin IIA, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• capreomycin IB, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• capreomycin IA, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• tuberactinamine, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• tuberactinomycin O, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• tuberactinomycin N, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• tuberactinomycin A, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• viomycin, submitted on 2006-11-20 (modification)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• allomalformin, submitted on 2006-11-20 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin B2, submitted on 2006-11-20 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin C, submitted on 2006-11-20 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin B1, submitted on 2006-11-20 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin A2, submitted on 2006-11-20 (modification)

  The two cysteins have a disulfide bridge between them.

• malformin A1, submitted on 2006-11-20 (modification)

  The two cysteins have a disulfide bridge between them.

• cyclochlorotine, submitted on 2006-11-20 (modification)

• bottromycin A2, submitted on 2006-11-20 (modification)

  3Me-Phe -> bMe-Phe

• tentoxin, submitted on 2006-11-20 (modification)

• chlamydocin, submitted on 2006-11-20 (modification)

  Chlamydocin is a putative NRPS product (no synthetase genes identified)

• foroxymithine, submitted on 2006-11-20 (modification)

  Foroxymithine is a putative NRPS product (no synthetase genes identified) and inhibits angiotensin I converting enzyme.

• tuberactinomycin N, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• isaridin B, submitted on 2006-11-20 (creation)

  Isaridins are putative NRPS products (no synthetase genes identified).

• virginiamycin S, submitted on 2006-11-20 (creation)

  Virginiamycin S is a member of the streptogramin B group.

• tentoxin, submitted on 2006-11-20 (creation)

• pristinamycin IC, submitted on 2006-11-20 (creation)

  Pristinamycins I are members of the streptogramin B group.

• isariin, submitted on 2006-11-20 (creation)

  Isariins are putative NRPS products (no synthetase genes identified).

• pristinamycin IB, submitted on 2006-11-20 (creation)

  Pristinamycins I are members of the streptogramin B group.

• tuberactinomycin A, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• pristinamycin IA, submitted on 2006-11-20 (creation)

  Pristinamycins I are members of the streptogramin B group.

• SF-1902 A3, submitted on 2006-11-20 (creation)

  SF-1902 are putative NRPS products (no synthetase genes identified).

• neoviridogrisein III, submitted on 2006-11-20 (creation)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• malformin A1, submitted on 2006-11-20 (creation)

  The two cysteins have a disulfide bridge between them.

• neoviridogrisein II, submitted on 2006-11-20 (creation)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• globomycin, submitted on 2006-11-20 (creation)

  Globomycin is a putative NRPS product (no synthetase genes identified).

• neoviridogrisein I, submitted on 2006-11-20 (creation)

  Neoviridogriseins are putative NRPS products (no synthetase genes identified).

• viomycin, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• viridogrisein, submitted on 2006-11-20 (creation)

  Etamycin is a putative NRPS product (no synthetase genes identified).

• kulomo opunalide 1, submitted on 2006-11-20 (creation)

  Kulomo opunalide is a putative NRPS product (no synthetase genes identified).

• phosphinothricin tripeptide, submitted on 2006-11-20 (creation)

• foroxymithine, submitted on 2006-11-20 (creation)

  Foroxymithine is a putative NRPS product (no synthetase genes identified) and inhibits angiotensin I converting enzyme.

• edeine F, submitted on 2006-11-20 (creation)

• pupukeamide, submitted on 2006-11-20 (creation)

  Pupukeamide is a putative NRPS product (no synthetase genes identified)

• edeine D, submitted on 2006-11-20 (creation)
  
• allomalformin, submitted on 2006-11-20 (creation)

  The two cysteins have a disulfide bridge between them.

• edeine B, submitted on 2006-11-20 (creation)

• kulokainalide, submitted on 2006-11-20 (creation)

  kulokainalide is a putative NRPS product (no synthetase genes identified)

• edeine A, submitted on 2006-11-20 (creation)

• cyclochlorotine, submitted on 2006-11-20 (creation)

• antipain, submitted on 2006-11-20 (creation)

  Antipain is a putative NRPS product (no synthetase genes identified).

• kulolide 1, submitted on 2006-11-20 (creation)

  kulolides are putative NRPS products (no synthetase genes identified).

• nocardicin A, submitted on 2006-11-20 (creation)

• malformin B2, submitted on 2006-11-20 (creation)

  The two cysteins have a disulfide bridge between them.

• ramoplanin A1, submitted on 2006-11-20 (creation)

  Ramoplanin factors A1, A2, and A3 were isolated in 12, 72, and 16% yields, respectively, from purification of the culture broth of Actinoplanes strain ATCC 33076.

• capreomycin IIB, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• enduracidin A, submitted on 2006-11-20 (creation)

  Ramoplanin is known to show a similar primary structure than enduracidins.

• chlamydocin, submitted on 2006-11-20 (creation)

  Chlamydocin is a putative NRPS product (no synthetase genes identified)

• mycobacillin, submitted on 2006-11-20 (creation)

• capreomycin IIA, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• montanastatin, submitted on 2006-11-20 (creation)

  Montanastatin is a putative NRPS product (no synthetase genes identified).

• malformin C, submitted on 2006-11-20 (creation)

  The two cysteins have a disulfide bridge between them.

• valinomycin, submitted on 2006-11-20 (creation)

  Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.

• capreomycin IB, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• gratisin, submitted on 2006-11-20 (creation)

  Gratisin is a putative NRPS product (no synthetase genes identified).

• bottromycin A2, submitted on 2006-11-20 (creation)

  3Me-Phe -> bMe-Phe

• cereulide, submitted on 2006-11-20 (creation)

• capreomycin IA, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• lysobactin, submitted on 2006-11-20 (creation)

• malformin B1, submitted on 2006-11-20 (creation)

  The two cysteins have a disulfide bridge between them.

• plusbacin B1, submitted on 2006-11-20 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• tuberactinamine, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• plusbacin A1, submitted on 2006-11-20 (creation)

  Plusbacins are putative NRPS products (no synthetase genes identified).

• majusculamide C, submitted on 2006-11-20 (creation)

  Majusculamide C is a putative NRPS product (no synthetase genes identified)

• tripropeptin A, submitted on 2006-11-20 (creation)

  Tripropeptins are putative NRPS products (no synthetase genes identified).

• tuberactinomycin O, submitted on 2006-11-20 (creation)

  The tuberactinomycin antibiotics are essential components in the drug arsenal against Mycobacterium tuberculosis infections and are specifically used for the treatment of multidrug-resistant tuberculosis.

• empedopeptin, submitted on 2006-11-20 (creation)

  empedopeptin is a putative NRPS product (no synthetase genes identified).

• malformin A2, submitted on 2006-11-20 (creation)

  The two cysteins have a disulfide bridge between them.

• isaridin A, submitted on 2006-11-20 (creation)

  Isaridins are putative NRPS products (no synthetase genes identified).

• ornibactin C4, submitted on 2006-11-06 (modification)

• geodiamolide K, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide J, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide G, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• neosiphoniamolide A, submitted on 2006-11-06 (modification)

  Neosiphoniamolide A is a putative NRPS product (no synthetase genes identified)

• geodiamolide TA, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide R, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide Q, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide P, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide O, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide N, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide M, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide L, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide F, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide E, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide D, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide C, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide B, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide A, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide I, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• geodiamolide H, submitted on 2006-11-06 (modification)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• aciculitin A, submitted on 2006-11-06 (modification)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• cyclocinamide A, submitted on 2006-11-06 (modification)

  Cyclocinamide is a putative NRPS product (no synthetase genes identified)

• oriamide, submitted on 2006-11-06 (modification)
  

• discobahamin B, submitted on 2006-11-06 (modification)

  Discobahamins are putative NRPS products (no synthetase genes identified)

• discobahamin A, submitted on 2006-11-06 (modification)

  Discobahamins are putative NRPS products (no synthetase genes identified)

• orbiculamide A, submitted on 2006-11-06 (modification)

  Orbiculamide A is a putative NRPS product (no synthetase genes identified)

• keramamide N, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide M, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide D, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide C, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide B, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide E, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide J, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide H, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide G, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide F, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide K, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide L, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• keramamide A, submitted on 2006-11-06 (modification)

  Keramamides are putative NRPS products (no synthetase genes identified)

• mozamide B, submitted on 2006-11-06 (modification)

  Mozamides are putative NRPS products (no synthetase genes identified)

• mozamide A, submitted on 2006-11-06 (modification)

  Mozamides are putative NRPS products (no synthetase genes identified)

• konbamide, submitted on 2006-11-06 (modification)

  Konbamide is a putative NRPS product (no synthetase genes identified)

• ceratospongamide, submitted on 2006-11-06 (modification)

  Ceratospongamide is a putative NRPS product (no synthetase genes identified)

• haligramide B, submitted on 2006-11-06 (modification)

  haligramides are putative NRPS products (no synthetase genes identified)

• haligramide A, submitted on 2006-11-06 (modification)

  haligramides are putative NRPS products (no synthetase genes identified)

• waiakeamide, submitted on 2006-11-06 (modification)

  Waiakeamide is a putative NRPS product (no synthetase genes identified)

• cupolamide A, submitted on 2006-11-06 (modification)

  Cupolamide A is a putative NRPS product (no synthetase genes identified)

• perthamide B, submitted on 2006-11-06 (modification)

  Perthamide B is a putative NRPS product (no synthetase genes identified)

• theopalauamide, submitted on 2006-11-06 (modification)

  Theopalauamide is a putative NRPS product (no synthetase genes identified)

• theonegramide, submitted on 2006-11-06 (modification)

  Theonegramide is a putative NRPS product (no synthetase genes identified)

• theonellamide F, submitted on 2006-11-06 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• theonellamide E, submitted on 2006-11-06 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• theonellamide D, submitted on 2006-11-06 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• theonellamide C, submitted on 2006-11-06 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• theonellamide B, submitted on 2006-11-06 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• theonellamide A, submitted on 2006-11-06 (modification)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• barangamide D, submitted on 2006-11-06 (modification)

  Barangamides are putative NRPS products (no synthetase genes identified)

• barangamide C, submitted on 2006-11-06 (modification)

  Barangamides are putative NRPS products (no synthetase genes identified)

• barangamide B, submitted on 2006-11-06 (modification)

  Barangamides are putative NRPS products (no synthetase genes identified)

• barangamide A, submitted on 2006-11-06 (modification)

  Barangamides are putative NRPS products (no synthetase genes identified)

• cyclolinopeptide A, submitted on 2006-11-06 (modification)

  Cyclolinopeptide was isolated from acetone extracts of linseed oil and its solid residues.Cyclolinopeptides are putative NRPS products (no synthetase genes identified)

• microsclerodermin I, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin H, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin G, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin F, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin E, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin D, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin C, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin B, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• microsclerodermin A, submitted on 2006-11-06 (modification)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• wainunuamide, submitted on 2006-11-06 (modification)

  Wainunuamide is a putative NRPS product (no synthetase genes identified)

• stylostatin 1, submitted on 2006-11-06 (modification)

  Stylostatin is a putative NRPS product (no synthetase genes identified)

• stylopeptide I, submitted on 2006-11-06 (modification)

  Stylopeptide is a putative NRPS product (no synthetase genes identified)

• hymenistatin I, submitted on 2006-11-06 (modification)

  Hymenistatin is a putative NRPS product (no synthetase genes identified)

• hymenamide K, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide J, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide H, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide G, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide F, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide E, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide D, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide C, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide B, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• hymenamide A, submitted on 2006-11-06 (modification)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• phakellistatin 14, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 13, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 12, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 11, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 10, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 9, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 8, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 7, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 6, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 5, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 4, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 3, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 2, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• phakellistatin 1, submitted on 2006-11-06 (modification)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• axinellin C, submitted on 2006-11-06 (modification)

  axinellin is a putative NRPS product (no synthetase genes identified)

• axinellin B, submitted on 2006-11-06 (modification)

  axinellin is a putative NRPS product (no synthetase genes identified)

• axinellin A, submitted on 2006-11-06 (modification)

  axinellin is a putative NRPS product (no synthetase genes identified)

• axinastatin 5, submitted on 2006-11-06 (modification)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• axinastatin 4, submitted on 2006-11-06 (modification)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• axinastatin 3, submitted on 2006-11-06 (modification)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• axinastatin 2, submitted on 2006-11-06 (modification)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• axinastatin 1, submitted on 2006-11-06 (modification)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• pallidin, submitted on 2006-11-06 (modification)

  pallidin is a putative NRPS product (no synthetase genes identified)

• dysamide Q, submitted on 2006-11-06 (modification)

  Dysamdes Q,R,S and T are isomers.Dysamides are putative NRPS products (no synthetase genes identified)

• dysamide P, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• dysamide O, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• dysamide N, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• dysamide M, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• dysamide K, submitted on 2006-11-06 (modification)

  Dysamides K and L are isomers.Dysamides are putative NRPS products (no synthetase genes identified)

• dysamide D, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• dyhydrodysamide C, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• dysamide C, submitted on 2006-11-06 (modification)

  Dysamide C and D are isomers.Dysamides are putative NRPS products (no synthetase genes identified)

• dysamide B, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• dysamide A, submitted on 2006-11-06 (modification)

  dysamides are putative NRPS products (no synthetase genes identified)

• theonellapeptolide IIIe, submitted on 2006-11-06 (modification)

• theonellapeptolide IIe, submitted on 2006-11-06 (modification)

• theonellapeptolide IId, submitted on 2006-11-06 (modification)

• theonellapeptolide Ie, submitted on 2006-11-06 (modification)

• theonellapeptolide Id, submitted on 2006-11-06 (modification)

• theonellapeptolide Ia, submitted on 2006-11-06 (modification)

• halicylindramide E, submitted on 2006-11-06 (modification)

• halicylindramide D, submitted on 2006-11-06 (modification)

• halicylindramide C, submitted on 2006-11-06 (modification)

• halicylindramide B, submitted on 2006-11-06 (modification)

• halicylindramide A, submitted on 2006-11-06 (modification)

• koshikamide A2, submitted on 2006-11-06 (modification)

• koshikamide A1, submitted on 2006-11-06 (modification)

  Adding of the SMILES and modification of the references

• nazumamide A, submitted on 2006-11-06 (modification)

• miraziridine A, submitted on 2006-11-06 (modification)

• leupeptin, submitted on 2006-11-06 (modification)

• tokaramide A, submitted on 2006-11-06 (modification)

• andrimid, submitted on 2006-11-06 (modification)

  andrimid is a NRPS-PKS product. Moiramide differs on the fatty acid moiety.

• kapakahine G, submitted on 2006-11-06 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine F, submitted on 2006-11-06 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine E, submitted on 2006-11-06 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine B, submitted on 2006-11-06 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• kapakahine A, submitted on 2006-11-06 (modification)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.Kapakahines C and D differ from A by the addition of the elements of H2O to the indole double bond of Trp-1 together with the formation of a bond between C-4 and N-1.

• cyclotheonamide E5, submitted on 2006-11-06 (modification)

• cyclotheonamide E4, submitted on 2006-11-06 (modification)

• cyclotheonamide E3, submitted on 2006-11-06 (modification)

• cyclotheonamide E2, submitted on 2006-11-06 (modification)

• cyclotheonamide E, submitted on 2006-11-06 (modification)

• cyclotheonamide D, submitted on 2006-11-06 (modification)

• cyclotheonamide C, submitted on 2006-11-06 (modification)

• cyclotheonamide B, submitted on 2006-11-06 (modification)

• cyclotheonamide A, submitted on 2006-11-06 (modification)

• dihydrocyclotheonamide A, submitted on 2006-11-06 (modification)

• pseudotheonamide D, submitted on 2006-11-06 (modification)

• pseudotheonamide C, submitted on 2006-11-06 (modification)

• pseudotheonamide A1, submitted on 2006-11-06 (modification)

• renieramide, submitted on 2006-11-06 (modification)

• eurypamide D, submitted on 2006-11-06 (modification)

• eurypamide C, submitted on 2006-11-06 (modification)

• eurypamide B, submitted on 2006-11-06 (modification)

• eurypamide A, submitted on 2006-11-06 (modification)

• criamide B, submitted on 2006-11-06 (modification)

• criamide A, submitted on 2006-11-06 (modification)

• hemiasterlin C, submitted on 2006-11-06 (modification)

• hemiasterlin B, submitted on 2006-11-06 (modification)

• hemiasterlin A, submitted on 2006-11-06 (modification)

• hemiasterlin, submitted on 2006-11-06 (modification)

• halipeptin D, submitted on 2006-11-06 (modification)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• halipeptin C, submitted on 2006-11-06 (modification)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• halipeptin B, submitted on 2006-11-06 (modification)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• halipeptin A, submitted on 2006-11-06 (modification)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• discodermin H, submitted on 2006-11-06 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discodermin G, submitted on 2006-11-06 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discodermin F, submitted on 2006-11-06 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discodermin E, submitted on 2006-11-06 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discodermin A, submitted on 2006-11-06 (modification)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• polydiscamide A, submitted on 2006-11-06 (modification)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• microspinosamide, submitted on 2006-11-06 (modification)

  Microspinosamide is a putative NRPS product (no synthetase genes identified).

• cyclolithistide A, submitted on 2006-11-06 (modification)

  Cyclolithistide A is a putative NRPS product (no synthetase genes identified).

• phoriospongin B, submitted on 2006-11-06 (modification)

  Phoriospongins are nematocidal depsipeptides and are putative NRPS products (no synthetase genes identified).

• phoriospongin A, submitted on 2006-11-06 (modification)

  Phoriospongins are nematocidal depsipeptides and are putative NRPS products (no synthetase genes identified).

• nagahamide A, submitted on 2006-11-06 (modification)

  Nagahamide A is a putative NRPS product (no synthetase genes identified).

• obyanamide, submitted on 2006-11-06 (modification)

  Obyanamide is a putative NRPS product (no synthetase genes identified).

• guineamide F, submitted on 2006-11-06 (modification)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• guineamide E, submitted on 2006-11-06 (modification)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• guineamide D, submitted on 2006-11-06 (modification)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• guineamide C, submitted on 2006-11-06 (modification)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• guineamide B, submitted on 2006-11-06 (modification)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• guineamide A, submitted on 2006-11-06 (modification)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• carmabin B, submitted on 2006-11-06 (modification)

  Carmabin is a putative NRPS product (no synthetase genes identified).

• carmabin A, submitted on 2006-11-06 (modification)

  Carmabin is a putative NRPS product (no synthetase genes identified).

• onchidin B, submitted on 2006-11-06 (modification)

  onchidin B is a putative NRPS product (no synthetase genes identified).

• onchidin, submitted on 2006-11-06 (modification)

  onchidin is a putative NRPS product (no synthetase genes identified).

• aurilide C, submitted on 2006-11-06 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• aurilide B, submitted on 2006-11-06 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• aurilide, submitted on 2006-11-06 (modification)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• gymnangiamide, submitted on 2006-11-06 (modification)

  Gymnangiamide is a putative NRPS product (no synthetase genes identified).

• papuamide D, submitted on 2006-11-06 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• papuamide C, submitted on 2006-11-06 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• papuamide B, submitted on 2006-11-06 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• papuamide A, submitted on 2006-11-06 (modification)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• callipeltin E, submitted on 2006-11-06 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin D, submitted on 2006-11-06 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin C, submitted on 2006-11-06 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin B, submitted on 2006-11-06 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• callipeltin A, submitted on 2006-11-06 (modification)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• neamphamide A, submitted on 2006-11-06 (modification)

  Neamphamide A is a putative NRPS product (no synthetase genes identified).

• cyclonellin, submitted on 2006-11-06 (modification)

  cyclonellin is a putative NRPS product (no synthetase genes identified).

• corrugatin, submitted on 2006-11-06 (modification)

• callynormine A, submitted on 2006-11-06 (modification)

  Callynormine is a putative NRPS product (no synthetase genes identified).

• oscillarin, submitted on 2006-11-06 (modification)

  Oscillarin is a putative NRPS product (no synthetase genes identified).

• apramide G, submitted on 2006-11-06 (modification)

  Apramides are putative NRPS products (no synthetase genes identified).

• apramide D, submitted on 2006-11-06 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• apramide A, submitted on 2006-11-06 (modification)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• micromide, submitted on 2006-11-06 (modification)

  micromide is a putative NRPS product (no synthetase genes identified)

• petrosifungin B, submitted on 2006-11-06 (modification)

  petrosifungins are putative NRPS products (no synthetase genes identified)

• petrosifungin A, submitted on 2006-11-06 (modification)

  petrosifungins are putative NRPS products (no synthetase genes identified)

• serrawettin W1, submitted on 2006-11-06 (modification)

  Serrawettin W1 is produced by strain 274 and ATCC 13880.

• serrawettin W2, submitted on 2006-11-06 (modification)

  Serrawettin W2 is produced by strain NS 25.

• dysamide P, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• hemiasterlin A, submitted on 2006-11-06 (creation)

• geodiamolide K, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide O, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide J, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• neamphamide A, submitted on 2006-11-06 (creation)

  Neamphamide A is a putative NRPS product (no synthetase genes identified).

• geodiamolide G, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide N, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• neosiphoniamolide A, submitted on 2006-11-06 (creation)

  Neosiphoniamolide A is a putative NRPS product (no synthetase genes identified)

• hemiasterlin, submitted on 2006-11-06 (creation)

• geodiamolide TA, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide M, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide R, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• aurilide C, submitted on 2006-11-06 (creation)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• geodiamolide Q, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide K, submitted on 2006-11-06 (creation)

  Dysamides K and L are isomers.Dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide P, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• halipeptin D, submitted on 2006-11-06 (creation)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• geodiamolide O, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide D, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide N, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• apramide A, submitted on 2006-11-06 (creation)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• geodiamolide M, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dyhydrodysamide C, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide L, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• halipeptin C, submitted on 2006-11-06 (creation)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• geodiamolide F, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide C, submitted on 2006-11-06 (creation)

  Dysamide C and D are isomers.Dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide E, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• aurilide B, submitted on 2006-11-06 (creation)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• geodiamolide D, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide B, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide C, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• halipeptin B, submitted on 2006-11-06 (creation)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• geodiamolide B, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• dysamide A, submitted on 2006-11-06 (creation)

  dysamides are putative NRPS products (no synthetase genes identified)

• geodiamolide A, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• cyclonellin, submitted on 2006-11-06 (creation)

  cyclonellin is a putative NRPS product (no synthetase genes identified).

• geodiamolide I, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• theonellapeptolide IIIe, submitted on 2006-11-06 (creation)

• geodiamolide H, submitted on 2006-11-06 (creation)

  Geodiamolides are putative NRPS products (no synthetase genes identified)

• halipeptin A, submitted on 2006-11-06 (creation)

  Halipeptin is a putative NRPS product (no synthetase genes identified).

• aciculitin A, submitted on 2006-11-06 (creation)

  Aciculitins are putative NRPS products (no synthetase genes identified).

• theonellapeptolide IIe, submitted on 2006-11-06 (creation)

• cyclocinamide A, submitted on 2006-11-06 (creation)

  Cyclocinamide is a putative NRPS product (no synthetase genes identified)

• aurilide, submitted on 2006-11-06 (creation)

  Aurilide is a putative NRPS,PKS product (no synthetase genes identified).

• oriamide, submitted on 2006-11-06 (creation)
  
• theonellapeptolide IId, submitted on 2006-11-06 (creation)

• discobahamin B, submitted on 2006-11-06 (creation)

  Discobahamins are putative NRPS products (no synthetase genes identified)

• discodermin H, submitted on 2006-11-06 (creation)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• discobahamin A, submitted on 2006-11-06 (creation)

  Discobahamins are putative NRPS products (no synthetase genes identified)

• theonellapeptolide Ie, submitted on 2006-11-06 (creation)

• orbiculamide A, submitted on 2006-11-06 (creation)

  Orbiculamide A is a putative NRPS product (no synthetase genes identified)

• serrawettin W2, submitted on 2006-11-06 (creation)

  Serrawettin W2 is produced by strain NS 25.

• keramamide N, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• theonellapeptolide Id, submitted on 2006-11-06 (creation)

• keramamide M, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• discodermin G, submitted on 2006-11-06 (creation)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• keramamide D, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• theonellapeptolide Ia, submitted on 2006-11-06 (creation)

• keramamide C, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• gymnangiamide, submitted on 2006-11-06 (creation)

  Gymnangiamide is a putative NRPS product (no synthetase genes identified).

• keramamide B, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• halicylindramide E, submitted on 2006-11-06 (creation)

• keramamide E, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• discodermin F, submitted on 2006-11-06 (creation)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• keramamide J, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• halicylindramide D, submitted on 2006-11-06 (creation)

• keramamide H, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• corrugatin, submitted on 2006-11-06 (creation)

• keramamide G, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• halicylindramide C, submitted on 2006-11-06 (creation)

• keramamide F, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• discodermin E, submitted on 2006-11-06 (creation)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• keramamide K, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• halicylindramide B, submitted on 2006-11-06 (creation)

• keramamide L, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• papuamide D, submitted on 2006-11-06 (creation)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• keramamide A, submitted on 2006-11-06 (creation)

  Keramamides are putative NRPS products (no synthetase genes identified)

• halicylindramide A, submitted on 2006-11-06 (creation)

• mozamide B, submitted on 2006-11-06 (creation)

  Mozamides are putative NRPS products (no synthetase genes identified)

• discodermin A, submitted on 2006-11-06 (creation)

  Discodermin A is a putative NRPS product (no synthetase genes identified).

• mozamide A, submitted on 2006-11-06 (creation)

  Mozamides are putative NRPS products (no synthetase genes identified)

• koshikamide A2, submitted on 2006-11-06 (creation)

• konbamide, submitted on 2006-11-06 (creation)

  Konbamide is a putative NRPS product (no synthetase genes identified)

• micromide, submitted on 2006-11-06 (creation)

  micromide is a putative NRPS product (no synthetase genes identified)

• ceratospongamide, submitted on 2006-11-06 (creation)

  Ceratospongamide is a putative NRPS product (no synthetase genes identified)

• koshikamide A1, submitted on 2006-11-06 (creation)

  Adding of the SMILES and modification of the references

• haligramide B, submitted on 2006-11-06 (creation)

  haligramides are putative NRPS products (no synthetase genes identified)

• polydiscamide A, submitted on 2006-11-06 (creation)

  Polydiscamides are putative NRPS products (no synthetase genes identified).

• haligramide A, submitted on 2006-11-06 (creation)

  haligramides are putative NRPS products (no synthetase genes identified)

• nazumamide A, submitted on 2006-11-06 (creation)

• waiakeamide, submitted on 2006-11-06 (creation)

  Waiakeamide is a putative NRPS product (no synthetase genes identified)

• papuamide C, submitted on 2006-11-06 (creation)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• cupolamide A, submitted on 2006-11-06 (creation)

  Cupolamide A is a putative NRPS product (no synthetase genes identified)

• miraziridine A, submitted on 2006-11-06 (creation)

• perthamide B, submitted on 2006-11-06 (creation)

  Perthamide B is a putative NRPS product (no synthetase genes identified)

• microspinosamide, submitted on 2006-11-06 (creation)

  Microspinosamide is a putative NRPS product (no synthetase genes identified).

• theopalauamide, submitted on 2006-11-06 (creation)

  Theopalauamide is a putative NRPS product (no synthetase genes identified)

• leupeptin, submitted on 2006-11-06 (creation)

• theonegramide, submitted on 2006-11-06 (creation)

  Theonegramide is a putative NRPS product (no synthetase genes identified)

• callynormine A, submitted on 2006-11-06 (creation)

  Callynormine is a putative NRPS product (no synthetase genes identified).

• theonellamide F, submitted on 2006-11-06 (creation)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• tokaramide A, submitted on 2006-11-06 (creation)

• theonellamide E, submitted on 2006-11-06 (creation)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• cyclolithistide A, submitted on 2006-11-06 (creation)

  Cyclolithistide A is a putative NRPS product (no synthetase genes identified).

• theonellamide D, submitted on 2006-11-06 (creation)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• andrimid, submitted on 2006-11-06 (creation)

  andrimid is a NRPS-PKS product. Moiramide differs on the fatty acid moiety.

• theonellamide C, submitted on 2006-11-06 (creation)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• papuamide B, submitted on 2006-11-06 (creation)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• theonellamide B, submitted on 2006-11-06 (creation)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• kapakahine G, submitted on 2006-11-06 (creation)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• theonellamide A, submitted on 2006-11-06 (creation)

  Theonellamides are putative NRPS products (no synthetase genes identified)

• phoriospongin B, submitted on 2006-11-06 (creation)

  Phoriospongins are nematocidal depsipeptides and are putative NRPS products (no synthetase genes identified).

• barangamide D, submitted on 2006-11-06 (creation)

  Barangamides are putative NRPS products (no synthetase genes identified)

• kapakahine F, submitted on 2006-11-06 (creation)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• barangamide C, submitted on 2006-11-06 (creation)

  Barangamides are putative NRPS products (no synthetase genes identified)

• serrawettin W1, submitted on 2006-11-06 (creation)

  Serrawettin W1 is produced by strain 274 and ATCC 13880.

• barangamide B, submitted on 2006-11-06 (creation)

  Barangamides are putative NRPS products (no synthetase genes identified)

• kapakahine E, submitted on 2006-11-06 (creation)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• barangamide A, submitted on 2006-11-06 (creation)

  Barangamides are putative NRPS products (no synthetase genes identified)

• phoriospongin A, submitted on 2006-11-06 (creation)

  Phoriospongins are nematocidal depsipeptides and are putative NRPS products (no synthetase genes identified).

• cyclolinopeptide A, submitted on 2006-11-06 (creation)

  Cyclolinopeptide was isolated from acetone extracts of linseed oil and its solid residues.Cyclolinopeptides are putative NRPS products (no synthetase genes identified)

• kapakahine B, submitted on 2006-11-06 (creation)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.

• microsclerodermin I, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• papuamide A, submitted on 2006-11-06 (creation)

  Papuamide is a putative NRPS product (no synthetase genes identified).

• microsclerodermin H, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• kapakahine A, submitted on 2006-11-06 (creation)

  Kapakahines share a unique structural feature: two tryptophan residues (Trp-1 and -2) are not linked by an amide bond but by a N-C bond from the indole nitrogen of Trp-1 to the indole carbon of Trp-2.Kapakahines C and D differ from A by the addition of the elements of H2O to the indole double bond of Trp-1 together with the formation of a bond between C-4 and N-1.

• microsclerodermin G, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• nagahamide A, submitted on 2006-11-06 (creation)

  Nagahamide A is a putative NRPS product (no synthetase genes identified).

• microsclerodermin F, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• cyclotheonamide E5, submitted on 2006-11-06 (creation)

• microsclerodermin E, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• oscillarin, submitted on 2006-11-06 (creation)

  Oscillarin is a putative NRPS product (no synthetase genes identified).

• microsclerodermin D, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• cyclotheonamide E4, submitted on 2006-11-06 (creation)

• microsclerodermin C, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• obyanamide, submitted on 2006-11-06 (creation)

  Obyanamide is a putative NRPS product (no synthetase genes identified).

• microsclerodermin B, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• cyclotheonamide E3, submitted on 2006-11-06 (creation)

• microsclerodermin A, submitted on 2006-11-06 (creation)

  Microsclerodermins are putative NRPS products (no synthetase genes identified)

• callipeltin E, submitted on 2006-11-06 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• wainunuamide, submitted on 2006-11-06 (creation)

  Wainunuamide is a putative NRPS product (no synthetase genes identified)

• cyclotheonamide E2, submitted on 2006-11-06 (creation)

• stylostatin 1, submitted on 2006-11-06 (creation)

  Stylostatin is a putative NRPS product (no synthetase genes identified)

• guineamide F, submitted on 2006-11-06 (creation)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• stylopeptide I, submitted on 2006-11-06 (creation)

  Stylopeptide is a putative NRPS product (no synthetase genes identified)

• cyclotheonamide E, submitted on 2006-11-06 (creation)

• hymenistatin I, submitted on 2006-11-06 (creation)

  Hymenistatin is a putative NRPS product (no synthetase genes identified)

• petrosifungin B, submitted on 2006-11-06 (creation)

  petrosifungins are putative NRPS products (no synthetase genes identified)

• hymenamide K, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• cyclotheonamide D, submitted on 2006-11-06 (creation)

• hymenamide J, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• guineamide E, submitted on 2006-11-06 (creation)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• hymenamide H, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• cyclotheonamide C, submitted on 2006-11-06 (creation)

• hymenamide G, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• callipeltin D, submitted on 2006-11-06 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• hymenamide F, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• cyclotheonamide B, submitted on 2006-11-06 (creation)

• hymenamide E, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• guineamide D, submitted on 2006-11-06 (creation)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• hymenamide D, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• cyclotheonamide A, submitted on 2006-11-06 (creation)

• hymenamide C, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• apramide G, submitted on 2006-11-06 (creation)

  Apramides are putative NRPS products (no synthetase genes identified).

• hymenamide B, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• dihydrocyclotheonamide A, submitted on 2006-11-06 (creation)

• hymenamide A, submitted on 2006-11-06 (creation)

  Hymenamides are putative NRPS products (no synthetase genes identified)

• guineamide C, submitted on 2006-11-06 (creation)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• phakellistatin 14, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• pseudotheonamide D, submitted on 2006-11-06 (creation)

• phakellistatin 13, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• callipeltin C, submitted on 2006-11-06 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• phakellistatin 12, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• pseudotheonamide C, submitted on 2006-11-06 (creation)

• phakellistatin 11, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• guineamide B, submitted on 2006-11-06 (creation)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• phakellistatin 10, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• pseudotheonamide A1, submitted on 2006-11-06 (creation)

• phakellistatin 9, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• ornibactin C4, submitted on 2006-11-06 (creation)

• phakellistatin 8, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• renieramide, submitted on 2006-11-06 (creation)

• phakellistatin 7, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• guineamide A, submitted on 2006-11-06 (creation)

  Guineamide is a putative NRPS product (no synthetase genes identified).

• phakellistatin 6, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• eurypamide D, submitted on 2006-11-06 (creation)

• phakellistatin 5, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• callipeltin B, submitted on 2006-11-06 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• phakellistatin 4, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• eurypamide C, submitted on 2006-11-06 (creation)

• phakellistatin 3, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• carmabin B, submitted on 2006-11-06 (creation)

  Carmabin is a putative NRPS product (no synthetase genes identified).

• phakellistatin 2, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• eurypamide B, submitted on 2006-11-06 (creation)

• phakellistatin 1, submitted on 2006-11-06 (creation)

  Phakellistatins are putative NRPS products (no synthetase genes identified)

• apramide D, submitted on 2006-11-06 (creation)

  Apramides are putative NRPS products (no synthetase genes identified). The variants differ on their fatty acid moiety.

• axinellin C, submitted on 2006-11-06 (creation)

  axinellin is a putative NRPS product (no synthetase genes identified)

• eurypamide A, submitted on 2006-11-06 (creation)

• axinellin B, submitted on 2006-11-06 (creation)

  axinellin is a putative NRPS product (no synthetase genes identified)

• carmabin A, submitted on 2006-11-06 (creation)

  Carmabin is a putative NRPS product (no synthetase genes identified).

• axinellin A, submitted on 2006-11-06 (creation)

  axinellin is a putative NRPS product (no synthetase genes identified)

• criamide B, submitted on 2006-11-06 (creation)

• axinastatin 5, submitted on 2006-11-06 (creation)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• callipeltin A, submitted on 2006-11-06 (creation)

  Callipeltin is a putative NRPS product (no synthetase genes identified).

• axinastatin 4, submitted on 2006-11-06 (creation)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• criamide A, submitted on 2006-11-06 (creation)

• axinastatin 3, submitted on 2006-11-06 (creation)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• onchidin B, submitted on 2006-11-06 (creation)

  onchidin B is a putative NRPS product (no synthetase genes identified).

• axinastatin 2, submitted on 2006-11-06 (creation)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• hemiasterlin C, submitted on 2006-11-06 (creation)

• axinastatin 1, submitted on 2006-11-06 (creation)

  axinastatin is a putative NRPS product (no synthetase genes identified)

• petrosifungin A, submitted on 2006-11-06 (creation)

  petrosifungins are putative NRPS products (no synthetase genes identified)

• pallidin, submitted on 2006-11-06 (creation)

  pallidin is a putative NRPS product (no synthetase genes identified)

• hemiasterlin B, submitted on 2006-11-06 (creation)

• dysamide Q, submitted on 2006-11-06 (creation)

  Dysamdes Q,R,S and T are isomers.Dysamides are putative NRPS products (no synthetase genes identified)

• onchidin, submitted on 2006-11-06 (creation)

  onchidin is a putative NRPS product (no synthetase genes identified).

• syringopeptin 22 PhvA, submitted on 2006-10-20 (modification)

  Syringopeptin 22 Phv was less active than syringopeptin 22 in inhibiting the growth of the test fungi Rhodotorula pilimanae and Geotrichum candidum and of the Gram-positive bacterium Bacillus megaterium. The amino acid stereochemistry has not been identified.

• amphibactin B, submitted on 2006-10-20 (modification)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• aquachelin A, submitted on 2006-10-20 (modification)

  4 variants which differ on the fatty acid moiety are encountered.

• marinobactin A, submitted on 2006-10-20 (modification)

• kahalalide K, submitted on 2006-10-20 (modification)

• kahalalide J, submitted on 2006-10-20 (modification)

• kahalalide H, submitted on 2006-10-20 (modification)

• kahalalide G, submitted on 2006-10-20 (modification)

  Kahalalide G is the acyclic analog of kahalalide F.

• kahalalide E, submitted on 2006-10-20 (modification)

  Kahalalide E was selective in action against the Herpes simplex II virus.

• kahalalide D, submitted on 2006-10-20 (modification)

• kahalalide C, submitted on 2006-10-20 (modification)

• kahalalide B, submitted on 2006-10-20 (modification)

• kahalalide A, submitted on 2006-10-20 (modification)

  Kahalalide A and F from Bryopsis sp. were noted for their in vitro activity against Mycobacterium tuberculosis

• kahalalide F, submitted on 2006-10-20 (modification)

  Kahalalide F alters the function of the lysosomal membrane, a mechanism that distinguishes it from all other known anti-tumour agents.

• tamandarin B, submitted on 2006-10-20 (modification)

• tamandarin A, submitted on 2006-10-20 (modification)

• [Hap2]didemnin B, submitted on 2006-10-20 (modification)

• [Hysp2]didemnin B, submitted on 2006-10-20 (modification)

• acyclodidemnin A, submitted on 2006-10-20 (modification)

• nordidemnin N, submitted on 2006-10-20 (modification)

• didemnin Y, submitted on 2006-10-20 (modification)

• didemnin X, submitted on 2006-10-20 (modification)

• didemnin N, submitted on 2006-10-20 (modification)

• didemnin M, submitted on 2006-10-20 (modification)

• nordidemnin C, submitted on 2006-10-20 (modification)

• nordidemnin A, submitted on 2006-10-20 (modification)

• nordidemnin B, submitted on 2006-10-20 (modification)

• didemnin C, submitted on 2006-10-20 (modification)
  

• didemnin A, submitted on 2006-10-20 (modification)

• didemnin B, submitted on 2006-10-20 (modification)

• dehydrodidemnin B, submitted on 2006-10-20 (modification)

  Aplidine is a compound found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers.

• dolastatin 12, submitted on 2006-10-20 (modification)

  Dolastatin 11 and dolastatin 12 inhibit growth of the murine P388 lymphocytic leukemia.

• dolastatin 11, submitted on 2006-10-20 (modification)

  Dolastatin 11 and dolastatin 12 inhibit growth of the murine P388 lymphocytic leukemia.

• dolastatin 15, submitted on 2006-10-20 (modification)

  Potent inhibitor of the proliferation of murine and leukemia cell lines and also an inhibitor of hematopoietic progenitor cells. Also shown to inhibit microtubule assembly and to induce apoptosis and Bcl2 phosphorylation in many malignant cells types.

• dolastatin 10, submitted on 2006-10-20 (modification)

  dolastatin 10 is an anticancer natural product, microtubule destabilizing agent

• lichenysin A iC12, submitted on 2006-10-20 (modification)

  This variant represents 0,3 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• putisolvin II, submitted on 2006-10-20 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• putisolvin I, submitted on 2006-10-20 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• cormycin A, submitted on 2006-10-20 (modification)

• pseudomycin A, submitted on 2006-10-20 (modification)

  The pseudomycin A is the major pseudomycin.

• syringotoxin B, submitted on 2006-10-20 (modification)

• syringostatin A, submitted on 2006-10-20 (modification)

• syringomycin E, submitted on 2006-10-20 (modification)

• [Phe25]syringopeptin 25A, submitted on 2006-10-20 (modification)

• syringopeptin SC 1, submitted on 2006-10-20 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified.

• syringopeptin 25A, submitted on 2006-10-20 (modification)

• syringopeptin 22A, submitted on 2006-10-20 (modification)

• corpeptin A, submitted on 2006-10-20 (modification)

  The stereoisomers (D or L form) of the amino acids are not identified.

• fuscopeptin A, submitted on 2006-10-20 (modification)

  Fuscopeptins are channel forming peptides active on biological and model membranes.

• tolaasin E, submitted on 2006-10-20 (modification)

• tolaasin D, submitted on 2006-10-20 (modification)

• tolaasin B, submitted on 2006-10-20 (modification)

• tolaasin II, submitted on 2006-10-20 (modification)

• tolaasin I, submitted on 2006-10-20 (modification)

  Tolaasin I and tolaasin A are structurally similar and the only difference is the number of carbons in the hydroxy fatty acyl moiety.

• arthrofactin, submitted on 2006-10-20 (modification)

  Arthrofactin was found to be five to seven times more effective than surfactin.

• lokisin, submitted on 2006-10-20 (modification)

  Anikasin is a synonymous of lokisin. Only anikasin structure was experimentally elucidated.

• pholipeptin, submitted on 2006-10-20 (modification)

  Pholipeptin inhibited PI-PLC of human carcinoma A431 cells.

• tensin, submitted on 2006-10-20 (modification)

  The peptide shows structural resemblance to the non-ribosomal cyclic lipopeptide fengycin from Bacillus subtilis.

• amphisin, submitted on 2006-10-20 (modification)

  Amphisin is a close analogue of the cyclic lipopeptides tensin and pholipeptin produced by Pseudomonas fluorescens.

• pseudophomin A, submitted on 2006-10-20 (modification)

  Pseudophomin A is a diastereoisomer of massetolide A.

• White Line Inducing Principle, submitted on 2006-10-20 (modification)

  WLIP is structurally similar to viscosin, except for the chirality of leucine in position 5 which has D configuration in WLIP and L configuration in viscosin.

• massetolide F, submitted on 2006-10-20 (modification)

• massetolide E, submitted on 2006-10-20 (modification)

• massetolide D, submitted on 2006-10-20 (modification)

• massetolide A, submitted on 2006-10-20 (modification)
  

• viscosinamide, submitted on 2006-10-20 (modification)

• viscosin, submitted on 2006-10-20 (modification)

• bacillibactin, submitted on 2006-10-20 (modification)

• jaspamide, submitted on 2006-10-20 (modification)

  Jaspamide showed ability to interact with actin filaments and in particular to produce structural and biophysical changes of cytoskeletal dynamics, resulting in a potent antiproliferative activity.

• jaspamide, submitted on 2006-10-20 (creation)

  Jaspamide showed ability to interact with actin filaments and in particular to produce structural and biophysical changes of cytoskeletal dynamics, resulting in a potent antiproliferative activity.

• dehydrodidemnin B, submitted on 2006-10-20 (creation)

  Aplidine is a compound found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers.

• [Hysp2]didemnin B, submitted on 2006-10-20 (creation)

• syringopeptin 22 PhvA, submitted on 2006-10-20 (creation)

  Syringopeptin 22 Phv was less active than syringopeptin 22 in inhibiting the growth of the test fungi Rhodotorula pilimanae and Geotrichum candidum and of the Gram-positive bacterium Bacillus megaterium. The amino acid stereochemistry has not been identified.

• [Hap2]didemnin B, submitted on 2006-10-20 (creation)

• didemnin B, submitted on 2006-10-20 (creation)

• tamandarin A, submitted on 2006-10-20 (creation)

• syringopeptin SC 1, submitted on 2006-10-20 (creation)

  The stereoisomers (D or L form) of the amino acids are not identified.

• tamandarin B, submitted on 2006-10-20 (creation)

• putisolvin I, submitted on 2006-10-20 (creation)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• kahalalide F, submitted on 2006-10-20 (creation)

  Kahalalide F alters the function of the lysosomal membrane, a mechanism that distinguishes it from all other known anti-tumour agents.

• syringopeptin 25A, submitted on 2006-10-20 (creation)

• kahalalide A, submitted on 2006-10-20 (creation)

  Kahalalide A and F from Bryopsis sp. were noted for their in vitro activity against Mycobacterium tuberculosis

• didemnin A, submitted on 2006-10-20 (creation)

• kahalalide B, submitted on 2006-10-20 (creation)

• syringopeptin 22A, submitted on 2006-10-20 (creation)

• kahalalide C, submitted on 2006-10-20 (creation)

• dolastatin 15, submitted on 2006-10-20 (creation)

  Potent inhibitor of the proliferation of murine and leukemia cell lines and also an inhibitor of hematopoietic progenitor cells. Also shown to inhibit microtubule assembly and to induce apoptosis and Bcl2 phosphorylation in many malignant cells types.

• kahalalide D, submitted on 2006-10-20 (creation)

• corpeptin A, submitted on 2006-10-20 (creation)

  The stereoisomers (D or L form) of the amino acids are not identified.

• kahalalide E, submitted on 2006-10-20 (creation)

  Kahalalide E was selective in action against the Herpes simplex II virus.

• didemnin C, submitted on 2006-10-20 (creation)
  
• kahalalide G, submitted on 2006-10-20 (creation)

  Kahalalide G is the acyclic analog of kahalalide F.

• fuscopeptin A, submitted on 2006-10-20 (creation)

  Fuscopeptins are channel forming peptides active on biological and model membranes.

• kahalalide H, submitted on 2006-10-20 (creation)

• cormycin A, submitted on 2006-10-20 (creation)

• kahalalide J, submitted on 2006-10-20 (creation)

• tolaasin E, submitted on 2006-10-20 (creation)

• kahalalide K, submitted on 2006-10-20 (creation)

• nordidemnin B, submitted on 2006-10-20 (creation)

• marinobactin A, submitted on 2006-10-20 (creation)

• tolaasin D, submitted on 2006-10-20 (creation)

• aquachelin A, submitted on 2006-10-20 (creation)

  4 variants which differ on the fatty acid moiety are encountered.

• dolastatin 10, submitted on 2006-10-20 (creation)

  dolastatin 10 is an anticancer natural product, microtubule destabilizing agent

• amphibactin B, submitted on 2006-10-20 (creation)

  Amphibactins are cell-associated siderophores. This cell association is likely an important defense against siderophore diffusion in the oceanic environment.

• tolaasin B, submitted on 2006-10-20 (creation)

• nordidemnin A, submitted on 2006-10-20 (creation)

• tolaasin II, submitted on 2006-10-20 (creation)

• pseudomycin A, submitted on 2006-10-20 (creation)

  The pseudomycin A is the major pseudomycin.

• tolaasin I, submitted on 2006-10-20 (creation)

  Tolaasin I and tolaasin A are structurally similar and the only difference is the number of carbons in the hydroxy fatty acyl moiety.

• nordidemnin C, submitted on 2006-10-20 (creation)

• arthrofactin, submitted on 2006-10-20 (creation)

  Arthrofactin was found to be five to seven times more effective than surfactin.

• dolastatin 11, submitted on 2006-10-20 (creation)

  Dolastatin 11 and dolastatin 12 inhibit growth of the murine P388 lymphocytic leukemia.

• lokisin, submitted on 2006-10-20 (creation)

  Anikasin is a synonymous of lokisin. Only anikasin structure was experimentally elucidated.

• didemnin M, submitted on 2006-10-20 (creation)

• pholipeptin, submitted on 2006-10-20 (creation)

  Pholipeptin inhibited PI-PLC of human carcinoma A431 cells.

• syringotoxin B, submitted on 2006-10-20 (creation)

• tensin, submitted on 2006-10-20 (creation)

  The peptide shows structural resemblance to the non-ribosomal cyclic lipopeptide fengycin from Bacillus subtilis.

• didemnin N, submitted on 2006-10-20 (creation)

• amphisin, submitted on 2006-10-20 (creation)

  Amphisin is a close analogue of the cyclic lipopeptides tensin and pholipeptin produced by Pseudomonas fluorescens.

• putisolvin II, submitted on 2006-10-20 (creation)

  The stereoisomers (D or L form) of the amino acids are not identified. Putisolvin I and putisolvin II influence the development of the biofilm and can inhibit the formation of Pseudomonas biofilms on polyvinyl chloride.

• pseudophomin A, submitted on 2006-10-20 (creation)

  Pseudophomin A is a diastereoisomer of massetolide A.

• didemnin X, submitted on 2006-10-20 (creation)

• White Line Inducing Principle, submitted on 2006-10-20 (creation)

  WLIP is structurally similar to viscosin, except for the chirality of leucine in position 5 which has D configuration in WLIP and L configuration in viscosin.

• syringostatin A, submitted on 2006-10-20 (creation)

• massetolide F, submitted on 2006-10-20 (creation)

• didemnin Y, submitted on 2006-10-20 (creation)

• massetolide E, submitted on 2006-10-20 (creation)

• dolastatin 12, submitted on 2006-10-20 (creation)

  Dolastatin 11 and dolastatin 12 inhibit growth of the murine P388 lymphocytic leukemia.

• massetolide D, submitted on 2006-10-20 (creation)

• nordidemnin N, submitted on 2006-10-20 (creation)

• massetolide A, submitted on 2006-10-20 (creation)
  
• syringomycin E, submitted on 2006-10-20 (creation)

• viscosinamide, submitted on 2006-10-20 (creation)

• acyclodidemnin A, submitted on 2006-10-20 (creation)

• viscosin, submitted on 2006-10-20 (creation)

• lichenysin A iC12, submitted on 2006-10-20 (creation)

  This variant represents 0,3 % of the total amount of beta-hydroxy fatty acids found in lychenysin.

• bacillibactin, submitted on 2006-10-20 (creation)

• [Phe25]syringopeptin 25A, submitted on 2006-10-20 (creation)

• gramicidin S, submitted on 2006-07-27 (modification)

  It is a decapeptide which forms a cylic beta-sheet conformation , consisting of two antiparallel beta-strands connected by type II-turns.

• beauverolide III, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide II, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide I, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide N, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide M, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide La, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide L, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ka, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ja, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide H, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide i, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Fa, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide F, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ea, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide E, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide D, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ca, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide C, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide Ba, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide B, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauverolide A, submitted on 2006-07-27 (modification)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• AM-toxin III, submitted on 2006-07-27 (modification)

• AM-toxin II, submitted on 2006-07-27 (modification)

• AM-toxin I, submitted on 2006-07-27 (modification)

• HC-toxin, submitted on 2006-07-27 (modification)

  HC-toxin is required for pathogenicity of the filamentous fungus Cochliobolus carbonum on maize.

• brevianamide F, submitted on 2006-07-27 (modification)

  Brevianamide F is the precursor of a variety of fungal prenylated alkaloids with biological activity, including fumitremorgins A, B and C and tryprostatin B.

• tyrocidine D, submitted on 2006-07-27 (modification)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• tyrocidine C, submitted on 2006-07-27 (modification)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• tyrocidine B, submitted on 2006-07-27 (modification)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• tyrocidine A, submitted on 2006-07-27 (modification)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• amphomycin A1437 A, submitted on 2006-07-27 (modification)

  The acyl residue is essential for antibiotic activity.

• friulimicin A, submitted on 2006-07-27 (modification)

  The acyl residue is essential for antibiotic activity.

• norcoronatine, submitted on 2006-07-27 (modification)

• coronatine, submitted on 2006-07-27 (modification)

  Coronatine contributes to virulence in several host-pathogen interactions and elicits diffuse chlorosis in a wide variety of plant species and also induces hypertrophy, inhibits root elongation, and stimulates ethylene production.

• PF1022E, submitted on 2006-07-27 (modification)

• PF1022D, submitted on 2006-07-27 (modification)

• PF1022C, submitted on 2006-07-27 (modification)

• PF1022B, submitted on 2006-07-27 (modification)

• PF1022A, submitted on 2006-07-27 (modification)

  It possesses strong anthelmintic properties.

• aureobasidin R, submitted on 2006-07-27 (modification)

• aureobasidin G, submitted on 2006-07-27 (modification)

• aureobasidin F, submitted on 2006-07-27 (modification)

• aureobasidin E, submitted on 2006-07-27 (modification)

• aureobasidin D, submitted on 2006-07-27 (modification)

• aureobasidin C, submitted on 2006-07-27 (modification)

• aureobasidin B, submitted on 2006-07-27 (modification)
  

• aureobasidin A, submitted on 2006-07-27 (modification)

• anguibactin, submitted on 2006-07-27 (modification)
  

• nodularin R, submitted on 2006-07-27 (modification)

• oscillamide Y, submitted on 2006-07-27 (modification)

• oscillamide C, submitted on 2006-07-27 (modification)

• oscillamide B, submitted on 2006-07-27 (modification)

• nodulapeptin B, submitted on 2006-07-27 (modification)

• nodulapeptin A, submitted on 2006-07-27 (modification)

• ferintoic acid B, submitted on 2006-07-27 (modification)

• ferintoic acid A, submitted on 2006-07-27 (modification)

• anabaenopeptin T, submitted on 2006-07-27 (modification)

• anabaenopeptin J, submitted on 2006-07-27 (modification)

• anabaenopeptin I, submitted on 2006-07-27 (modification)

• anabaenopeptin H, submitted on 2006-07-27 (modification)

• anabaenopeptin G, submitted on 2006-07-27 (modification)

• anabaenopeptin F, submitted on 2006-07-27 (modification)

• anabaenopeptin E, submitted on 2006-07-27 (modification)

• anabaenopeptin D, submitted on 2006-07-27 (modification)

• anabaenopeptin C, submitted on 2006-07-27 (modification)

• anabaenopeptin B, submitted on 2006-07-27 (modification)

• anabaenopeptin A, submitted on 2006-07-27 (modification)

• anabaenopeptilide 202B, submitted on 2006-07-27 (modification)

• anabaenopeptilide 202A, submitted on 2006-07-27 (modification)

• anabaenopeptilide 90B, submitted on 2006-07-27 (modification)

• anabaenopeptilide 90A, submitted on 2006-07-27 (modification)

• beauvericin F, submitted on 2006-07-27 (modification)

• beauvericin E, submitted on 2006-07-27 (modification)

• beauvericin D, submitted on 2006-07-27 (modification)

• beauvericin A, submitted on 2006-07-27 (modification)

  Isomery from pubChem entry 3010885

• beauvericin, submitted on 2006-07-27 (modification)

  This antibiotic is active against Gram-positive bacteria and mycobacteria, as well against insects.

• enterobactin, submitted on 2006-07-27 (modification)

• vibriobactin, submitted on 2006-07-27 (modification)
  

• enterobactin, submitted on 2006-07-27 (creation)

• aureobasidin R, submitted on 2006-07-27 (creation)

• beauverolide III, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptin H, submitted on 2006-07-27 (creation)

• beauverolide II, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aureobasidin G, submitted on 2006-07-27 (creation)

• beauverolide I, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptilide 90B, submitted on 2006-07-27 (creation)

• beauverolide N, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aureobasidin F, submitted on 2006-07-27 (creation)

• beauverolide M, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptin G, submitted on 2006-07-27 (creation)

• beauverolide La, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aureobasidin E, submitted on 2006-07-27 (creation)

• beauverolide L, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauvericin A, submitted on 2006-07-27 (creation)

  Isomery from pubChem entry 3010885

• beauverolide Ka, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aureobasidin D, submitted on 2006-07-27 (creation)

• beauverolide Ja, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptin F, submitted on 2006-07-27 (creation)

• beauverolide H, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aureobasidin C, submitted on 2006-07-27 (creation)

• beauverolide i, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptilide 90A, submitted on 2006-07-27 (creation)

• beauverolide Fa, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aureobasidin B, submitted on 2006-07-27 (creation)
  
• beauverolide F, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptin E, submitted on 2006-07-27 (creation)

• beauverolide Ea, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• aureobasidin A, submitted on 2006-07-27 (creation)

• beauverolide E, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• gramicidin S, submitted on 2006-07-27 (creation)

  It is a decapeptide which forms a cylic beta-sheet conformation , consisting of two antiparallel beta-strands connected by type II-turns.

• beauverolide D, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anguibactin, submitted on 2006-07-27 (creation)
  
• beauverolide Ca, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptin D, submitted on 2006-07-27 (creation)

• beauverolide C, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• nodularin R, submitted on 2006-07-27 (creation)

• beauverolide Ba, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• beauvericin F, submitted on 2006-07-27 (creation)

• beauverolide B, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• oscillamide Y, submitted on 2006-07-27 (creation)

• beauverolide A, submitted on 2006-07-27 (creation)

  Recent studies have indicated that beauverolides could potentially serve as new drugs for the treatment of atherosclerosis.

• anabaenopeptin C, submitted on 2006-07-27 (creation)

• AM-toxin III, submitted on 2006-07-27 (creation)

• oscillamide C, submitted on 2006-07-27 (creation)

• AM-toxin II, submitted on 2006-07-27 (creation)

• beauvericin, submitted on 2006-07-27 (creation)

  This antibiotic is active against Gram-positive bacteria and mycobacteria, as well against insects.

• AM-toxin I, submitted on 2006-07-27 (creation)

• oscillamide B, submitted on 2006-07-27 (creation)

• HC-toxin, submitted on 2006-07-27 (creation)

  HC-toxin is required for pathogenicity of the filamentous fungus Cochliobolus carbonum on maize.

• anabaenopeptin B, submitted on 2006-07-27 (creation)

• brevianamide F, submitted on 2006-07-27 (creation)

  Brevianamide F is the precursor of a variety of fungal prenylated alkaloids with biological activity, including fumitremorgins A, B and C and tryprostatin B.

• nodulapeptin B, submitted on 2006-07-27 (creation)

• tyrocidine D, submitted on 2006-07-27 (creation)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• beauvericin E, submitted on 2006-07-27 (creation)

• tyrocidine C, submitted on 2006-07-27 (creation)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• nodulapeptin A, submitted on 2006-07-27 (creation)

• tyrocidine B, submitted on 2006-07-27 (creation)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• anabaenopeptin A, submitted on 2006-07-27 (creation)

• tyrocidine A, submitted on 2006-07-27 (creation)

  Tyrocidine kills bacteria by interacting with their cytoplasmic membrane and causing leakage of their intracellular content. It also affects intracellular membranes such as those of mitochondria.

• ferintoic acid B, submitted on 2006-07-27 (creation)

• amphomycin A1437 A, submitted on 2006-07-27 (creation)

  The acyl residue is essential for antibiotic activity.

• vibriobactin, submitted on 2006-07-27 (creation)
  
• friulimicin A, submitted on 2006-07-27 (creation)

  The acyl residue is essential for antibiotic activity.

• ferintoic acid A, submitted on 2006-07-27 (creation)

• norcoronatine, submitted on 2006-07-27 (creation)

• anabaenopeptilide 202B, submitted on 2006-07-27 (creation)

• coronatine, submitted on 2006-07-27 (creation)

  Coronatine contributes to virulence in several host-pathogen interactions and elicits diffuse chlorosis in a wide variety of plant species and also induces hypertrophy, inhibits root elongation, and stimulates ethylene production.

• anabaenopeptin T, submitted on 2006-07-27 (creation)

• PF1022E, submitted on 2006-07-27 (creation)

• beauvericin D, submitted on 2006-07-27 (creation)

• PF1022D, submitted on 2006-07-27 (creation)

• anabaenopeptin J, submitted on 2006-07-27 (creation)

• PF1022C, submitted on 2006-07-27 (creation)

• anabaenopeptilide 202A, submitted on 2006-07-27 (creation)

• PF1022B, submitted on 2006-07-27 (creation)

• anabaenopeptin I, submitted on 2006-07-27 (creation)

• PF1022A, submitted on 2006-07-27 (creation)

  It possesses strong anthelmintic properties.

• [D-Asp3.ADMAdda5]microcystin-LHar, submitted on 2006-06-13 (modification)

• [Glu7] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [Aib6.Glu7] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [Aib6.desPheol] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [desPheol] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [des(1-6).Pyr7] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [Aib6.Glu19] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [Glu19] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [Aib6] alamethicin F30, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [des(1-6).Pyr7] alamethicin F50, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• alamethicin F50, submitted on 2006-06-13 (modification)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• ACV, submitted on 2006-06-13 (modification)

  ACV is the penicillin and cephalosporin precursor.

• A54145 F, submitted on 2006-06-13 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 C, submitted on 2006-06-13 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 B, submitted on 2006-06-13 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• A54145 A, submitted on 2006-06-13 (modification)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• daptomycin, submitted on 2006-06-13 (modification)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• Ile-gramicidin C, submitted on 2006-06-13 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Ile-gramicidin B, submitted on 2006-06-13 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Ile-gramicidin A, submitted on 2006-06-13 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Val-gramicidin C, submitted on 2006-06-13 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Brevibacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Val-gramicidin B, submitted on 2006-06-13 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• Val-gramicidin A, submitted on 2006-06-13 (modification)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria.Gramicidin A is a naturally-occurring ion channel-forming pentadecapeptide. The association of two gramicidin A peptides causes the formation of a monovalent cation-selective ion channel.

• actinomycin pip2, submitted on 2006-06-13 (modification)

• actinomycin pip1-beta, submitted on 2006-06-13 (modification)

• actinomycin pip1-alpha, submitted on 2006-06-13 (modification)

• actinomycin Z5, submitted on 2006-06-13 (modification)

• actinomycin Z4, submitted on 2006-06-13 (modification)

• actinomycin Z3, submitted on 2006-06-13 (modification)

• actinomycin Z2, submitted on 2006-06-13 (modification)

• actinomycin Z1, submitted on 2006-06-13 (modification)

• actinomycin VII, submitted on 2006-06-13 (modification)

  The principal effect of D-alloisoleucine and, especially, D-isoleucine, is to bring about synthesis of two new actinomycins which contain N-methylisoleucine.

• actinomycin VI, submitted on 2006-06-13 (modification)

  The principal effect of D-alloisoleucine and, especially, D-isoleucine, is to bring about synthesis of two new actinomycins which contain N-methylisoleucine.

• actinomycin V, submitted on 2006-06-13 (modification)

• actinomycin III, submitted on 2006-06-13 (modification)

  If sarcosine is added to the medium, the micro-organism produces, in addition to actinomycins D and I, actinomycin II and actinomycin III, characterized by the substitution by sarcosine of one or both the proline molecules present in actinomycin D.

• actinomycin II, submitted on 2006-06-13 (modification)

  If sarcosine is added to the medium, the micro-organism produces, in addition to actinomycins D and I, actinomycin II and actinomycin III, characterized by the substitution by sarcosine of one or both the proline molecules present in actinomycin D.

• actinomycin I, submitted on 2006-06-13 (modification)

• actinomycin D, submitted on 2006-06-13 (modification)

  Dactinomycin belongs to the group of medicines known as antineoplastics. It is used to treat some kinds of cancer of the bones and soft tissue, including muscles and tendons, Wilms tumor (a cancer of the kidney found primarily in children), tumors in the uterus or womb, and cancer of the testicles.

• fengycin B, submitted on 2006-06-13 (modification)

  The lipid moiety of both analogs is more variable, as fatty acids have been identified as anteiso-pentadecanoic acid (ai-C15), iso-hexadecanoic acid (i-C16), n-hexadecanoic acid (n-C16), and there is evidence for further saturated and unsaturated residues up to C18.

• fengycin A, submitted on 2006-06-13 (modification)

  The lipid moiety of both analogs is more variable, as fatty acids have been identified as anteiso-pentadecanoic acid (ai-C15), iso-hexadecanoic acid (i-C16), n-hexadecanoic acid (n-C16), and there is evidence for further saturated and unsaturated residues up to C18.

• bacillomycin D-1, submitted on 2006-06-13 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• bacillomycin F-6, submitted on 2006-06-13 (modification)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• bacillomycin L-1, submitted on 2006-06-13 (modification)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• mycosubtilin 4, submitted on 2006-06-13 (modification)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• iturin C-1, submitted on 2006-06-13 (modification)

  Iturins C are inactive metabolites (no antibiotic activity).

• iturin A-2, submitted on 2006-06-13 (modification)

  The iturin A-2 isomer is the predominat isomer.

• [Ile2.4.7]surfactin, submitted on 2006-06-13 (modification)

  This variant has increased surface properties compared with that of surfactin.

• [Ile4.7]surfactin, submitted on 2006-06-13 (modification)

  This variant has increased surface properties compared with that of surfactin.

• [Ile4]surfactin, submitted on 2006-06-13 (modification)

• [Leu4]surfactin, submitted on 2006-06-13 (modification)

• [Ala4]surfactin iC14, submitted on 2006-06-13 (modification)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The iC14 isoform represents 11% of total isoforms.

• [Ile7]surfactin, submitted on 2006-06-13 (modification)

• [Val7]surfactin, submitted on 2006-06-13 (modification)

• [Gln1]surfactin, submitted on 2006-06-13 (modification)

• surfactin aC15, submitted on 2006-06-13 (modification)

• chrysobactin, submitted on 2006-06-13 (modification)

• bacilysin, submitted on 2006-06-13 (modification)

  Some experimental results indicated that the mechanism of bacilysin biosynthesis is not typical of the general multicarrier thiotemplate model.

• azotobactin D, submitted on 2006-06-13 (modification)

• azotobactin 87 -1, submitted on 2006-06-13 (modification)

• pyoverdin BTP16, submitted on 2006-06-13 (modification)

• pyoverdin C, submitted on 2006-06-13 (modification)

• pyoverdin I-III, submitted on 2006-06-13 (modification)

• pyoverdin D-TR133, submitted on 2006-06-13 (modification)

• pyoverdin P19, submitted on 2006-06-13 (modification)

• pseudobactin A214, submitted on 2006-06-13 (modification)

• pyoverdin R, submitted on 2006-06-13 (modification)

• pyoverdin 19310, submitted on 2006-06-13 (modification)

• PaB, submitted on 2006-06-13 (modification)

• pyoverdin R prime, submitted on 2006-06-13 (modification)

• azoverdin, submitted on 2006-06-13 (modification)

• pyoverdin 18-1, submitted on 2006-06-13 (modification)

• pyoverdin 96-318, submitted on 2006-06-13 (modification)

• pyoverdin 13525, submitted on 2006-06-13 (modification)

• pyoverdin 12, submitted on 2006-06-13 (modification)

• pyoverdin 95-275, submitted on 2006-06-13 (modification)

• pyoverdin C-E, submitted on 2006-06-13 (modification)

• pyoverdin 96.188, submitted on 2006-06-13 (modification)

• pyoverdin 96-312, submitted on 2006-06-13 (modification)

• pyoverdin G173, submitted on 2006-06-13 (modification)

• pyoverdin 1547, submitted on 2006-06-13 (modification)

• pyoverdin GM, submitted on 2006-06-13 (modification)

• pyoverdin 51W, submitted on 2006-06-13 (modification)

• isopyoverdin 90-44, submitted on 2006-06-13 (modification)

• pyoverdin 2192, submitted on 2006-06-13 (modification)

• pyoverdin 1.3, submitted on 2006-06-13 (modification)

• pyoverdin 1.2, submitted on 2006-06-13 (modification)

• pyoverdin 17400, submitted on 2006-06-13 (modification)

• pyoverdin 2798, submitted on 2006-06-13 (modification)

• pyoverdin 3b, submitted on 2006-06-13 (modification)

• pyoverdin 2461, submitted on 2006-06-13 (modification)

• pseudobactin 589A, submitted on 2006-06-13 (modification)

• pyoverdin 2392, submitted on 2006-06-13 (modification)

• pyoverdin Pau, submitted on 2006-06-13 (modification)

• pyoverdin 90-51, submitted on 2006-06-13 (modification)

• isopyoverdin 90-33, submitted on 2006-06-13 (modification)

• pyoverdin 11370, submitted on 2006-06-13 (modification)

• pyoverdin PL8, submitted on 2006-06-13 (modification)

• pyoverdin T II, submitted on 2006-06-13 (modification)

• pyoverdin 2908, submitted on 2006-06-13 (modification)

• pyoverdin G4R, submitted on 2006-06-13 (modification)

• pyoverdin BTP2, submitted on 2006-06-13 (modification)

• pyoverdin PL7, submitted on 2006-06-13 (modification)

• isopyoverdin BTP1, submitted on 2006-06-13 (modification)

• pyoverdin 4a, submitted on 2006-06-13 (modification)

• pyoverdin 9AW, submitted on 2006-06-13 (modification)

• pseudobactin, submitted on 2006-06-13 (modification)

• [D-Asp3.ADMAdda5.Dhb7]microcystin-RR, submitted on 2006-06-13 (modification)

• [Dha7]microcystin-HphR, submitted on 2006-06-13 (modification)

• [D-Asp3. Dha7]microcystin-HtyR, submitted on 2006-06-13 (modification)

• microcystin-YM(O), submitted on 2006-06-13 (modification)

• microcystin-M(O)R, submitted on 2006-06-13 (modification)

• [DAsp3.ADMAdda5.Dhb7]microcystin-HtyR, submitted on 2006-06-13 (modification)

• [L-Ser7]microcystin-HtyR, submitted on 2006-06-13 (modification)

• microcystin-HtyR, submitted on 2006-06-13 (modification)

• [Dha7]microcystin-HtyR, submitted on 2006-06-13 (modification)

• [D-Asp3]microcystin-HtyR, submitted on 2006-06-13 (modification)

• [L-MeLan7]microcystin-LR, submitted on 2006-06-13 (modification)

• microcystin-WR, submitted on 2006-06-13 (modification)

• [D-Asp3.MeSer7]microcystin-RR, submitted on 2006-06-13 (modification)

• [L-Ser7]microcystin-RR, submitted on 2006-06-13 (modification)

• [ADMAdda5.MeSer7]microcystin-LR, submitted on 2006-06-13 (modification)

• [D-Ser1. ADMAdda5]microcystin-LR, submitted on 2006-06-13 (modification)

• [ADMAdda5]microcystin-LHar, submitted on 2006-06-13 (modification)

• [D-Asp3]microcystin-YR, submitted on 2006-06-13 (modification)

• [Dha7]microcystin-YR, submitted on 2006-06-13 (modification)

• microcystin FR, submitted on 2006-06-13 (modification)

• [Dha7]microcystin-RR, submitted on 2006-06-13 (modification)

• [D-Asp3]microcystin-RR, submitted on 2006-06-13 (modification)

• bacitracin A1, submitted on 2006-06-13 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• [ADMAdda5]microcystin-LR, submitted on 2006-06-13 (modification)

• [L-Ser7]microcystin-E(OMe)E(OMe), submitted on 2006-06-13 (modification)

• [Dha7]microcystin-FR, submitted on 2006-06-13 (modification)

• [L-MeSer7]microcytin-LR, submitted on 2006-06-13 (modification)

• [D-Asp3.Dha7]microcystin-RR, submitted on 2006-06-13 (modification)

• [D-Glu(OCH3)6]microcystin-LR, submitted on 2006-06-13 (modification)

• [D-Asp3.ADMAdda5]microcystin-LR, submitted on 2006-06-13 (modification)

• [DMAdda5]microcystin-LR, submitted on 2006-06-13 (modification)

• microcystin HilR, submitted on 2006-06-13 (modification)

• [D-Asp3.Ser7]microcystin-E(OMe)E(OMe), submitted on 2006-06-13 (modification)

• [L-Ser7]microcytin-EE(OMe), submitted on 2006-06-13 (modification)

• microcystin LY, submitted on 2006-06-13 (modification)

• [L-Ser7]microcystin-LR, submitted on 2006-06-13 (modification)

• [Dha7]MCYST-E(OMe)E(OMe), submitted on 2006-06-13 (modification)

• [D-Asp3.D-Glu(OCH3)6]microcystin-LR, submitted on 2006-06-13 (modification)

• microcystin LF, submitted on 2006-06-13 (modification)

• [D-Asp3.Dha7]microcystin-E(OMe)E(OMe), submitted on 2006-06-13 (modification)

• [Dha7]microcystin-EE(OMe), submitted on 2006-06-13 (modification)

• [Dha7]microcystin-LR, submitted on 2006-06-13 (modification)

• [D-Asp3]microcystin-LR, submitted on 2006-06-13 (modification)

• microcystin VF, submitted on 2006-06-13 (modification)

• [D-Asp3.Dha7]microcystin-EE(OMe), submitted on 2006-06-13 (modification)

• [D-Asp3.Dha7]microcystin-LR, submitted on 2006-06-13 (modification)

• microcystin YA, submitted on 2006-06-13 (modification)

• microcystin AR, submitted on 2006-06-13 (modification)

• microcystin LL, submitted on 2006-06-13 (modification)

• microcystin LW, submitted on 2006-06-13 (modification)

• microcystin LR, submitted on 2006-06-13 (modification)

• microcystin YR, submitted on 2006-06-13 (modification)

• microcystin RR, submitted on 2006-06-13 (modification)

• microcystin LA, submitted on 2006-06-13 (modification)

• enniatin G, submitted on 2006-06-13 (modification)

• enniatin F, submitted on 2006-06-13 (modification)
  

• enniatin B4, submitted on 2006-06-13 (modification)

• MK1688, submitted on 2006-06-13 (modification)

• enniatin C, submitted on 2006-06-13 (modification)

• enniatin I, submitted on 2006-06-13 (modification)
  

• enniatin H, submitted on 2006-06-13 (modification)
  

• enniatin N, submitted on 2006-06-13 (modification)

• enniatin L, submitted on 2006-06-13 (modification)

• enniatin B1, submitted on 2006-06-13 (modification)

• enniatin B, submitted on 2006-06-13 (modification)

• enniatin A1, submitted on 2006-06-13 (modification)

• enniatin A, submitted on 2006-06-13 (modification)

• destruxin E diol, submitted on 2006-06-13 (modification)

• destruxin E2 chlorohydrin, submitted on 2006-06-13 (modification)

• destruxin E chlorohydrin, submitted on 2006-06-13 (modification)

• destruxin E2, submitted on 2006-06-13 (modification)

• destruxin E1, submitted on 2006-06-13 (modification)

• destruxin E, submitted on 2006-06-13 (modification)

• destruxin D2, submitted on 2006-06-13 (modification)

• destruxin D1, submitted on 2006-06-13 (modification)

• destruxin D, submitted on 2006-06-13 (modification)

• desmethylDestruxin C, submitted on 2006-06-13 (modification)

• destruxin C2, submitted on 2006-06-13 (modification)

• destruxin C, submitted on 2006-06-13 (modification)

• beta-D-Glucopyranosyl-hydroxyDestruxin B, submitted on 2006-06-13 (modification)

• hydroxyhomoDestruxin B, submitted on 2006-06-13 (modification)

• hydroxyDestruxin B, submitted on 2006-06-13 (modification)

• protoDestruxin, submitted on 2006-06-13 (modification)

• homoDestruxin B, submitted on 2006-06-13 (modification)

• desmethylDestruxin B2, submitted on 2006-06-13 (modification)

• desmethylDestruxin A, submitted on 2006-06-13 (modification)

• destruxin A4 chlorohydrin, submitted on 2006-06-13 (modification)

• destruxin A4, submitted on 2006-06-13 (modification)

• destruxin A3, submitted on 2006-06-13 (modification)

• destruxin B2, submitted on 2006-06-13 (modification)

• destruxin A2, submitted on 2006-06-13 (modification)

• destruxin B1, submitted on 2006-06-13 (modification)

• destruxin A1, submitted on 2006-06-13 (modification)

• destruxin B, submitted on 2006-06-13 (modification)
  

• destruxin A, submitted on 2006-06-13 (modification)

• cyclosporin 32, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin 31, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin 30, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin 29, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin 28, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin 27, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin 26, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin Z, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin Y, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin X, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin W, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin V, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin U, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin S, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin R, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin Q, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin P, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin O, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin N, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin M, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin L, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin K, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin I, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin H, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin G, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin F, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin E, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin D, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin C, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin B, submitted on 2006-06-13 (modification)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• cyclosporin A, submitted on 2006-06-13 (modification)

  Cyclosporin is the primary tool used to prevent rejection following solid organ and bone marrow transplantation. It was first isolated as anti-fungal compound.

• CDA2fb, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2fa, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2d, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA4b, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA4a, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA3b, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA3a, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2b, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA2a, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• CDA1b, submitted on 2006-06-13 (modification)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• bacitracin C, submitted on 2006-06-13 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin B3, submitted on 2006-06-13 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin B2, submitted on 2006-06-13 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• bacitracin A2, submitted on 2006-06-13 (modification)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• daptomycin, submitted on 2006-06-13 (creation)

  A21978C is a complex of lipopeptides which differ on their fatty acid moiety. It is used to treat complicated skin infections.

• microcystin LY, submitted on 2006-06-13 (creation)

• cyclosporin X, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [L-Ser7]microcystin-LR, submitted on 2006-06-13 (creation)

• Ile-gramicidin C, submitted on 2006-06-13 (creation)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• [Dha7]MCYST-E(OMe)E(OMe), submitted on 2006-06-13 (creation)

• cyclosporin W, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [D-Asp3.D-Glu(OCH3)6]microcystin-LR, submitted on 2006-06-13 (creation)

• CDA3b, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• microcystin LF, submitted on 2006-06-13 (creation)

• cyclosporin V, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [D-Asp3.Dha7]microcystin-E(OMe)E(OMe), submitted on 2006-06-13 (creation)

• A54145 B, submitted on 2006-06-13 (creation)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• [Dha7]microcystin-EE(OMe), submitted on 2006-06-13 (creation)

• cyclosporin U, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [Dha7]microcystin-LR, submitted on 2006-06-13 (creation)

• bacitracin A2, submitted on 2006-06-13 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• [D-Asp3]microcystin-LR, submitted on 2006-06-13 (creation)

• cyclosporin S, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• microcystin VF, submitted on 2006-06-13 (creation)

• A54145 C, submitted on 2006-06-13 (creation)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• [D-Asp3.Dha7]microcystin-EE(OMe), submitted on 2006-06-13 (creation)

• cyclosporin R, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [D-Asp3.Dha7]microcystin-LR, submitted on 2006-06-13 (creation)

• CDA3a, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• microcystin YA, submitted on 2006-06-13 (creation)

• cyclosporin Q, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• microcystin AR, submitted on 2006-06-13 (creation)

• A54145 F, submitted on 2006-06-13 (creation)

  A54145 products are antibiotics for the traitment of infections caused by gram-positive pathogens.

• microcystin LL, submitted on 2006-06-13 (creation)

• cyclosporin P, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• microcystin LW, submitted on 2006-06-13 (creation)

• [Aib6.desPheol] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• microcystin LR, submitted on 2006-06-13 (creation)

• cyclosporin O, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• actinomycin III, submitted on 2006-06-13 (creation)

  If sarcosine is added to the medium, the micro-organism produces, in addition to actinomycins D and I, actinomycin II and actinomycin III, characterized by the substitution by sarcosine of one or both the proline molecules present in actinomycin D.

• microcystin YR, submitted on 2006-06-13 (creation)

• actinomycin II, submitted on 2006-06-13 (creation)

  If sarcosine is added to the medium, the micro-organism produces, in addition to actinomycins D and I, actinomycin II and actinomycin III, characterized by the substitution by sarcosine of one or both the proline molecules present in actinomycin D.

• ACV, submitted on 2006-06-13 (creation)

  ACV is the penicillin and cephalosporin precursor.

• actinomycin I, submitted on 2006-06-13 (creation)

• microcystin RR, submitted on 2006-06-13 (creation)

• actinomycin D, submitted on 2006-06-13 (creation)

  Dactinomycin belongs to the group of medicines known as antineoplastics. It is used to treat some kinds of cancer of the bones and soft tissue, including muscles and tendons, Wilms tumor (a cancer of the kidney found primarily in children), tumors in the uterus or womb, and cancer of the testicles.

• cyclosporin N, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• fengycin B, submitted on 2006-06-13 (creation)

  The lipid moiety of both analogs is more variable, as fatty acids have been identified as anteiso-pentadecanoic acid (ai-C15), iso-hexadecanoic acid (i-C16), n-hexadecanoic acid (n-C16), and there is evidence for further saturated and unsaturated residues up to C18.

• microcystin LA, submitted on 2006-06-13 (creation)

• fengycin A, submitted on 2006-06-13 (creation)

  The lipid moiety of both analogs is more variable, as fatty acids have been identified as anteiso-pentadecanoic acid (ai-C15), iso-hexadecanoic acid (i-C16), n-hexadecanoic acid (n-C16), and there is evidence for further saturated and unsaturated residues up to C18.

• CDA2b, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• bacillomycin D-1, submitted on 2006-06-13 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• enniatin G, submitted on 2006-06-13 (creation)

• bacillomycin F-6, submitted on 2006-06-13 (creation)

  The lipid moiety consists of minor isoCI5, anteisoC15 beta-amino acids and major isoC16, isoC17 and anteisoC17 beta-amino acids.

• cyclosporin M, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• bacillomycin L-1, submitted on 2006-06-13 (creation)

  C14 and C15 beta-amino acids were the major components with a lower percentage of C16 components.

• enniatin F, submitted on 2006-06-13 (creation)
  
• mycosubtilin 4, submitted on 2006-06-13 (creation)

  The major components of mycosubtilin are iso C16 (29 %) and anteisoC17 (54 %) with small amounts of nC16 (6 %) and isoCl7 (7 %) beta-amino acids.

• alamethicin F50, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• iturin C-1, submitted on 2006-06-13 (creation)

  Iturins C are inactive metabolites (no antibiotic activity).

• enniatin B4, submitted on 2006-06-13 (creation)

• iturin A-2, submitted on 2006-06-13 (creation)

  The iturin A-2 isomer is the predominat isomer.

• cyclosporin L, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [Ile2.4.7]surfactin, submitted on 2006-06-13 (creation)

  This variant has increased surface properties compared with that of surfactin.

• MK1688, submitted on 2006-06-13 (creation)

• [Ile4.7]surfactin, submitted on 2006-06-13 (creation)

  This variant has increased surface properties compared with that of surfactin.

• bacitracin B2, submitted on 2006-06-13 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• [Ile4]surfactin, submitted on 2006-06-13 (creation)

• enniatin C, submitted on 2006-06-13 (creation)

• [Leu4]surfactin, submitted on 2006-06-13 (creation)

• cyclosporin K, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [Ala4]surfactin iC14, submitted on 2006-06-13 (creation)

  The substitution of L-valine by L-alanine led to a decrease of the surfactant power of surfactin. The iC14 isoform represents 11% of total isoforms.

• enniatin I, submitted on 2006-06-13 (creation)
  
• [Ile7]surfactin, submitted on 2006-06-13 (creation)

• [des(1-6).Pyr7] alamethicin F50, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [Val7]surfactin, submitted on 2006-06-13 (creation)

• enniatin H, submitted on 2006-06-13 (creation)
  
• [Gln1]surfactin, submitted on 2006-06-13 (creation)

• cyclosporin I, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• surfactin aC15, submitted on 2006-06-13 (creation)

• enniatin N, submitted on 2006-06-13 (creation)

• chrysobactin, submitted on 2006-06-13 (creation)

• CDA2a, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• bacilysin, submitted on 2006-06-13 (creation)

  Some experimental results indicated that the mechanism of bacilysin biosynthesis is not typical of the general multicarrier thiotemplate model.

• enniatin L, submitted on 2006-06-13 (creation)

• azotobactin D, submitted on 2006-06-13 (creation)

• cyclosporin H, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• azotobactin 87 -1, submitted on 2006-06-13 (creation)

• enniatin B1, submitted on 2006-06-13 (creation)

• pyoverdin BTP16, submitted on 2006-06-13 (creation)

• [Aib6] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• pyoverdin C, submitted on 2006-06-13 (creation)

• enniatin B, submitted on 2006-06-13 (creation)

• pyoverdin I-III, submitted on 2006-06-13 (creation)

• cyclosporin G, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• pyoverdin D-TR133, submitted on 2006-06-13 (creation)

• enniatin A1, submitted on 2006-06-13 (creation)

• pyoverdin P19, submitted on 2006-06-13 (creation)

• [Aib6.Glu7] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• pseudobactin A214, submitted on 2006-06-13 (creation)

• enniatin A, submitted on 2006-06-13 (creation)

• pyoverdin R, submitted on 2006-06-13 (creation)

• cyclosporin F, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• pyoverdin 19310, submitted on 2006-06-13 (creation)

• destruxin E diol, submitted on 2006-06-13 (creation)

• PaB, submitted on 2006-06-13 (creation)

• alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• pyoverdin R prime, submitted on 2006-06-13 (creation)

• destruxin E2 chlorohydrin, submitted on 2006-06-13 (creation)

• azoverdin, submitted on 2006-06-13 (creation)

• cyclosporin E, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• pyoverdin 18-1, submitted on 2006-06-13 (creation)

• destruxin E chlorohydrin, submitted on 2006-06-13 (creation)

• pyoverdin 96-318, submitted on 2006-06-13 (creation)

• CDA1b, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• pyoverdin 13525, submitted on 2006-06-13 (creation)

• destruxin E2, submitted on 2006-06-13 (creation)

• pyoverdin 12, submitted on 2006-06-13 (creation)

• cyclosporin D, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• pyoverdin 95-275, submitted on 2006-06-13 (creation)

• destruxin E1, submitted on 2006-06-13 (creation)

• pyoverdin C-E, submitted on 2006-06-13 (creation)

• [Glu19] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• pyoverdin 96.188, submitted on 2006-06-13 (creation)

• destruxin E, submitted on 2006-06-13 (creation)

• pyoverdin 96-312, submitted on 2006-06-13 (creation)

• actinomycin V, submitted on 2006-06-13 (creation)

• pyoverdin G173, submitted on 2006-06-13 (creation)

• destruxin D2, submitted on 2006-06-13 (creation)

• pyoverdin 1547, submitted on 2006-06-13 (creation)

• cyclosporin C, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• pyoverdin GM, submitted on 2006-06-13 (creation)

• destruxin D1, submitted on 2006-06-13 (creation)

• pyoverdin 51W, submitted on 2006-06-13 (creation)

• actinomycin VI, submitted on 2006-06-13 (creation)

  The principal effect of D-alloisoleucine and, especially, D-isoleucine, is to bring about synthesis of two new actinomycins which contain N-methylisoleucine.

• isopyoverdin 90-44, submitted on 2006-06-13 (creation)

• destruxin D, submitted on 2006-06-13 (creation)

• pyoverdin 2192, submitted on 2006-06-13 (creation)

• bacitracin A1, submitted on 2006-06-13 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin 1.3, submitted on 2006-06-13 (creation)

• desmethylDestruxin C, submitted on 2006-06-13 (creation)

• pyoverdin 1.2, submitted on 2006-06-13 (creation)

• actinomycin VII, submitted on 2006-06-13 (creation)

  The principal effect of D-alloisoleucine and, especially, D-isoleucine, is to bring about synthesis of two new actinomycins which contain N-methylisoleucine.

• pyoverdin 17400, submitted on 2006-06-13 (creation)

• destruxin C2, submitted on 2006-06-13 (creation)

• pyoverdin 2798, submitted on 2006-06-13 (creation)

• cyclosporin B, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• pyoverdin 3b, submitted on 2006-06-13 (creation)

• destruxin C, submitted on 2006-06-13 (creation)

• pyoverdin 2461, submitted on 2006-06-13 (creation)

• actinomycin Z1, submitted on 2006-06-13 (creation)

• pseudobactin 589A, submitted on 2006-06-13 (creation)

• beta-D-Glucopyranosyl-hydroxyDestruxin B, submitted on 2006-06-13 (creation)

• pyoverdin 2392, submitted on 2006-06-13 (creation)

• [Aib6.Glu19] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• pyoverdin Pau, submitted on 2006-06-13 (creation)

• hydroxyhomoDestruxin B, submitted on 2006-06-13 (creation)

• pyoverdin 90-51, submitted on 2006-06-13 (creation)

• actinomycin Z2, submitted on 2006-06-13 (creation)

• isopyoverdin 90-33, submitted on 2006-06-13 (creation)

• hydroxyDestruxin B, submitted on 2006-06-13 (creation)

• pyoverdin 11370, submitted on 2006-06-13 (creation)

• cyclosporin A, submitted on 2006-06-13 (creation)

  Cyclosporin is the primary tool used to prevent rejection following solid organ and bone marrow transplantation. It was first isolated as anti-fungal compound.

• pyoverdin PL8, submitted on 2006-06-13 (creation)

• protoDestruxin, submitted on 2006-06-13 (creation)

• pyoverdin T II, submitted on 2006-06-13 (creation)

• actinomycin Z3, submitted on 2006-06-13 (creation)

• pyoverdin 2908, submitted on 2006-06-13 (creation)

• homoDestruxin B, submitted on 2006-06-13 (creation)

• pyoverdin G4R, submitted on 2006-06-13 (creation)

• bacitracin C, submitted on 2006-06-13 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• pyoverdin BTP2, submitted on 2006-06-13 (creation)

• desmethylDestruxin B2, submitted on 2006-06-13 (creation)

• pyoverdin PL7, submitted on 2006-06-13 (creation)

• actinomycin Z4, submitted on 2006-06-13 (creation)

• isopyoverdin BTP1, submitted on 2006-06-13 (creation)

• desmethylDestruxin A, submitted on 2006-06-13 (creation)

• pyoverdin 4a, submitted on 2006-06-13 (creation)

• CDA2fb, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• pyoverdin 9AW, submitted on 2006-06-13 (creation)

• destruxin A4 chlorohydrin, submitted on 2006-06-13 (creation)

• pseudobactin, submitted on 2006-06-13 (creation)

• actinomycin Z5, submitted on 2006-06-13 (creation)

• [D-Asp3.ADMAdda5.Dhb7]microcystin-RR, submitted on 2006-06-13 (creation)

• destruxin A4, submitted on 2006-06-13 (creation)

• [Dha7]microcystin-HphR, submitted on 2006-06-13 (creation)

• [des(1-6).Pyr7] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [D-Asp3. Dha7]microcystin-HtyR, submitted on 2006-06-13 (creation)

• destruxin A3, submitted on 2006-06-13 (creation)

• microcystin-YM(O), submitted on 2006-06-13 (creation)

• actinomycin pip1-alpha, submitted on 2006-06-13 (creation)

• microcystin-M(O)R, submitted on 2006-06-13 (creation)

• destruxin B2, submitted on 2006-06-13 (creation)

• [DAsp3.ADMAdda5.Dhb7]microcystin-HtyR, submitted on 2006-06-13 (creation)

• CDA2fa, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• [L-Ser7]microcystin-HtyR, submitted on 2006-06-13 (creation)

• destruxin A2, submitted on 2006-06-13 (creation)

• microcystin-HtyR, submitted on 2006-06-13 (creation)

• actinomycin pip1-beta, submitted on 2006-06-13 (creation)

• [Dha7]microcystin-HtyR, submitted on 2006-06-13 (creation)

• destruxin B1, submitted on 2006-06-13 (creation)

• [D-Asp3]microcystin-HtyR, submitted on 2006-06-13 (creation)

• [Glu7] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [L-MeLan7]microcystin-LR, submitted on 2006-06-13 (creation)

• destruxin A1, submitted on 2006-06-13 (creation)

• microcystin-WR, submitted on 2006-06-13 (creation)

• actinomycin pip2, submitted on 2006-06-13 (creation)

• [D-Asp3.MeSer7]microcystin-RR, submitted on 2006-06-13 (creation)

• destruxin B, submitted on 2006-06-13 (creation)
  
• [L-Ser7]microcystin-RR, submitted on 2006-06-13 (creation)

• CDA2d, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• [ADMAdda5.MeSer7]microcystin-LR, submitted on 2006-06-13 (creation)

• destruxin A, submitted on 2006-06-13 (creation)

• [D-Ser1. ADMAdda5]microcystin-LR, submitted on 2006-06-13 (creation)

• Val-gramicidin A, submitted on 2006-06-13 (creation)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria.Gramicidin A is a naturally-occurring ion channel-forming pentadecapeptide. The association of two gramicidin A peptides causes the formation of a monovalent cation-selective ion channel.

• [ADMAdda5]microcystin-LHar, submitted on 2006-06-13 (creation)

• cyclosporin 32, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [D-Asp3]microcystin-YR, submitted on 2006-06-13 (creation)

• [desPheol] alamethicin F30, submitted on 2006-06-13 (creation)

  The natural alpha-helical peptide antibiotic alamethicin forms voltage-gated ion channels in lipid membranes.

• [Dha7]microcystin-YR, submitted on 2006-06-13 (creation)

• cyclosporin 31, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• microcystin FR, submitted on 2006-06-13 (creation)

• Val-gramicidin B, submitted on 2006-06-13 (creation)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• [Dha7]microcystin-RR, submitted on 2006-06-13 (creation)

• cyclosporin 30, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [D-Asp3]microcystin-RR, submitted on 2006-06-13 (creation)

• CDA4b, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• [D-Asp3.ADMAdda5]microcystin-LHar, submitted on 2006-06-13 (creation)

• cyclosporin 29, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [ADMAdda5]microcystin-LR, submitted on 2006-06-13 (creation)

• Val-gramicidin C, submitted on 2006-06-13 (creation)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Brevibacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• [L-Ser7]microcystin-E(OMe)E(OMe), submitted on 2006-06-13 (creation)

• cyclosporin 28, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [Dha7]microcystin-FR, submitted on 2006-06-13 (creation)

• bacitracin B3, submitted on 2006-06-13 (creation)

  Bacitracin is a mixture a many similar compounds. The major compound is the bacitracin A1.

• [L-MeSer7]microcytin-LR, submitted on 2006-06-13 (creation)

• cyclosporin 27, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [D-Asp3.Dha7]microcystin-RR, submitted on 2006-06-13 (creation)

• Ile-gramicidin A, submitted on 2006-06-13 (creation)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• [D-Glu(OCH3)6]microcystin-LR, submitted on 2006-06-13 (creation)

• cyclosporin 26, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [D-Asp3.ADMAdda5]microcystin-LR, submitted on 2006-06-13 (creation)

• CDA4a, submitted on 2006-06-13 (creation)

  CDA shares a similar structure and possibly a related mode of action to other acidic lipopeptide antibiotics, including daptomycin, friulimicins, and amphomycins.

• [DMAdda5]microcystin-LR, submitted on 2006-06-13 (creation)

• cyclosporin Z, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• microcystin HilR, submitted on 2006-06-13 (creation)

• Ile-gramicidin B, submitted on 2006-06-13 (creation)

  Gramicidin is a heterogeneous mixture of six antibiotic compounds divided into three catagories: Gramicidin A, B and C, all of which are obtained from the soil bacterial species Bacillus brevis and called collectively Gramicidin D. Gramicidin is active against Gram-positive organisms,except for the Gram-positive bacilli, and against certain Gram-negative organisms, such as Neisseria. It is useful in combination with tyrocidin in the local treatment of a variety of superficial infections caused by susceptible Gram-positive bacteria.

• [D-Asp3.Ser7]microcystin-E(OMe)E(OMe), submitted on 2006-06-13 (creation)

• cyclosporin Y, submitted on 2006-06-13 (creation)

  Natural analogs of cyclosporin A are obtain in different nutrient broths

• [L-Ser7]microcytin-EE(OMe), submitted on 2006-06-13 (creation)